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The prototypic costimulatory molecule CD28 is essential for proper CD4+ T cell 
activation and initiation of clonal expansion. CD28 ligation regulates metabolic 
adaptation, the production of cytokines, survival, differentiation but also T follicular 
helper cell generation and germinal center response. Moreover, CD28 signaling 
induces the expression of microRNA cluster miR-17~92 during CD4+ T cell activation. 
However, despite the importance of this receptor, the molecular understanding of 
how CD28 exerts its function remains incomplete.  
In this thesis, we extend previous reports by showing that miR-17~92 expression 
directly correlates with CD4+ T cell activation, and miR-17~92-deficiency phenocopies 
CD28-deficiency in mice. We therefore hypothesized that transgenic miR-17~92 
expression could substitute for the loss of CD28. Using a 
B6.CD4cre.R26floxstopfloxmiR1792tg.CD28ko mouse model, we demonstrate that 
transgenic miR-17~92 expression compensates for CD28 expression during CD4+ T cell 
activation and differentiation in vitro, but also in vivo during acute LCMV infection.  
Even though many targets of miR-17~92 have been identified so far, the mechanisms 
by which miR-17~92 contributes to CD4+ T cell activation have not yet been fully 
explained. We generate transcriptomic datasets from activated CD4+ T cells with 
distinct amounts of miR-17~92 expression, with which we identify a new list of bona 
fide canonical miR-17~92 target genes. Furthermore, we demonstrate with a second 
dataset that these genes are not only regulated by miR-17~92 but also by CD28 
expression. This shows that in addition to the activation of transcription during CD28 
dependent CD4+ T cell activation, also the repression of genes which is mediated by 
miR-17~92 is essential. Moreover, the identified target genes mediate a rescue of the 
CD28ko transcriptome in rescue cells.  
We furthermore identify a new miR-17 target regulator of calcineurin 3 (RCAN3) 
among the list of target genes. Our data strongly support a model in which miR-17~92, 
in addition to known pathways like PI3K, also regulates the NFAT pathway. This 
qualifies this miRNA cluster as an important regulator of CD28 co-stimulation, which 







3.1. T cell activation 
3.1.1. Activation needs co-stimulation  
The activation of CD4+ T cells is a cornerstone for a proper adaptive immune response. 
Only with the help of CD4+ T cells, B cells can undergo affinity maturation and class 
switch in order to reach an optimal antigen recognition and antibody response. 
Bretscher and Cohn proposed in 1970 that there are actually two signals needed in 
order to get full T cell activation [1], and this concept was  further extended by Lafferty 
and Cunningham [2]. Schwartz and Jenkins later showed that T cell activation starts 
with binding of the T cell receptor (TCR) to an antigen presented on a major 
histocompatibility complex (MHC) molecule, but without other signals, the cell may 
turn unresponsive and anergic [3, 4], suggesting that activation of T cells needs co-
stimulatory signals. 
Co-stimulatory signals can either be generated from members of the CD28 family 
(which is the most important for T cells) or Tumor Necrosis Factor (TNF) receptor 
superfamily (for example CD40, which is more relevant for B cells). Early reports 
distinguished between TCR and CD28 signaling based on their differential reaction to 
Cyclosporin A (CsA), which on one hand led to the conclusion that TCR signaling is 
calcium (Ca2+) dependent, but secondly that CD28 has another, Ca2+ independent 
signaling mechanism that was not inhibited by CsA [5]. Later, several groups reported 
that CD28 can be phosphorylated and then binds to Phosphatidyl Inositol 3-Kinase 
(PI3K) [6-8]. This binding of PI3K to CD28 is essential for downstream processes of T 
cell activation since it recruits the enzyme to the cell surface, providing proximity to 
target substrates which initiate pathways like glucose uptake, and cytoskeletal re-
organization [9].  
3.1.2. T cell receptor signaling cascade  
The classical TCR is composed of an α and a β chain that span the cell membrane. Both 
of the chains have a variable and a constant region, and the combination of the 





binding of antigen by α/β is not sufficient to initiate signaling. Instead, the TCR needs 
interaction partners for its function [10, 11], which then represent the starting point 
for further signaling: CD3 signaling chains as well as the ζ-chains are associated with 
the α - and β chain, forming the TCR complex. The intracellular parts of these 
additional signaling chains bear so-called immunoreceptor tyrosine-based activation 
motifs (ITAMs) which are important for downstream signaling [12]. The signaling 
processes are in fact a cascade of phosphorylation and dephosphorylation events, 
which are tightly regulated and initiate recruitment and interaction of key molecules. 
During antigen recognition, the TCR recognizes the antigen that is presented on MHC. 
In the case of CD4+ T cells, the CD4 expressed on the T cell surface binds to the MHC 
class II molecule presenting the antigen to the TCR [13]. This binding moves the 
intracellular part of CD4 closer to the intracellular part of CD3, which is essential for 
the phosphorylation of ITAM: the Src-family kinase Lck is associated with CD4 and 
thought to be the main responsible kinase for the phosphorylation of ITAM (Figure 1) 
[14]. The activity of Lck is regulated by CD45, which can dephosphorylate both Lck 
tyrosine phosphorylation sites, opening its conformation [15]. Another regulating 
enzyme is C-terminal Src kinase (Csk), whose activity leads to a “closed” confirmation 
of Lck [16], which is a catalytically inactive state.  
 
 
Figure 1. ITAMs of the T cell receptor complex are 
phosphorylated by Lck 
The TCR α and β chains bind to MHCII:antigen. 
CD4 binds to MHCII, bringing the associated Lck in 
closer proximity to the TCR complex, so that ITAMs 
as well as CD28 can be phosphorylated  
  
The phosphorylation of the ITAMs is the beginning of several downstream pathways: 
tandem Src Homology 2 (SH2) and SH3 domain-containing enzymes (e.g. ZAP70) 
recognize their binding motif, initiating further signaling. Once Lck has phosphorylated 
the ITAM on the intracellular part of CD3, ZAP70 binds to it and is as well 
phosphorylated by Lck [17]. This ZAP70 activation is the pre-requisite for subsequent 





T cells (LAT) [19] and another adaptor protein called SLP-76. The two of them are 
linked by the adaptor protein Gads, which leads to a three-protein complex 
(LAT:Gads:SLP-76), which is key for T cell activation, acting as a scaffold. This scaffold 
can be generated by TCR signaling alone, while all subsequent events in T cell 
activation are dependent on co-stimulatory signals. ZAP70 activation additionally 
leads to the recruitment and activation of PI3K [20], but more importantly, PI3K is 
getting recruited and phosphorylated by the intracellular domain of CD28. CD28 is 
previously phosphorylated upon TCR signaling by p56Lck and p59Fyn [21] which 
enables binding of further molecules to this receptor. PI3K subsequently 
phosphorylates Phosphatidylinositol 4,5-bisphosphate (PIP2) at the inner membrane 
[22], resulting in Phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which is essential 




Figure 2. Phosphorylated ITAMs recruit SH2 domain containing molecules like ZAP70, so that a scaffold 
for further signaling can be created.  
Phosphorylated ITAMs are bound by SH2 domain-containing molecules like ZAP70, which in turn get 
activated and phosphorylated. This creates new binding- and phosphorylation sites for e.g. LAT and 
SLP-76, which are linked to a complex via Gads. PI3K is recruited to this complex as well as to the 
phosphorylated part of CD28, so that PI3K can phosphorylate PIP2, resulting in PIP3. 
 
3.1.3. Phosphatidylinositol-3 kinase activity and other downstream 
effects of T cell activation 
Already in early reports from 1989, Thompson et al. described the augmentation of T 
cell responses, i.e. stronger cytokine production, if the stimulation of human T cells 
via CD3 complex was complemented with stimulation of CD28 [23]. The most 





expression [24].	The joint action of the LAT:Gads:SLP-76 scaffold and PI3K or both 
together initiate processes which are essential for proper T cell activation, starting 
from metabolic changes to cell adhesion, actin polymerization and alterations in 
transcription. Transcriptional changes initiated by TCR are mostly modulated by 
phospholipase C-γ (PLC-γ): PI3K phosphorylates PIP2 on the cell membrane which 
leads to PIP3, to which PLC-γ binds via its PH-domain. PLC-γ then binds to the 
LAT:GADS:SLP-76 complex, and is phosphorylated by Itk (IL-2 inducible T cell kinase, 
which is recruited to the membrane via its PH domain binding to PIP3). Phosphorylated 
PLC-γ can then break down PIP2 into diacylglycerol (DAG), which will stay bound to the 
membrane, and a diffusible second messenger called inositol 1,4,5-triphosphate (IP3) 




Figure 3. PLC-γ cleaves PIP2 into IP3 and DAG, initiating downstream pathways 
PLC-γ interacts with LAT:Gads:SLP-76 scaffold before it cleaves PIP2 to IP3 and DAG, both leading to 
transcriptional changes. Other molecules like ADAP can also bind to the scaffold, initiating other 
downstream mechanisms, in this case increased integrin adhesion.  
 
DAG recruits other molecules to the membrane, like PKCΘ and RasGRP. RasGRP 
activates Ras [26], which is an initiator of the MAPK pathway leading to Erk1 
expression [27], which promotes generation of activator protein 1 (AP-1). AP-1 is a 
heterodimer consisting of Fos and Jun [28], which is transcriptionally inactive until Jun 
kinase (JNK) phosphorylates Jun, thereby activates AP-1 and initiates the transcription 
of many genes that are essential for T cell activation. AP-1 is an important interaction 
partner of nuclear factor of activated T cells (NFAT). PKCΘ is also recruited to the 
membrane by DAG, promoting a pathway which results in the activation of nuclear 





TCR stimulation furthermore leads to increased integrin adhesion [30]. This process is 
mediated by the LAT:GADS:SLP-76 complex as well: the adaptor protein ADAP is 
recruited to the complex, which recruits two more proteins SKAP55 and RIAM. This 
complex in turn activates a small GTPase Rap1 [31], which promotes LFA-1 
aggregation and its conformational change [32]. In this state, LFA-1 has a higher 
affinity for ICAM-1, which is important for the T cell if it should extravasate from e.g. 
a blood vessel to the surrounding tissue. 
For a stable interaction between the antigen presenting cell (APC) and the T cell, which 
is essential for the proper activation of the T cell, the cytoskeleton has to reorganize 
[33]. This process depends on Vav, which is recruited to PIP3 via its PH domain. At the 
same time, it also interacts with the LAT:GADS:SLP-76 complex via its SH2 domain. 
Also WASp is recruited to the LAT:GADS:SLP-76 complex, binding via the adaptor 
protein Nck. Vav activates Cdc42, which induces a conformational change in WASp 
[34]. This binds to WIP, and the complex recruits Arp2 and 3, which induces actin 
polymerization. 
The PI3K is also especially important for the metabolic changes underlying T cell 
activation [35, 36]. Protein kinase B, also known as Akt [37], binds to PIP3 in the 
membrane, where it is phosphorylated by PDK1. Phosphorylated Akt initiates a couple 
of important downstream pathways, for example it promotes the mammalian target 
of rapamycin (mTOR) pathway [38], leading to metabolic changes (Figure 4).  
	
	
Figure 4. PIP3 is an important interaction partner for 
different pathways of T cell activation 
PIP3 interacts with Vav, inducing Cdc42 activation 
and later actin polymerization. Furthermore, PIP3 
activates Akt, leading to mTOR pathway activation. 
PLC- γ importance is shown in Figure 3.	
 
All of these processes that are partially or fully dependent on the activity of PI3K 
already argue for the importance of co-stimulation in the T cell activation process. We 
will now go into detail on the downstream mechanism of IP3, which will be of 














3.1.4. IP3 initiates Store Operated Calcium Entry (SOCE) 
IP3 binds to Ca2+ channels in the endoplasmic reticulum (ER) membrane, so that Ca2+ 
is released from the ER store [39, 40], leading to an acute drop of Ca2+ abundance 
inside the ER lumen. This induces a conformational change [41] and clustering of 
stromal interaction molecules (STIM1/2) within the ER membrane [42, 43]. The STIM 
molecules then interact with the plasma membrane and ORAI [44, 45], which belong 
to the family of Ca2+-release activated Ca2+ channels (CRAC). The concentration of 
intracellular Ca2+ is mainly controlled by CRAC channels, in T cells ORAI1/2 [42, 46-48],  
which are located in the plasma membrane. The CRAC channels open upon interaction 
with STIM1/2 [44], which allows extracellular Ca2+ influx and activation of further 
signaling to replenish Ca2+ stores in the ER. Since the Ca2+ concentration of the ER 
regulates the Ca2+ influx, this process is called store operated Ca2+ entry (SOCE) [40, 
49, 50]. The Ca2+ in the cytosol bind to calmodulin, changing its conformation so that 
it interacts with and activates calcineurin. Upon conformational change of calmodulin 
and activation of calcineurin, NFAT is de-phosphorylated in multiple serine and 
threonine residues in its regulatory domains and translocates to the nucleus [51] 




Figure 5. IP3 induces Store Operated Calcium Entry (SOCE) 
IP3 interacts with ER calcium channels, so that Ca2+ is released from ER Ca2+ stores. STIM1/2 sense this 
drop in Ca2+ within the ER, and interact with ORAI1/2 to initiate extracellular Ca2+ influx. Ca2+ binds to 
calmodulin, leading to a conformational change and interaction with calcineurin. Calcineurin then de-






The phosphatase activity of calcineurin can be blocked by CsA and FK506 (also known 
as Tacrolimus) in a calmodulin independent manner [52, 53], which is one important 
aspect of immunosuppressive medication that is used in the clinics [54].  
Mice that are deficient in ORAI1/2 or STIM1/2 expression in T cells display impaired T 
cell mediated immune responses, marked by impaired cytokine production and 
antigen-dependent proliferation [47, 55, 56]. Also for humans, mutations of ORAI and 
STIM result in severe combined immunodeficiency [46], underlining the importance 
of this pathway for proper T cell activation and function. 
3.1.5. NFAT and its targets 
NFAT was found in the end of the 1980s in the extract of activated T cells and several 
cell lines [57]. Shaw et al. described “an inducible DNA-binding factor that is expressed 
minutes before the activation of the interleukin 2 (IL-2) gene”. NFAT was found not 
only in the cytoplasm but also in the nuclear fraction of stimulated Jurkat cells [58], 
with a different sensitivity to inhibition by FK506  and CsA, indicating that the 
translocation to the nucleus must be regulated by calcineurin. Meanwhile, the 
importance of the NFAT family was also demonstrated in other cell types of the 
hematopoietic system like megakaryocytes [59], dendritic cells [60] and B cells [61] as 
well as for developmental processes [62] and in other tissues, for example pancreatic 
β cells [63] and osteoclasts [64]. 
The NFAT family consists of five members [65-67]: NFAT1 (NFATc2, NFATp), NFAT2 
(NFATc1, NFATc), NFAT3 (NFATc4, NFATx), NFAT4 (NFATc3) and NFAT5 (TonEBP, 
OREBP) [68]. Each of them is expressed in a different tissue-specific pattern and none 
is restricted to lymphocytes in its expression [66]. All of the family members are 
evolutionary related to the Rel-nuclear-factor-κB family of transcription factors (TF), 
but only NFAT1-4 are regulated by intracellular Ca2+ abundance via calcineurin [69].  
In T cells, three of the Ca2+ regulated NFAT family members are expressed in two or 
more splice forms: NFATc1, NFATc2 and NFATc3 [68, 70]. All of them contain essential 
domains: First of all, the NFAT homology region that contains interaction domains for 
calcineurin (TAD-A, transactivation domain) and NFAT kinases (regulatory domain, 
serine-rich regions that are phosphorylated by kinases such as dual-specificity 





targeted and thereby de-phosphorylated by calcineurin [53, 71, 72] in order to permit 
nuclear localization [57, 73]: for example NFATc2 is heavily phosphorylated on 14 
sites, and 13 of them can be de-phosphorylated by calcineurin [74]. 
Secondly, the Rel homology region harbors the DNA-binding domain of the protein 
[75, 76] via a DNA-binding loop that also confers base-specific recognition at its N-
terminal region, but also has a protein interaction domain at its C-terminus. This 
protein interaction domain is of special importance regarding the targets of the NFAT 
family: the diversity of interaction partners enable NFAT to act on a variety of different 
pathways, which are essential for T cell activation and differentiation. 
NFAT can have an activating or deactivating transcriptional function depending on its 
binding partners [68]. For the initiation of transcription, NFAT needs to form a complex 
with AP-1, MEF2, or GATA proteins. The most commonly known interaction partner 
of NFAT is AP-1 [28, 77]. This interaction can promote expression of IL-2 [78], CD25 
[79], interferon gamma (IFNγ) [80], IL-4 [81], RAR related orphan receptor gamma t 
(Rorγt) [82] or Forkhead box p3 (FoxP3) [83]. The transcription of IL-2 is initiated when 
NFAT interacts with AP-1 to form a heterodimer that binds DNA [28, 75, 77, 84]. 
However,  addition of exogenous IL-2 only poorly rescues in vitro proliferation capacity 
of CD4cre.ORAI2fl/fl murine CD4+ T cells [47] which argues that cytokines are not the 
exclusive NFAT downstream targets that strongly influence proliferation. Moreover, 
the regulation of IL-2 is a good example of how complex the regulation actually might 
be: NFAT-AP1 promotes IL-2 transcription, whereas NFAT-Foxp3 actually represses 
this process [85]. Furthermore, additional factors like runt-related TFs (Runx1 and 3) 
regulate NFAT-induced IL-2 transcription as well.  
Other binding partners of NFAT have also been described to initiate transcription: 
upon interaction with C/EBP, binding to the PPAR-γ promoter is promoted [86], 
subsequent binding of NFAT to PPAR-γ then leads to binding of the IL-2 promoter 
while blocking the DNA binding of NFAT, thereby inhibiting IL-2 transcription [87]. 
Interaction with MAF [88, 89], GATA3 [89] or IRF4 [90] leads to binding in IL-4 
promoter or enhancer regions. Upon interaction with T box expressed by T cells (Tbet), 
NFAT binds to the 5’ enhancer of interferon γ (IFNγ) [89, 91]. TNF promoter is bound 
when EGR1 or EGR4 interact with NFAT [92], and synergy with MEF2 recruits the 





NFAT actually binds both promoters of IFNγ and IL-4 [94], and as soon as T cell 
differentiation has been initiated the inappropriate locus is silenced. 
Besides effects on cytokine production, NFAT activity also mediates metabolic 
reprogramming and clonal expansion [95]. Vaeth et al. demonstrated that SOCE, 
calcineurin and NFAT induce glycolysis and oxidative phosphorylation by regulating 
the expression of glucose transporters, glycolytic and mitochondrial enzymes. 
However, they also show that these pathways do not entirely depend on NFAT and 
that also the PI3K-Akt-mTOR pathway is to some extent regulated by SOCE and 
calcineurin.  
Ca2+ signaling can have a stimulatory but also an inhibitory role in gene expression 
[96]. Feske et al. performed gene expression analysis on two T cell lines from patients 
with defects in Ca2+ signaling and found that about a third of the genes were down-
regulated in the control, but not in patient samples upon activation, among these they 
identified Lck, Fas, E2F-3, IRF-2 and Signal transducer and activator of transcription 1 
(STAT1). 
Sustained Ca2+ signaling induced by TCR in the absence of co-stimulation induces a 
state of anergy in B and T cells [97-99], in the latter this is marked by the expression 
of anergy-associated genes like GRAIL which negatively regulates T cell activation 
signals by targeting them for degradation. NFATc2 knockout cells were shown to be 
more resistant to anergy induction than wild-type cells and T cell anergy was induced 
in the absence of AP-1 [97], underlining NFATs critical role in anergy induction. 
3.1.6. Regulation of NFAT 
One downstream effect of CD28 co-stimulation is that Akt [100] is activated via PI3K 
pathway. Glycogen-synthase kinase 3 (GSK3) [101], similar to casein kinase 1 (CK1) 
[102] as well as p38 and JNK [103, 104], is a kinase that re-phosphorylates NFAT and 
thereby mediates nuclear export, but upon Akt activity GSK3 is phosphorylated which 
inhibits its kinase activity [105, 106]. Thereby, CD28 indirectly promotes NFAT 
signaling via PI3K signaling and the prevention of its export to cytoplasm [106, 107].   
Calcineurin is regulated by so-called calcipressins, some of which are CABIN1 [108], 
AKAP79 [109, 110] and members of the Down’s syndrome critical region (DSCR, also 





Esau et al. reported increased cytokine expression in stimulated T cells [113], 
demonstrating the negative regulation of calcineurin by calcipressins. 
There are three regulators of calcineurin (RCAN1-3) described in humans. They bind 
and inhibit the activity of calcineurin via the CIC motif [112], thereby preventing the 
dephosphorylation and nuclear translocation of NFAT [114]. The RCAN molecules 
differ in their N-terminal region, but are conserved among their central and C-terminal 
regions [112]. Expression of RCAN3 was reported in peripheral blood leukocytes, 
heart, skeletal muscle, liver and kidney [115]. However,  in murine T cells mostly 
RCAN3 is expressed while RCAN2 is barely detectable and RCAN1 shows low 
expression (Figure 6) ([116], http://rstats.immgen.org/Skyline/skyline.html). 
 
 
Figure 6. ImmGen 
Skylines of RCAN1, 
RCAN2, RCAN3 in 
murine T cells 
Normalized expression 
value of RCAN1-3 are 






3.1.7. Differentiation of CD4+ T cells 
We can experimentally determine the activation state of a CD4+ T cell by staining for 
early (e.g. CD25, also known as IL-2Rα), and CD69 [117] and late (e.g. CD44/CD62L 
[118]) activation markers. Furthermore, activated CD4+ T cells are expected to blast, 
proliferate and produce cytokines, typically IL-2, in a CD28 dependent manner as 
described in previous sections. 
When activated in the presence of different cytokines, as it is typically the case in 
different types of infection, CD4+ T cells differentiate into different T Helper (TH) cell 
subsets. The decision to differentiate into a certain TH subset is mainly initiated by the 
surrounding of the CD4+ T cell: the antigen, the type of cell that presents it and also 
the presence of cytokines (that can be released provided by cells of the innate immune 
system as well) act in concert to drive a specific type of differentiation. However, after 
the initiation of the process there are multiple feedback mechanisms inside the cell 
that emphasize the signal, leading to commitment. Among them are epigenetic 
changes and locus availability [119, 120], which is of major importance also for NFAT 
activity (see section 3.1.5). This can also be simulated to some extent in vitro by the 
addition of cytokines and blocking antibodies during the activation process. The 
individual T follicular Helper (TFH), TH1, TH2, TH17, and regulatory T (Treg) cells are 
characterized by the expression of different subset specific hallmark TFs and cytokines 
(Figure 7).  
 
 
Figure 7. Classical view of T 
helper populations (Figure 







In this thesis, TFH and TH1 cells are of particular interest. TH1 cells are an important part 
of intracellular pathogen immunity, because they are able to activate macrophages 
[122] e.g. by the secretion of IFNγ. TH1 are defined by the expression of the hallmark 
TF Tbet [123], which actively suppresses TH2 fate and induces production of IFNγ. This 
phenomenon is restricted to CD4+ T cells: CD8+ T cells can produce IFNγ without Tbet 
expression [124]. Via signaling on STAT1, IFNγ activates the TF T-bet [125], which is 
also supported by STAT5 signaling coming from IL-2R. Tbet then promotes IFNγ 
production [123]. When TCR signaling stops, IL12Rβ2 is induced [126], so that IL-12 
can promote STAT4 signaling [127], which additionally promotes IFNγ and enhances 
STAT1 signaling. This illustrates how NFAT as a part of a positive feedback loop is 
essential for the differentiation of a TH cell subset, in this case TH1, but also in TH2 and 
TH17 similar synergistic action of sequential processes have been described [128].  
The interaction between TFH providing specialized help to B cells is essential for the 
formation of germinal centers (GC) [129]. These are histologically distinct structures 
within the B cell follicles of secondary lymphoid organs, and the main place where B 
cell affinity maturation and class switch recombination occur. TFH are characterized by 
the expression of their master regulatory factor Bcl-6 [130], and further characterized 
by the expression of CXCR5, programmed death 1 (PD-1), inducible T cell co-stimulator 
(ICOS) and IL-21 [131]. Bcl-6 represses Blimp-1 [132] and opposes the differentiation 
into other helper lineages [130], but it also modulates microRNA (miRNA) expression 
[133]. TFH are dependent on the global expression of miRNA (see section 3.2), which 
was shown in mice with CD4 intrinsic deficiency for DGCR8: the differentiation and 
function of TFH was severely reduced [134]. Even though more and more evidence 
accumulates of which signals are needed for Bcl-6 induction and TFH differentiation, 
i.e. IL-21 and IL-6 [131], TFH so far cannot be generated in vitro. However, there are 
well established viral models (like acute lymphocytic choriomengitis model virus 
(LCMV), Armstrong [135]) to address the differentiation of this T cell subset in vivo, 






3.1.8.1. The family of CD28 
The so-called receptor family of CD28 is grouped by their similar structure. All of the 
family members are expressed on lymphocytes and bind B-7 family ligands. Their role 
can be divided into activating and inhibitory molecules [136]. Expression of each of 
those molecules depends on context, activation state and cell type as well as on the 
presence of cytokines [137]. Moreover, the peptide affinity of the TCR complex to the 
antigen decides about the amount of co-stimulatory signals, which has led to some 
confounding results in different studies [137]. The net result of cell activation with co-
stimulation is finally a complex combination of overlapping and opposing signals, 
which will only be briefly described here. 
Cytotoxic T lymphocyte antigen 4 (CTLA-4) and PD-1 are typical examples for inhibitory 
receptors of the CD28 family. T cells from CTLA-4 deficient mice are hyper responsive 
to antigen [138, 139], and show increased TFH and GC B cell differentiation in a CD28 
dependent manner [140]. CTLA-4-Ig is a widely used tool to study co-stimulation: upon 
application of αCTLA-4 antibodies, TCR and TCR/CD28 triggered proliferation is 
inhibited [141] and T cell dependent antibody responses are strongly reduced [142].  
PD-1 binds its ligand PD-L1 [143], and signals via this pathway regulate initial 
activation, which represents an important aspect of immune regulation [144]. Mice 
that are deficient for this receptor develop lupus-like symptoms and splenomegaly 
[145]. On the other hand, expression of PD-1 is elevated in some cancer and chronic 
viral infections, which led to the development of the PD-1 immune checkpoint 
blockade therapy [146]. In this approach, PD-1 signaling is blocked in order promote 
immunity to cancer. Lately, it was shown that this therapy might depend on the 
activating signaling via CD28 [147, 148].  
ICOS and CD28 are activating receptors. The expression of ICOS is only induced via 
independent signaling pathways NFAT or MEK-ERK during CD4+ T cell activation [149], 
while CD28 is expressed on naïve as well as activated cells. Weber et al. showed that 
while ICOS is dispensable for early events in TFH differentiation like the upregulation 
of Bcl-6, it is essential for late GC reactions [150].  However, CD28 regulates key events 





the reduced GC response known from CD28 deficient mice is similarly seen in ICOS 
deficient patients [151].  
Overall, the family of CD28 receptors is very diverse, some of the function is redundant 
yet the expression of each receptor is timing- and context dependent. Moreover, 
receptors of opposing role can be competing for the same ligand: CD28 and CTLA-4 
both bind to the same receptors B7.1 and B7.2 (also called CD80 and CD86) [152], 
whereas CTLA-4 binds with a higher affinity. In this thesis, we will focus on CD28 in 
early CD4+ T cell activation. 
3.1.8.2. Structure and important motifs of CD28  
CD28 is expressed on naïve CD4+ T cells and binds to B7.1 (CD80) and B7.2 (CD86) 
which are expressed on APCs.  When CD28 is bound to its ligand, the cytoplasmic part 
is phosphorylated by Lck. Different motifs of the intracellular part have been described 
to be essential for different functions. Of note, since the structure of the intracellular 
part of CD28 is very similar to CTLA-4 and ICOS, some of the motifs are shared between 
these domains as illustrated in Figure 8.  
 
	
Figure 8. Motifs in the cytoplasmic tail of CD28 are partially shared with other family members (figure 
taken from [137]) 
 
The tyrosine residues in a YXN motif can recruit the adaptor protein Growth factor 
receptor-bound protein 2 (Grb2) via a non-ITAM motif YXXM. This is a shared motif 
between CD28, ICOS and CTLA-4, which acts as a consensus binding site for the p85 
subunit of PI3K. More specifically, in CD28 this motif is YMNM. The asparagine residue 
confers specificity for Grb2 and Gads (see section 3.1), which might account for 





The distal, proline-rich motif PXXP was shown to bind the SH3 domains of Lck and Itk. 
It is essential for the signaling leading to normal IL-2 secretion as well as for the 
downstream phosphorylation of key kinases like PDK1, GSK3β and PKCΘ. Mutation of 
this distal motif led to decreased proliferation and IL-2 production, while mutation of 
the proximal YMNM motif was phenotypically indifferent [154]. Actually, the 
importance of the YMNM motif is a matter of debate, since others reported inhibition 
of proliferation and IL-2 secretion [155] in the same mouse model. 
In humans, recurrent mutations in CD28 were reported for peripheral T cell 
lymphomas. Some of these mutations led to an increase of the affinity for CD86, GRB2 
and GADS/GRAP2 with consequently increased NFκB signaling in response to CD28 
stimulation [156]. 
3.1.8.3. The role of CD28 in CD4+ T cell differentiation 
Studies with CD28 deficient mice have been reported since 1993. In the first 
publication from Shahinian et al., CD28 deficient mice were shown to have normal 
numbers in B and T cells but reduced serum immunoglobulin (Ig) for the subclasses 
IgG1, IgG2b and a slight reduction in IgG3 [157]. In the meantime, many other and 
more specific cell subsets were investigated: CD28 was shown to be essential for the 
generation of TFH cells and GC B cells [158]. The dominant ligand for this differentiation 
to TFH is CD86 [140]. Apart from priming, maintained CD28 stimulation is also required 
for the differentiation and maintenance of TH1 as well as TFH cells during response to 
viral infection, and for the clearance of Citrobacter rodentium from the 
gastrointestinal tract [159]. 
As for TH2 differentiation, King et al. reported in 1996 that CD28 deficient mice 
generate reduced IL-4 and IL-5 production in a Schistosoma mansoni infection [160]. 
In their study, they concluded that early CD28 signaling during CD4+ T cell priming was 
required for the generation of a TH2 response. 
Treg cell populations are reduced in CD28 deficient mice in blood, spleen and lymph 
nodes. Moreover, naïve CD28ko CD4+ T cells show reduced de novo Treg differentiation 
potential in vivo and in vitro, which can be rescued by addition of exogenous IL-2 [161]. 
This might actually explain part of the Treg phenotype, because CD28 was shown to 





of IL-2, and on the other the activation of PI3K with subsequent nuclear localization of 
NFAT leads to more IL-2 transcription [162]. FoxP3creCD28fl/fl mice have normal 
populations of Tregs but show highly activated effector cells, leading to lethal 
autoimmunity as of 8-12 weeks of age. Addition of exogenous IL-2 could rescue for 
the proliferation defect of CD28 deficient Tregs in vitro, nevertheless these Tregs still 
showed competitive disadvantage in vivo and were less suppressive as compared to 
wild type (wt) cells [163]. Furthermore, it was shown that CD28 expression during Treg 
maturation is essential for the generation of CD44hiCD62Llo effector Tregs and the 
induction of CCR6 expression. The deficiency of CCR6 expression when CD28 was 
absent led to a defect in skin homing, which was partially responsible for skin 
inflammation in this mouse model [164]. 
The only subset in which CD28 co-stimulation was shown to have inhibitory effects 
was TH17 differentiation. Bouguermouh et al. reported that CD28 co-stimulation 
reduced TH17 polarization in comparison to αCD3 stimulus alone [165]. They then 
neutralized IL-2 and IFNγ with blocking antibodies and found that this restores IL-17A 
production even in the presence of CD28 co-stimulation, which might suggest that TH1 
response is favored by CD28 co-stimulation. 
In summary, CD28 co-stimulation contributes to the polarization of different TH 
subsets, however different mechanisms might come into play here and suggest a 
complex network of differentiation. 
3.1.8.4. CD28 and metabolism 
Naïve CD4+ T cells only show low activity of genes that are involved in glycolysis, 
glutaminolysis and lipid biosynthesis. They efficiently generate ATP via glycolysis, 
during which glucose is metabolized to pyruvate. However, since the metabolic need 
in naïve cells is quite low, they also only take up low amounts of glucose [166]. Upon 
activation, rapid transcriptional activation of genes is initiated and essential to meet 
the needs for cell growth and differentiation [167, 168]. For example, as soon as the 
T cell gets activated, glucose intake is greatly increased in CD28 dependent manner 
[37]. This is mainly regulated by glucose transporter 1 (GLUT1), whose expression is 
low in naïve but upregulated in activated T cells [169]. Increasing glucose uptake by 





as a limiting factor in activation [170].  The pyruvate that is generated via glycolysis is 
further metabolized in aerobic glycolysis, which leads to lactate production, or in 
oxidative phosphorylation. 
Activated and differentiated T cells can use various pathways for their energetic 
supply [171, 172] and metabolize glucose, fatty acids, glutamine or arginine [173]. The 
rewiring of metabolic pathways upon T cell activation is regulated by distinct pathways 
depending on the T cell subset. For example, activation of Akt (see section 3.1.3) leads 
to GLUT1 upregulation [169] and consequently more glucose uptake, while ERK 
activation increases glutamine uptake [174].  
Especially important for the initial reprogramming of metabolism in T cells are the TF 
c-Myc and mTORC1. mTORC1 maintains the high expression of c-Myc, which binds to 
promotors of glycolytic genes to induce gene expression [171, 175]. Another 
important TF is hypoxia induced factor 1 α (HIF1α). HIF1α drives TH17 differentiation 
and sustains elevated glycolysis [176] but prevents Treg generation [177]. Together 
with its β subunit, HIF1α binds hypoxia responsive element sequences and activates 
transcriptional programs that help the cell to adapt to lower oxygen availability. Upon 
CD28 co-stimulation, HIF1α protein is upregulated, presumably through PI3K and 







3.2. Gene regulation through microRNAs 
3.2.1. Posttranscriptional regulation and microRNAs 
A wide range of mechanisms have been established that may regulate the expression 
of a gene or protein. Regarding mechanisms involving RNA, we distinguish between 
transcriptional regulation (e.g. initiation of transcription), which refers to the 
regulation of the DNA to RNA transcription, and post-transcriptional regulation, which 
focuses on the regulation that acts directly on RNA. Posttranscriptional regulation 
includes all sorts of different mRNA modifications which lead to e.g. stabilization, 
storage or decay. In this thesis, we are especially interested in the effects of miRNAs.  
MiRNAs are usually 22nt in length and were shown to have essential roles in animals 
[181] as well as plants [182]. They can be encoded in a host gene but also in an intron 
[183], often in polycistronic miRNA “clusters”, so that multiple miRNAs are generated 
from one transcript [184]. However, this does not necessarily mean that all members 
of the same cluster are expressed to the same extent, since post-transcriptional 
mechanisms can introduce an additional regulation also for miRNAs [184, 185].  
A potentially important role for miRNAs was suggested by Blevins et al. in 2015: they 
reported that the absence of miRNA in lymphocytes led to more variation in protein 
expression within a population of cells [186]. In feed forward loops, the target gene 
(e.g. CD69) and the targeting miRNA (miR-17 and miR-20a) are expressed 
simultaneously, which reduces cell to cell variation. Additionally, single cell studies 
show that the effect of repression can actually be very striking [187]. Mukherji et al. 
suggested that miRNAs introduce a threshold of target mRNA expression [187], and 
at this threshold great sensitivity of regulation is reached. This means that miRNAs not 
only can fine-tune gene expression, but also act as switches if the target mRNA is 
expressed at threshold levels.  
3.2.2. MicroRNA biogenesis  
Transcription of the miRNA results in a long primary transcript (pri-miRNA) [188] 
which is capped and polyadenylated [189]. This primary transcript is processed in the 
nucleus by key enzymes Drosha and DGCR8 into 60-70nt pieces (pre-miRNA) [190], 





processed by an RNAseIII endonuclease called Dicer into double stranded RNA 
duplices: the miRNA and its antisense strand [191] (Figure 9).   
 
 
Figure 9. Canonical pathway of miRNA biogenesis (figure taken from [192]) 
 
The mature miRNA then forms an RNA induced silencing complex (RISC) with several 
proteins, for example Argonaute 2 (Ago2). RISC is guided by the miRNA to its targeting 
sequence. The major determining factor of this is the seed region of the miRNA: a 6-
8nt sequence at the 5’ end of the miRNA [182, 193].  Upon targeting of the mRNA, the 
protein expression is usually down regulated by mRNA decay or mRNA deadenylation 
[194-196]. Of note, one 3’ untranslated region (UTR) can be targeted by more than 
one miRNA, which is also supported by bioinformatics predictions [197], and vice 
versa one miRNA family can have hundreds of targets [198].  
Notably, mRNA targeting at the 3’UTR via Watson-Crick base pairing is some sort of a 
classical, straight-forward understanding of targets (canonical targets). Further 
targeting sites like the 5’ end [199] of an mRNA or even non-protein coding transcripts 
[200] were reported. Additionally, seed-matched base pairing as a pre-requisite for 
miRNA function was challenged by reports about G:U wobbles and bulges in the seed 
region, leading to inexact pairing but preserved function [201, 202]. This introduced 
“non-canonical” targets to the field, which do not harbor the seed sequence of the 
targeting miRNA. 
As for nomenclature, the field distinguishes between the same miRNA generated from 
different loci with numbering (e.g. miR-125b-1 and miR-125b-2). Moreover, we 
distinguish the sense and the antisense strand of the generated miRNA duplex, 
resulting in two miRNAs, a 5’ and a 3’ strand version (miR-17-5p and miR-17-3p). 
Importantly, which one finally is the more abundant (“guide” strand) and which one 





to be determined by thermodynamic stability and Ago preference. Usually, the guide 
with the less stable 5’ terminus is selected as the guide strand, but also Ago proteins 
prefer guides with a U as a starting nucleotide [204]. 
The miRNA biogenesis pathway described above explains the canonical pathway of 
miRNA biogenesis. Notably, also alternative mechanisms have been described, which 
are Dicer- or Drosha-independent [205, 206]. However, these non-canonical miRNAs 
only represent approximately 1% of the miRNAs and their functional relevance is 
unclear [203]. 
Posttranscriptional regulation by miRNAs was reported for approximately half of all 
protein-encoding genes [198]. It is of note that additional layers of regulation add even 
more complexity to the system: miRNA clusters are processed, resulting in differential 
expression for each cluster members [207, 208]. This suggests that actually miRNAs of 
the same cluster can play a role in different functions, at different time points, in 
different cell types, depending on their context. 
Interfering with the miRNA biogenesis pathway has severe impacts on the immune 
system, which is was shown in several mouse models: deletion of Dicer [209] or 
Drosha [210] in a CD4cre-system led to multiorgan inflammatory syndrome which was 
most likely due to dysfunctional Treg cells. Deletion of Dicer in immature thymocytes 
caused a severe reduction in double positive CD4+CD8+ and CD4+ or CD8+ single 
positive cells in the thymus as well as to a reduction in T cells in the periphery [209, 
211]. Muljo et al. showed that T cells deficient for Dicer are biased towards TH1 
differentiation [212] due to their failure to suppress IFNγ production. The deletion of 
Dicer additionally also led to a reduced Treg cell population, which then led to severe 
immunopathology [209] with splenomegaly, colitis and enlarged intestinal lymph 
nodes. When Dicer expression is ablated in Treg cells only, the mice develop a fatal 
systemic autoimmune disease due to loss of their suppressive capacity [213]. DGCR8 
deficiency in Treg cells also led to a scurfy-like phenotype and unstable Foxp3 
expression [214], supporting the concept that canonical miRNA expression is essential 






While there is an overall massive increase in RNA transcription upon T cell activation, 
miRNA expression is globally down regulated within 12h of activation [84].  Moreover, 
within two days post activation the majority of all miRNA is downregulated in murine 
as well as human primary CD4+ T cells. Further examination of key enzymes of the 
miRNA generation pathway showed that the expression of Ago2 was reduced, leading 
to a stop in miRNA processing [84]. One miRNA cluster breaking with this pattern is 
the expression of miR-17~92, which is induced during CD4+ T cell priming with CD28 
co-stimulation [140, 215, 216].  
3.2.3.1. miR-17~92 and its paralogues 
In mice, the miR-17~92 cluster, also known as oncomir-1 or chromosome 13 open 
reading frame 25 (C13orf25) [217], is encoded in the non-protein coding miR-17~92 
host gene (MIR17HG) on chromosome 14. Expression of miR-17~92 was shown from 
early developmental stages to adult cells in different kinds of tissue, in variable 
amounts [218, 219]. The cluster codes for six miRNAs (miR-17, miR-18a, miR-19a, miR-
20a, miR-19b, and miR-92) that can be grouped regarding their four seed families 
(miR-17 family, miR-18 family, miR-19 family and miR-92 family) as illustrated in Figure 
10.  
The cluster is highly conserved among vertebrates [184], and duplication events 
during evolution led to the development of two paralogue clusters miR-106a∼363 
cluster on the X and miR-106b∼25 cluster on the fifth chromosome, which also give 
rise to individual miRNAs that can be grouped to the same seed families, so that from 
miR-17~92 and its paralogs, 15 adult miRNAs are generated [220].  
 
 
Figure 10. miR-17~92, its paralogue clusters and grouping of seed families (figure taken from [218]) 
A) illustrates the three paralogue clusters while B) shows the grouping of the different miRNAs of each 





Germline knockout of miR-106a∼363 or miR-106b∼25 in mice was phenotypically 
indifferent while miR-17~92 knockout led to smaller size and perinatal lethality [218]. 
The combination of a knockout of miR-106b∼25 with a knockout of miR-17~92 led to 
an even more severe phenotype, which suggests that miR-17~92 can compensate for 
the loss of miR-106b∼25 and that homologous miRNA clusters that display similar 
expression patterns can be functionally redundant [221]. Furthermore, it was 
reported that there is functional cooperation between members of the miR-17~92 
cluster [222]. 
3.2.3.2. miR-17~92 as an oncogene 
The expression of miR-17~92 is known to be elevated in solid tumors and 
hematopoietic malignancies, e.g. in B cell lymphomas [217, 223]. Retroviral expression 
of miR-17~92 in a mouse B cell lymphoma model led to increased c-Myc expression 
and tumor formation [223]. Genetic ablation of the cluster in Myc-driven lymphomas 
reduces tumor cell growth [224]. This demonstrates the potential oncogenic role of 
miRNAs, especially miR-17~92, in vivo, which is also the reason why miR-17~92 is 
sometimes named oncomiR-1. Also vice versa, Myc induces miR-17~92 [225], and with 
this influences metabolism in Myc lymphoma cells [226]. In this publication, Izreig et 
al. show that miR-17 and miR-20 are especially important for this miR-17~92 
dependent reprogramming. miR-17 targets the tumor suppressor LKB1, which 
regulates metabolism and cell growth through mTOR signaling [226]. However, the 
authors also suggest that since the effects on metabolic reprogramming by miR-17~92 
are rather large, it might be that not individual metabolic genes but TFs are targeted 
by the miRNA cluster. 
3.2.3.3. Known miR-17~92 targets in CD4+ T cells 
With the increasing amount of literature on miR-17~92, many roles for the expression 
of miR-17~92 and its targets have been reported [227, 228]. The ENCODE 
(Encyclopedia of DNA Elements) project provided some information on transcriptional 
regulation: this study with 118 TFs revealed 34 that were connected to the miR-17~92 
cluster [229]. All E2Fs were shown to bind to the promoter region of miR-17~92,  but 
in turn they are as well known to be regulated by the cluster [230], which is a good 





Xiao et al. generated a mouse model in which miR-17~92 is artificially expressed in 
lymphocytes with hCD2-iCre [231]. This led to increased proliferation up to 
lymphoproliferative and autoimmune disease and premature death. In the same 
paper, the proapoptotic protein BIM (also known as Bcl-2-like protein 11, BCL2L11) 
and phosphatase and tensin homolog (PTEN) were suggested as targets of miR-17 and 
miR-19: limitation of the protein expression to one allele only led to a similar 
phenotype as in miR-17~92 overexpressing cells. 
Among the first targets to be validated was PTEN, a repressor of PI3K, which is a target 
of miR-19a and miR-19b-1 [218]. Buckler et al. even reported that the requirement for 
CD28 during T cell activation is caused by the negative regulation of TCR signals by 
PTEN [232], which might even suggest that the induction of miR-17~92 is required for 
proper T cell activation, e.g. in the suppression of PTEN.  
Jiang et al. examined the effect of miR-17~92 expression on TH1 differentiation [208]. 
They showed that decreased miR-17~92 expression reduced proliferation and survival 
in vitro, and vice versa for miR-17~92 overexpression. In TH1 differentiation, Tbet and 
IFNγ production were reduced in miR-17~92 knockout cells. As a mechanism, they 
showed that miR-19b targets PTEN while miR-17 targeted cAMP response element 
binding (CREB1) and transforming growth factor beta receptor II (TGFβRII), which 
facilitated effector T cell responses. Later, Wu et al. confirmed that the differentiation 
and expansion of TH1 cells is diminished in CD4+ T cells that are deficient for miR-17~92 
expression [208, 233], and further reported that the formation of memory CD4+ T cells 
after LCMV infection is reduced.  
TH2 differentiation is impaired in CD4cre.miR-17~92fl/fl, while it is increased in 
CD4cre.miR-17~92tg mice [234]. Simpson et al. showed that this was linked to miR-19a 
and miR-19b expression, and their targeting effect on the mRNA of SOCS1, TNFAIP, 
and PTEN. 
The same pattern was reported for TH17 differentiation [235]. However, Zhu et al. 
could not confirm this finding: in their hands, miR-20b expression reduced TH17 
differentiation in vitro and also suppressed extracerbated experimental autoimmune 
encephalitis (EAE) progression in vivo [236]. Additionally, Montoya et al. showed that 
miR-18a acts as an inhibitor of TH17 differentiation by targeting SMAD4, HIF1α and 





targeted by other members of the cluster before – but in that case promoting 
differentiation and cytokine production. This suggests that the role of individual 
members of the same miRNA cluster is probably time and context dependent. 
Similar to TH17 differentiation, the reports regarding Treg cells and miR-17~92 
expression are controversial: Jiang et al. reported that artificial miR-17~92 expression 
prevents inducible Treg differentiation [208]. In contrast to this, de Kouchkovsky et al. 
found that Foxp3cre.miR1792fl/fl mice were not able to control EAE [215], antigen 
specific Tregs could not accumulate and also IL-10 production was reduced, which 
suggested that there is an important role for miR-17~92 in Tregs as well. Interestingly, 
two years after this publication Yang et al. reported that CD4cre.miR1792fl/fl as well as 
Foxp3cre.miR1792fl/fl mice were less susceptible to EAE [238]. Moreover, they found 
that Foxp3cre.miR1792fl/fl CD4 cells were more suppressive in vitro. In their 
experiments they validated EOS, a Foxp3 co-regulator, as a target gene of miR-17. EOS 
was reduced upon miR-17 induction, whereas the expression of Foxp3 was 
unchanged. They suggested that the differences of their data in comparison to the 
previous study might be explained by the fact that their Tregs were not deficient in IL-
10 production. Another explanation could be that two distinct Foxp3cre mouse 
models were used, which might explain differences in the knockout specificity. 
The differentiation of TFH and consequently GC B cells was shown to be dependent on 
miR-17~92 [134]. Baumjohann et al. confirmed in this publication the contribution of 
PTEN as a miR-17~92 target to TFH differentiation. However, they also showed that 
this gene could not be the only contributor to TFH differentiation in this context and 
additionally proposed RORα as a target gene. Limiting RORα to one allele only also led 
to a partial rescue in CD4cre.miR1792fl/fl cells, confirming that this gene was a target 
of miR-17~92 in TFH differentiation. PTEN is an inhibitor of PI3K, and PH Domain and 
Leucine Rich Repeat Protein Phosphatase 2 (PHLPP2, whose 3’UTR has one binding 
site for miR-17 and two for miR-92) acts on the same pathway by inactivating Akt. 
Using a mouse model in which miR-17~92 as well as paralogue clusters were knocked 
out, Kang et al. showed that knockdown of PHLPP2 partially rescued the effect of miR-
17~92 (and paralogues) knockout in TFH differentiation [216]. After differentiation into 
TFH, the expression of miR-17~92 was reported to decline [216], probably due to Bcl-





Lastly, it was shown in a murine chronic graft-versus-host-disease (cGVHD) model that 
miR-17~92 expression in donor T and B cells is essential for the induction of 
scleroderma and bronchiolitis obliterans [239]. miR-17~92 enhanced the 
differentiation of pathogenic TH1 and TH17 cells as well as TFH and GC B cells, which 
are required for the generation of autoantibody production. The systemic application 
of anti-miR-17 in a lupus-like cGVHD model led to a milder phenotype of disease, with 
reduced skin damage and TH17 differentiation. 
These partially contrasting studies from the literature exemplify the complexity of 
regulation with miRNAs. It is therefore difficult to pinpoint “the one and only” role of 
miR-17~92 in CD4+ T cells. So far, we can conclude from existing studies that miR-
17~92 promotes proliferation and survival, and to some extent differentiation as well 
as cytokine production of distinct TH subsets. However, it also becomes increasingly 
clear that single targets alone cannot explain for the large number of effects that were 
reported [240] and that instead, the understanding of the cooperation of different 
miRNAs targeting different genes at the same time might lead to a global 
understanding. One example for this is the cooperation of different miR-17~92 
members in the regulation of TGFβ signaling, with miR-17 targeting TGFβRII and 
others targeting downstream signaling molecules SMAD2 and SMAD4 [184, 227]. In 
this case, cluster members can be functionally redundant, but also act synergistically 
[184].  
3.2.3.4. miR-17~92 in human  
In humans, the miR-17~92 host gene is located at chromosome 13q31, with the 
transcript spanning 800bp. This genomic region is also often amplified in solid cancer 
and lymphomas, and the mature miRNAs are expressed in high amounts. Especially, 
significant overexpression of pri-mir1792 was reported in a study where 46 lymphoma 
samples were examined [223]. Germline deletion of miR-17~92 in humans is only 
reported in heterozygous manner, resulting in developmental defects reported in 
patients with Feingold syndrome [241]. Next to skeletal abnormalities, these patients 
also can show microcephaly as well as learning and developmental disabilities [227]. 
Moreover, also for human CD4+ T cells the miR-17~92 was shown to be important: 





phenotype by suppression of negative regulators of TH2 cytokines like PTEN, SOCS1, 
and A20 [234]. Moreover, miR-92a was shown to control the frequency of TFH 
precursors in type 1 diabetes islet autoimmunity by targeting FOXO1, PTEN and KLF2. 
In a humanized mouse model, miRNA-92a antagomir application ameliorated the 








4. Aim of the project and Hypotheses 
Before this thesis project was started, it was known that CD4cre.miR-17~92fl/fl 
knockout mice show a phenotype which resembles CD28ko mice, and transgenic 
expression of miR-17~92 in CD4+ T cells led to a more activated phenotype. This led to 
the hypothesis that miR-17~92 might promote CD4+ T cell activation. Moreover, since 
miR-17~92 expression was known to be induced with CD28 co-stimulation, we 
suggested that exogenous expression of miR-17~92 might compensate for CD28 
signaling during CD4+ T cell activation. If this was the case, processes which are 
dependent on CD4+ T cell activation, e.g. proliferation and differentiation, might be 
rescued as well. Mechanistically, miR-17~92 target genes should be repressed in 
overexpressing cells and increased if miR-17~92 expression was absent. Based on 
these hypotheses, we defined three main aims in this project: 
 
Aim 1: Correlate miR-17~92 expression with CD4+ T cell activation 
In this first part of the project, we asked: 
1) Is miR-17~92 expression correlating with CD4+ T cell activation? 
2) Does miR-17~92 promote a metabolic checkpoint which influences activation? 
 
Aim 2: Investigate if transgenic miR-17~92 expression rescues CD28 deficiency in 
CD4+ T cells 
The following questions were asked to specifically address this aim: 
3) Can we rescue CD4+ T cell activation of CD28ko cells in vitro, e.g. IL-2 
production, proliferation, and surface activation markers? 
4) Can we rescue more complex processes like CD4+ T cell differentiation in vitro? 
5) Does transgenic miR-17~92 expression rescue CD28ko CD4+ T cells in vivo, e.g. 
during LCMV response in the differentiation into TH1 and TFH? 
 
Aim 3: Identify miR-17~92 targets that explain for influences on CD4+ T cell activation 
In this part of the thesis, we wanted to address the molecular mechanism behind the 
rescue with the following questions: 
6) Which are bona fide canonical miR-17~92 target genes in our specific system? 
7) Is the CD28ko transcriptome rescued by transgenic miR-17~92 expression? 
8) How does miR-17~92 promote CD4+ T cell activation? 
9) Can we exploit the activating effect of miR-17~92 therapeutically? 
  




5. Mouse models and Methods 
5.1. Mice 
5.1.1. B6.CD4cre.miR-17~92lox 
In this mouse model, the miR-17~92 cluster (Mir17, Mir18, Mir19a, Mir20a, Mir19b-
1, Mir92-1) is flanked by loxP sites [218]. When crossing the mouse to CD4cre mice 
[243], the locus is excised in all cells that do or did express CD4 (B6.CD4cre.miR-
17~92lox, in the following abbreviated: miR1792lox). These mice were shown to have 
a defect in TFH differentiation during LCMV infection. In addition, CD4+ T cells are 
known to be less proliferative. 
5.1.2. B6.CD4cre.Rosa26loxSTOPloxCAG-miR-17~92Tg 
For these mice, the human miR-17~92 locus was cloned into the Rosa26 locus as a 
transgene, preceded by a floxed stop cassette [231]. Upon crossing to CD4cre mice 
[243] the stop cassette is excised and all cells do or did express CD4 start to artificially 
overexpress the human miR-17~92 cluster (B6.CD4cre.Rosa26loxSTOPloxCAG-miR-
17~92, in the following abbreviated: miR1792tg).  Transgenic overexpression of miR-
17~92 was reported to induce lymphoproliferative disease and splenomegaly in 
ageing mice. 
5.1.3. B6.CD4cre.Rosa26loxSTOPloxCAG-miR-17-92Tg.Cd28ko(SMARTA) 
We crossed CD28ko mice [157] to the B6.CD4cre.Rosa26loxSTOPloxCAG-miR-17~92 
mice. In the CD28ko mice, part of Exon 2 of the receptor was replaced by a neomycin 
resistance cassette so that there is very little remaining CD28 expression in all cells. 
The resulting strain was for some experiments additionally crossed to the SMARTA 
line, which expresses an MHC II restricted transgenic TCR that is specific for LCMV-
glycoprotein (GP) [244].  
  






Toes were clipped at day 10 and digested in tail lysis buffer with proteinase K for at 
least 3h at 55°C shaking at 600rpm. Remaining debris were pelleted and discarded, 
DNA was then precipitated with isopropanol (1:1 ratio) and spun down. The pellet was 
washed with 70% Ethanol and resuspend in dH2O. Most genotypings were performed 
according to the protocols indicated at the vendors webpage. As for SMARTA 
genotyping, in addition to the PCR blood was taken at the time of organ harvest for 
the experiments and mixed with Heparin. Erythrocytes were then lysed with ACK lysis 
buffer for 2min. Remaining lymphocytes were washed with FACS buffer and stained 
for CD3, CD4, Vα2 and Vβ8.3. 
5.2.2. Organ and blood isolation 
Organs were obtained after CO2 euthanization and kept on ice during processing. 
Mesenteric lymph nodes (LN), inguinal LN, axillary LN, brachial LN, six cervical LN and 
spleen were taken for most of the experiments. Spleens were injected with 0.5ml ACK 
lysis buffer for erythrolysis before processing. The organs were meshed with 0.4µm 
filters to obtain single cell suspensions which were then washed with FACS buffer.  
5.2.3. Naïve CD4+ T cell isolation 
Naïve CD4+ T cells were isolated from cell suspensions with pooled lymph nodes and 
spleen. Isolation was performed with StemCell mouse naïve CD4+ T cell isolation kit 
according to manufacturer’s instructions. In brief, the cell suspensions were incubated 
with rat serum and CD4 isolation antibody for 7.5 minutes, then with memory 
depletion antibody for 2.5 minutes, and in the end with magnetic beads for another 
2.5min before incubating with the isolation magnet for 2.5min. The resulting 
untouched naïve CD4+ T cells were then washed with FACS buffer, and purity was 
routinely checked with a staining for CD4, CD44 and viability. 
5.2.4. Plate-bound CD4+ T cell activation 
Plates were coated over night with 0.2µg αCD28 and 0.5µg αCD3 per ml PBS for most 
of the experiments (low stimulation as according to [134]). Plates were washed with 




PBS before plating 2*105 naïve CD4+ T cells per well in 96 well flat-bottom in 200µl 
medium. For 24 well plates, 2*106 naïve CD4+ T cells per ml medium were plated. 
5.2.5. In vitro differentiation 
TH1 differentiation conditions were generated with 50U IL-2, 5ng/ml IL-12 and 
10µg/ml αIL-4 per ml T cell medium [245]. iTregs were either differentiated with or 
without retinoic acid (0.9mM), but always with 250U IL-2, 0.75ng/ml TGFβ, 10µg/ml 
αIFNγ and 10µg/ml αIL-4 [246]. TH17 were generated with 50ng/ml IL-6, 3ng/ml TGFβ, 
5µg/ml αIFNγ and 10µg/ml αIL-4 per ml T cell medium [247]. For the differentiation, 
2*105 naïve CD4+ T cells were plated on a pre-coated 96-well flat bottom plate (coated 
over night with 0.2µg αCD28, 0.5µg αCD3 per ml PBS) and harvested at 24h, 48h or 
72h after plating. 
5.2.6. Seahorse 
This protocol was adapted from our collaborators from the Hess laboratory at the 
Department of Biomedicine, Basel. Calibration plates were coated over night with 
200µl calibrant. Cell plates were coated with 18µl 0.1M NaHCO3 pH8.0 6.67% CellTak 
(Seahorse XF96 flux pack, Bucher Biotech, CH). The following day, cell plates were 
washed with H2O and left for drying during cell preparation. Compounds were 
prepared for a final in-well concentration of 1µM for Oligomycin, 2µM for FCCP and 
11µM for Rotenone. CD4+ T cells (naïve or activated) were harvested with glucose-
free, unbuffered RPMI, washed and counted multiple times before plating 3*105 cells 
per well. Mitochondrial perturbation was performed by sequential injection of glucose 
(80mM stock), oligomycin, FCCP and rotenone. Measurements of oxygen 
consumption rate (OCR, pMoles/min) and extracellular acidification rate (ECAR; 
mpH/min) were performed with a Seahorse XF96 flux analyzer (Seahorse Bioscience, 
USA). Data analysis was performed using Prism (Version7.0d), mitochondrial 
parameters were calculated as described by Gubser et al.[248]. 
5.2.7. FACS Staining 
For cytokine stainings after in vitro differentiation or ex vivo e.g. for IL-2 staining, cells 
were stimulated with 50ng/ml PMA, 500ng/ml Ionomycin and 10 µg/ml Brefeldin A 
(BFA) for 3h at 37°C before staining. Cells were then first stained for viability with 




viability dye 780 in PBS for 20min at 4°C and then washed with PBS. Non-specific 
binding was blocked with αCD16/αCD32 0.5mg/ml on ice for 10min. Surface stainings 
were performed in FACS buffer for 20-30min at 4°C. Cell fixation was performed with 
Fix-Perm for 20min on 4°C (1h for LCMV experiments). Intracellular staining was done 
in permeabilization buffer for 1h at 4°C. 
Data was acquired with an LSR Fortessa (BD) and analyzed with FlowJo (version 10.4.1) 
5.2.8. Proliferation assay with cell trace violet (CTV) 
Freshly isolated naïve CD4+ T cells were washed with PBS. 1µl of Cell Trace stock 
solution (dissolved in DMSO according to the manufacturer’s instructions) was then 
used per ml PBS for 10*106 cells. Cells were incubated at 37°C for 20min, then 5x the 
original staining volume of normal T cell culture medium was added for 5min to 
remove residual dye. Cells were washed and plated in complete culture medium 
supplied with 50U IL-2 per ml. 
5.2.9. RNA extraction for qPCR 
For any experiment involving RNA, cells were washed with PBS before counting and 
the RNA was kept on ice during the experiments, storage at -80°C. All pipetting was 
performed with filter-tips and RNAse-free tubes. 
5*105 cells were washed resuspend in 400µl TRIreagent. RNA isolation was then 
performed according to the isolation protocol from TRIreagent supplier (SIGMA). In 
brief, 0.1ml of 1-bromo-3-chloropropane per ml of TRI Reagent was added, samples 
were mixed by vigorous shaking, incubated for 15min at room temperature and then 
centrifuged at 12’000g for 15min at 4°C for phase separation. The aqueous phase was 
then mixed with 0.5 ml of isopropanol per ml of TRI Reagent used, again centrifuged 
for 10min for RNA precipitation. RNA was then washed with 70% Ethanol and finally 
resuspend in RNAse-free water. RNA concentration and purity was determined with a 
Nanodrop2000 Spectrophotometer (ThermoScientific). 
5.2.10. RNA extraction for RNA sequencing, protein extraction 
and digestion for proteomics 
All procedures for the extractions were performed at the facilities with materials, 
protocols and supervision of the facility experts.  




For RNA sequencing, 2.5*105 cells were washed with PBS and resuspend in 200µl TRI 
Reagent. RNA was extracted from Trizol-samples in the RNA sequencing facility at the 
Biozentrum Basel with a Zymo Direct-zol kit which includes DNAse treatment. Quality 
control was run with a Bioanalyzer. 
For targeted proteomics, 2.5*105 cells were washed with PBS and pellets were frozen 
on dry ice. Proteins were extracted at the proteomics facility at the Biozentrum Basel 
and digested for mass spectrometry with Lys-C and Trypsin. Samples were spiked with 
heavy labeled synthetic peptides of our RCAN3 target protein for measurement. 
5.2.11. RNA sequencing data analysis 
Data analysis for the RNA sequencing data was performed by Julien Roux from the 
Swiss Institute of bioinformatics, Department of Biomedicine, Basel. He describes his 
procedure as the following: 
“RNA quality was assessed with a Fragment Analyzer (Advanced Analytical) and RNA-
seq library preparation (Illumina Truseq stranded kit) was performed at the Genomics 
Facility Basel of the ETH Zurich. Sequencing was performed on an Illumina NexSeq 500 
machine to produce single-end 76-mers reads. Read quality was assessed with the 
FastQC tool (version 0.11.5).  
Reads were mapped to the mouse genome (UCSC version mm10) with STAR (version 
2.5.2a) [249] with default parameters, except filtering out reads mapping to more than 
10 genomic locations (outFilterMultimapNmax=10), reporting only one hit in the final 
alignment for multimappers (outSAMmultNmax=1) and filtering reads without 
evidence in the spliced junction table (outFilterType="BySJout").  
All subsequent gene expression data analysis was performed using the R software 
(version 3.5). Read alignment quality was evaluated using the qQCReport function of 
the R Bioconductor package QuasR (version 1.18). Gene expression was quantified 
using the qCount function of QuasR [250] as the number of reads (5'ends) overlapping 
with the exons of each gene assuming an exon union model (using the UCSC 
knownGenes annotation downloaded on 2015-12-18). To quantify intronic expression 
levels, exonic coordinates were extended by 10 bp on each side of the exons, and for 
each gene the resulting read count was subtracted to the read count obtained on the 
whole gene (extended by 10 bp on each side). 




The R Bioconductor package edgeR (version 3.24.3)[251] was used for differential gene 
expression analysis. Between samples normalization was done using the TMM method 
[252]. Only genes with CPM (counts per million reads mapped) values more than 1 in 
at least 4 samples (the number of biological replicates) were retained. An generalized 
linear model including a genotype effect, an activation effect, and a replicate effect 
(nested within genotype) was fitted to the raw counts (function glmFit), and 
differential expression was tested using likelihood ratio tests (function glmLRT). P-
values were adjusted by controlling the false-discovery rate (Benjamini-Hochberg 
method) and genes with a FDR lower than 1% were considered differentially expressed.  
Gene set enrichment analysis was performed with the function camera [253] from the 
edgeR package (using the default parameter value of 0.01 for the correlations of genes 
within gene sets) using gene sets from the curated gene set collection of the Molecular 
Signature Database (MSigDB v6.0)[254] with special focus on KEGG [255], Biocarta 
and Reactome [256] gene sets. We considered only sets containing more than 10 genes 
and gene sets with a false discovery rate lower than 5% were considered significant.” 
5.2.12. Reverse transcription (RT) and quantitative PCR (qPCR) 
Reverse transcription was performed with RNA extracted with TRIzol and the SIGMA 
MMLV kit on 1µg RNA according to the manufacturer’s instructions. qPCR was run 
with TaqMan FAST Universal PCR master mix on an Applied Biosystems® Real-Time 
PCR System. 18S was used as a reference gene. 
5.2.13. Glucose uptake staining with 2-NBDG 
2*105 naïve CD4+ T cells were washed with complete T cell medium and then 
incubated with complete T cell culture medium plus 50µM 2-NBDG for 30min at 37°c. 
5X the original staining volume of complete T cell culture medium was then added for 
5min to remove residual dye. Cells were washed again with PBS and stained for 
viability and surface markers before FACS analysis. 
5.2.14. Cell preparation for metabolomics 
5*106 CD4+ T cells were washed with PBS and centrifuged several times with 
decreasing the volume, so that the cell pellet could be frozen. The pellets were then 




shipped on dry ice to the NIH West Coast Metabolomics center for further processing 
and metabolomic analysis. 
5.2.15. GC-MS data 
Detailed information on the procedure with frozen cell pellets performed by the 
Metabolomics Central Service Core facility at the University of California Davis 
Genome Center can be found in their protocol provided in the Appendix (see section 
13.2). Data analysis for the metabolomic data was performed by Julien Roux from the 
Swiss Institute of bioinformatics, Department of Biomedicine, Basel. He describes his 
procedure as the following: 
“Raw data (unnormalized peak heights) were obtained from the West Coast 
Metabolomics Center (University of California, Davis). Normalization and differential 
metabolite abundance was performed similarly to the RNA-seq differential expression 
analysis, but instead of edgeR, the Bioconductor package limma (function eBayes with 
options trend=TRUE and robust=TRUE)[257] was used on the log-transformed peak 
heights divided by the sum of peak heights for each sample (analogous to counts-per-
million values for RNA-seq analyses).” 
5.2.16. Enzyme-linked immunosorbent assay (ELISA) 
IL-2 ELISA was performed with the BioLegend ELISA MAX mouse IL-2 set according to 
the manufacturer’s instructions. After the last washing step, TMB substrate was added 
for the readout. Absorbance was measured with an ELISA plate reader (Synergy H1 
Hybrid Reader, BioTek) at 450nm as well as 570nm wavelength, and normalized to 
wild type controls.  
5.2.17. LCMV Armstrong infection model 
Mice were infected with 2*105 PFU LCMV-Armstrong strain intra peritoneally with U-
100 insulin syringes (0.30mm (30G) x 8mm). LCMV-Armstrong was a gift from Annaïse 
Jauch, Recher laboratory. Eight days post infection, the animals were euthanized with 
CO2 and the spleens were harvested for staining (for gating strategy, see Appendix, 
Figure 40). Restimulation of splenocytes was performed in flat bottom 96 well plates 
with 1µg/ml LCMV-specific peptide GP-64 in comparison to polyclonal 50ng/ml PMA, 




500ng/ml Ionomycin stimulation for one hour, then 10µg/ml Brefeldin A was added 
for another three hours before staining. 
5.2.18. Histology 
Spleens were embedded in cryo embedding medium and frozen on dry ice before 
storage at -80°C. Sections were cut at a thickness of 6µm and dried on air. Single 
sections were then fixed with acetone for 5min and circled with PAP pen. Staining for 
CD19, CD4 and GL-7 was performed in FACS buffer with αCD16/CD32 in a wet chamber 
overnight. Slides were then washed with PBS on a shaker for 15min before drying and 
mounting. Imaging was performed with a 20x objective on a Nikon Ti2 microscope. 
5.2.19. Adoptive transfer with subsequent LCMV infection 
Naïve SMARTA+ CD4+ T cells from wt, CD28ko and rescue mice were isolated 
transferred into CD28ko recipients. Each recipient received 1*105 cells in 100µl PBS 
i.v.. The recipients were infected with 2*105 PFU LCMV Armstrong i.p. two days after 
cell transfer. Eight days after infection, the mesenteric and peripheral LN as well as 
the spleen were analyzed separately for the presence of Vα2+Vβ8.3+ T cells as well as 
CD44 expression (for gating strategy, see Appendix, Figure 41). One CD28ko mouse 
that did not receive donor cells was used as a negative control to display the recipient-
intrinsic Vα2+Vβ8.3+ population. 
5.2.20. CsA titration 
The sensitivity of CD28ko and rescue cells to compounds interfering with Ca2+ signaling 
was tested. Increasing amounts of CsA were added to the cultures during activation: 
2*105 naïve CD4+ T cells were plated in 100µl complete T cell medium in pre-coated 
96 well plates. 100µl of a serial dilution of CsA were then added to result in in-well 
concentrations of 100ng/ml, 50ng/ml, 25ng/ml, 12.5ng/ml, 6.5ng/ml, 3.125ng/ml, 
1.5625ng/ml or 0ng/ml. Cells were then activated in the presence of these CsA 
concentrations for 48h before harvesting and staining for viability and activation 
markers. 





Naïve CD4+ T cells were isolated and activated for 48h in the presence of 6.25ng/ml 
CsA as described before. They were then harvested and washed with PBS before 
fixation for 20min at 4°C. Intracellular staining for NFATc2 was performed in a two-
step staining with first 1h at room temperature (RT) with αNFATc2 in permeabilization 
buffer, and subsequently 1h at room temperature (RT) with goat anti-mouse IgG1 in 
permeabilization buffer. Nuclei were stained with DAPI in the last 5min of incubation. 
Acquisition was run on an ImageStreamX Mark2 Imaging flow cytometer (Amnis), and 
data analysis was performed with the IDEAS software (v6.2). 
5.2.22. Statistical analysis 
Statistical analysis was performed with GraphPad Prism (v7.0d, Graphpad Software). 
No Gaussian Distribution was assumed for any of the experiments, and tests were 
chosen individually depending on the type of experiment. The overall statistical 
significance was set to 5% (α=0.05), and error bars represent standard deviation (SD). 
We used Kruskal-Wallis tests for most of the experiments where more than two 
unpaired groups were compared in one parameter (e.g. %Fas+GL7+ population in three 
genotypes), followed by Dunn’s multiple comparison. We used two-way Anova for 
experiments in which samples were in different in two parameters (e.g. 
%CD44hiCD62lo population in three genotypes activated with or without αCD28), 
followed by Tukey’s multiple comparison. 
T-test was used for the analysis of targeted proteomics (each sample compared to wt) 







So far, most studies in murine lymphocytes that investigated the role of miR-17~92 in 
CD4+ T cells focused on either the comparison between miR-17~92 knockout to wt or 
miR-17~92 overexpression to wt. For example, Xiao et al. showed that elevated miR-
17~92 expression in lymphocytes results in lymphoproliferative and autoimmune 
phenotypes with increased proliferation and cytokine expression in CD4+ T cells [231]. 
This observation led us to our first hypothesis that miR-17~92 promotes T cell 
activation. However, like in most of the other studies on miR-17 B6.CD4cre.miR-
17~92lox 92 in lymphocytes, they did not do a side-by-side comparison of these two 
genotypes (see section 3.2.3.3). To directly compare the effect of lack or 
overexpression of miR-17~92  on the activation of CD4+ T cells we took advantage of 
previously published mouse models B6.CD4cre.miR-17~92lox (miR1792lox) and 
B6.CD4cre.Rosa26loxSTOPloxCAG-miR-17~92 (miR1792tg) [218, 231, 243] and used 
CD4cre negative littermates as wt controls. 
6.1. miR-17~92 expression promotes CD4+ T cell activation 
6.1.1. IL-2 production and proliferation is promoted by miR-17~92 
expression 
To test our hypothesis if miR-17~92 expression promotes T cell activation ex vivo, we 
followed previous literature [231] and investigated IL-2 production and proliferation 
in a side by side comparison in CD4+ T cells from miR1792lox, wt and miR1792tg mice.  
In order to determine intracellular IL-2 production, freshly isolated murine naïve CD4+ 
T cells were activated with PMA and ionomycin (iono) for three hours. Already at this 
very early time point we found an ~0.6-fold reduced production of IL-2 in miR1792lox 
cells in comparison to wt, whereas miR1792tg cells showed an ~1.7-fold increase in 
comparison to wt cells (Figure 11A). This pattern was also true for IL-2 secretion 
measured by ELISA from 48h culture supernatants (Figure 11B): miR1792lox cells 
secreted only half of the IL-2 that was secreted by wt cells while miR1792tg secreted  
~1.2-fold more. The proliferation capacity was slightly, but not significantly (probably 
due to small number of samples) reduced in miR1792lox as compared to wt, and 





of exogenous recombinant  IL-2, which is consistent with previous reports [134, 231].  
The direct comparison between miR1792lox and miR1792tg shows significantly more 
proliferation with increased miR-17~92 expression, which suggests that miR-17~92 
positively correlates with proliferation. From these results, we concluded that miR-
17~92 indeed promotes IL-2 production and proliferation in murine CD4+ T cells.  
 
 
Figure 11. miR-17~92 expression promotes IL-2 production and proliferation in CD4+ T cells.  
miR1792lox (grey), wt (black), miR1792tg (blue). Error bars show mean ±SD, Dunn’s multiple 
comparison test, p values: ns=not significant, *<0.05 **<0.002 ***<0.0002 ****<0.0001. A) IL-2 
intracellular staining in CD4+ T cells stimulated with PMA/Iono/BFA for 3h after isolation. Data 
represent four independent experiments with 3-4 biological replicates per group. B) IL-2 secretion 
measured by ELISA in supernatants of 48h cultured cells activated with plate-bound 0.2µg αCD28/ 
0.5µg αCD3 per ml PBS for coating. Data represent four independent experiments with 3-4 biological 
replicates per group. C) Proliferation of CD4+ T cells activated for 48h with αCD3/αCD28 stimulation 
and 50U IL-2 per ml T cell medium. Data represent two independent experiments. 
 
6.1.2. miR-17~92 and metabolism in CD4+ T cell activation 
Upon activation, CD4+ T cells are expected to undergo glycolytic switch [37] in a CD28-
dependent manner (see section 3.1.8.4). The TF Myc which controls metabolic 
reprogramming in T cells [171] was also shown to induce miR-17~92 expression [225]. 
Izreig et al. reported that miR-17~92 expression is essential for the metabolic 
reprogramming of Myc+ tumor cells [226], and others had previously shown that 
metabolic checkpoints can restrict differentiation of distinct T cell subsets [258]. We 
therefore hypothesized that miR-17~92 expression promotes CD4+ T cell activation by 
promoting one specific metabolic pathway, leading to the passage through such a 
checkpoint. We examined the metabolic profile of naïve CD4+ T cells by metabolic flux 
analysis and by performing a glucose uptake assay using 2-NBDG. Glycolytic 





OCR) activity of naïve CD4+ T cells, as determined by using a mitochondria stress test, 
appeared similar between genotypes (Figure 12A). There was, however, a marked 
difference in 2-NBDG uptake between all groups with miR1792tg T cells taking up 20% 
more 2-NBDG than wt cells (Figure 12B), whereas 2-NBDG uptake was proportionally 
lower in miR1792lox cells.  
 
 
Figure 12. miR-17~92 expression modifies glucose uptake but not mitochondrial activity in naïve CD4+ 
T cells.  
miR1792lox (grey), wt (black), miR1792tg (blue) A) Mitochondria stress test measured with a 96-well 
seahorse in naïve CD4+ T cells. Eight biological replicates from two experiments are shown. left: 
Extracellular acidification rate (ECAR), right: Oxygen consumption rate (OCR) B) Glucose-uptake 
measured with 2-NBDG. red: unstained control, median fluorescence intensity of the high uptake 
population is compared to wt. Data represent three independent experiments. Dunn’s multiple 
comparison test, p values: ns=not significant,  ****<0.0001  
 
Since our previous results indicated that miR-17~92 cluster influences the outcome of 
CD4+ T cell activation, we also performed metabolic flux analysis on activated CD4+ T 
cells from all three genotypes. Activated CD4+ T cells that were deficient in miR-17~92 
expression displayed slightly lower glycolytic rates than wt and miR1792tg T cells 
(Figure 13A) as well as lower basal and ATP coupled respiration (Figure 13B). These 
findings indicate that the miR-17~92 cluster might be involved in the regulation of 









Figure 13. miR-17~92 expression modifies mitochondrial activity in activated CD4+ T cells. 
A) Mitochondria stress test measured with a 96-well seahorse in 48h activated CD4+ T cells. 3-8 
biological replicates from four experiments are shown. Tukey’s multiple comparison test, p values: 
*<0.0332 C) left: Extracellular acidification rate (ECAR), right: Oxygen consumption rate (OCR) B) Basal 
respiration (after glucose- but before oligomycin addition [248]) and ATP coupled respiration (before-
after oligomycin addition [248]) 
 
To further evaluate the metabolic profile of these cells and elucidate which pathways 
are influenced by miR-17~92 expression, we performed mass spectrometry-based 
global metabolomic analysis on activated T cell lysates. Principal component analysis 
(PCA) showed small differences in the metabolome between all three genotypes 
(Figure 14).  
 
 
Figure 14. miR-17~92 expression introduces small differences in the metabolome of activated CD4+ T 
cells. 
CD4+ T cells were activated for 48h with plate-bound αCD3 and αCD28 before harvest as described in 
the Methods section. miR1792lox (grey), wt (black), miR1792tg (blue)  
 
However, direct comparison of miR1792lox and miR1792tg cells revealed only eight 
metabolites that were differentially abundant (minimum 2-fold change (FC), p 
value<0.01, logFC>1 indicates higher abundance in miR1792tg) (Table 1). Intriguingly, 





metabolism. Lactic acid, which is the end-product of glycolysis, was also found to be 
less abundant in miR1792lox cells as compared to miR1792tg cells. This confirmed our 
seahorse data where miR1792lox cells showed slightly lower glycolytic rate. 
 
Table 1. List of differentially abundant metabolites in the comparison between miR1792tg and 
miR1792lox. 
metabolite logFC p-value associated pathway 
glutathione 1.8636 0.0004 cysteine  
taurine 1.1961 0.0065 cysteine  
lactic acid 1.1317 0.0047 glycolysis 
oleic acid -1.2940 0.0055 fatty acid 
lauric acid -1.3339 0.0012 fatty acid 
arachidonic acid -1.4744 0.0019 fatty acid 
inosine -1.6948 0.0009 purine 
guanosine -1.9344 6.70E-08 purine 
 
 
For further analysis of the metabolomic data set, we took advantage of an RNA 
sequencing data set that we generated for the same project but will be analyzed in 
more detail later (see section 6.3.1). Here, we focused on samples of 48h activated 
CD4+ T cells from miR1792lox, wt and miR1792tg mice of which we isolated total RNA 
for sequencing. We investigated the RNA sequencing data set for enzymes that are 
promoting the build-up or processing of the differentially abundant metabolites 
(Table 1) or metabolic pathways that are promoted. Direct target genes would be e.g. 
inhibitors of glycolysis, thereby possibly promoting activation of CD4+ T cells following 
modulation of miR-17~92 expression. However, even if single metabolism-associated 
genes were differentially expressed, the RNA sequencing data did not show any 
metabolic pathway that was globally impacted by modulation of miR-17~92 
expression. Moreover, changes in metabolite abundance were rather small. With this, 
we conclude that our data does not support the hypothesis that miR-17~92 expression 
promotes or represses one specific metabolic pathway during CD4+ T cell activation. 
Instead, since we do see a slightly increased glycolytic activity, our data suggests that 
miR-17~92 expression might affect metabolism indirectly, i.e. by promoting a “more 





6.2. Transgenic miR-17~92 expression rescues CD28 
deficiency  
From the data illustrated above, and from previous publications we concluded that 
miR-17~92 indeed promotes T cell activation. Moreover, it promotes the processes 
that are known to be strongly dependent on CD28 co-stimulation, and in turn loss of 
miR-17~92 expression phenocopies loss of CD28 signaling. This was true for IL-2 
production [162] and proliferation [259] but also more complex processes like TFH 
differentiation [134]. Additionally, Xiao et al. had shown that miR1792tg cells 
proliferated more than wt cells when they received αCD3 stimulus without αCD28 co-
stimulation [231]. This suggested that ectopic miR-17~92 expression does confer a co-
stimulatory signal. Based on these observations, we hypothesized that miR-17~92 is 
part of the CD28 signaling cascade, and contributes to the essential “signal 2”. To test 
this hypothesis, we created a new mouse model by crossing 
B6.CD4cre.Rosa26loxSTOPloxCAG-miR-17~92 to CD28ko [157], resulting in 
B6.CD4cre.Rosa26loxSTOPloxCAG-miR-17~92.CD28ko mice, called “rescue” in the 
following results. If our hypothesis holds true, we expect in this mouse model that the 
transgenic expression of miR-17~92 should (partially) compensate for loss of CD28 
signaling. We first analyzed mesenteric lymph nodes (LN), peripheral LN, thymus, 
spleen and Peyer’s patches of this new mouse model to determine the baseline 
phenotype of CD28ko and rescue in comparison to wt. We did not find any significant 
difference in organ size or CD4+ T cell numbers, neither between CD28ko and wt nor 
between CD28ko and rescue (data not shown), as it had been shown for CD28 
deficient mice by Shahinian et al. [157]. We furthermore stained for baseline 
populations of TFH and Tregs and also there did not find differences in CD28ko (and 
subsequent rescue). We therefore decided to isolate CD4+ T cells to specifically test 
CD4+ T cell activation in vitro. 
6.2.1. Transgenic miR-17~92 expression rescues CD28 deficiency in 
vitro 
We isolated naïve CD4+ T cells from wt, CD28ko and rescue mice to investigate IL-2 
and proliferation and see if the transgenic expression of miR-17~92 could compensate 





miR1792lox/wt/miR1792tg comparisons (see Figure 11A), we stimulated CD28ko, wt 
and rescue cells for three hours with PMA and iono. CD28ko CD4+ T cells produced 
half of the IL-2 amount that was measured in wt cells, while rescue cells produced 
~2.5-fold more than wt (Figure 15A). This suggested that transgenic miR-17~92 could 
not only compensate for CD28 signaling, the transgene even led to increased 
production of IL-2 in the absence of CD28. Moreover, the proliferation capacity of wt 
clearly depended on αCD28 co-stimulation (proliferation index of wt with αCD28 
1.51±0.13, without 1.28±0.07), which was expected from the literature [259], and 
CD28ko cells only proliferated at very basal levels (proliferation index of CD28ko with 
αCD28 1.17±0.07, without 1.16±0.08). However, the rescue cells proliferated like 
αCD3/αCD28 stimulated wt cells (Figure 15B) (proliferation index of rescue cells with 
αCD28 1.45±0.16, without 1.40±0.10), suggesting that transgenic miR-17~92 
expression can compensate for the signal given by CD28 also for proliferation. Of note, 
since the proliferation experiment was performed in the presence of exogenous IL-2, 
this effect was unlikely to be due to differential IL-2 production.  
 
 
Figure 15. Transgenic miR-17~92 expression rescues IL-2 production and proliferation of CD28 deficient 
CD4+ T cells in vitro. 
wt (black), CD28ko (purple), CD28ko with miR1792tg = rescue (dark blue). Data from three 
independent experiments with three to four biological replicates per group are shown. Error bars 
represent mean ±SD, statistical tests as indicated. A) Intracellular staining for IL-2 in viable CD4+ T cells 
after three hours PMA/Iono/BFA stimulation. Dunn’s multiple comparison test, p values: ns=not 
significant, *<0.05 ****<0.0001 B) Proliferation shown with CTV staining, gated on viable CD4+ T cells. 
Left side: representative histograms of each genotype activated with (white) or without (colored) 
αCD28. Right: proliferation indices. Naïve CD4+ T cells were stimulated for 48h with 0.5µg/ml plate-
bound αCD3 with (+) or without (-) 0.2µg /ml αCD28 Tukey’s multiple comparisons test, p values: 






We furthermore noticed that T cell blasting, another important hallmark of CD4+ T cell 
activation, was reduced in CD28ko cell culture (microscope observation), which led us 
to quantify cell size by FACS. After 48h activation with αCD28 co-stimulation, the size 
of cells, shown as FSC-A (Figure 16), was increased in αCD28/αCD3 stimulated wt cells 
in comparison to samples that were stimulated with αCD3 alone (median fluorescence 
intensity (MFI) FSC-A of wt with αCD28 161k±12k, without 144k±9k). CD28ko cells 
were significantly smaller (MFI FSC-A of CD28ko with αCD28 130k±15k, without 
126k±18k), and transgenic miR-17~92 expression rescued blasting of rescue cells to 
an extent that was comparable to αCD28/αCD3 stimulated wt cells (MFI FSC-A of 
rescue with αCD28 162k±11k, without 156k±16k). This indicated that also for the 
induction of blasting, transgenic miR-17~92 expression could compensate for the 
CD28 co-stimulatory signal. 
 
  
Figure 16. miR-17~92 or CD28 signaling is essential for blasting of CD4+ T cells during activation. 
Blasting of CD4+ T cells shown as MFI of FSC-A of the lymphocyte gate.  Naïve CD4+ T cells were 
stimulated for 48h with 0.5µg/ml plate-bound αCD3 with (+) or without (-) 0.2µg/ml αCD28 Error bars 
represent mean ±SD, Tukey’s multiple comparisons test, p values: ns=not significant, *<0.05, 
****<0.0001 
 
Since we saw a rescue effect in IL-2 production, proliferation and blasting, we 
hypothesized that miR-17~92 mediated increase of cell activation could be marked by 
increased expression of typical early- and late surface activation markers. We 
therefore activated wt, CD28ko and rescue cells for 48h and stained for early 
activation markers CD25 and CD69. CD25, the high affinity IL-2 receptor α subunit, is 
essential for proper T cell activation and IL-2 uptake [79, 260] and known to be CD28 
dependent. All genotypes and conditions developed similar percentages of 
CD69+CD25+ populations (Figure 17A). CD69 expression was not significantly changed 





is dependent on TCR signaling [117]. In contrast, the MFI of CD25 was strongly 
dependent on CD28 signaling (MFI CD25 of wt with αCD28 15.6k±2.7, without 
10.9k±2.7k; CD28ko with αCD28 7.5k±2.6k, without 6.9k±3k) and rescued to wt MFI 
by transgenic miR-17~92 expression (MFI CD25 of rescue with αCD28 16.3±2.3k, 
without 15.9k±2.6k).  
We additionally stained for “late” activation markers CD44/CD62L: while naïve cells 
show a CD44loCD62Lhi phenotype, activated cells are expected to express high CD44 
but low CD62L. αCD28/αCD3 stimulated wt cells showed a significant increase in their 
CD44hiCD62Llo population (%CD44hiCD62Llo of wt with αCD28 25.4±9.9%, without 
13.5±5.6%) as compared to αCD3 stimulation alone (Figure 17B), and CD28ko cells 
resembled αCD3 stimulated wt cells (%CD44hiCD62Llo of CD28ko with αCD28 
8.5±5.2%, without 9.2±5.5%). However, exogenous miR-17~92 expression led to even 
higher percentages of CD44hiCD62Llo populations (%CD44hiCD62Llo of rescue with 
αCD28 38.5±10.4%, without 36.3±8.9%) in rescue cells as compared to wt.  
 
 
Figure 17. miR-17~92 or CD28 signaling is essential for CD44 and CD25, but not for CD69 upregulation. 
Naïve CD4+ T cells were stimulated for 48h with 0.5µg/ml plate-bound αCD3 with (+) or without (-) 
0.2µg/ml αCD28. Tukey’s multiple comparisons test, p values: ns=not significant, **<0.002 
***<0.0002 ****<0.0001 A) representative dot plots of early activation markers CD25/CD69 
expression gated on viable CD4+ T cells, gate marks CD25+/CD69+ population. left diagram: percentage 
of CD25+/CD69+ population, middle: MFI of CD25 in the CD25+/CD69+ population, right: MFI of CD69 
in the CD25+/CD69+ population B) representative dot plots of CD44/CD62L expression gated on viable 





Collectively, these in vitro activation experiments demonstrate that exogenous miR-
17~92 expression can compensate for CD28 signaling in IL-2 production, proliferation, 
blasting and activation markers.  
6.2.2. Exogenous miR-17~92 expression compensates for CD28 
deficiency during in vitro differentiation 
The miR-17~92 cluster was reported to promote the differentiation of TH1 [208, 233], 
TH2 [234] and TH17 [235] cells, but inhibit iTreg generation [208]. Moreover, CD28 was 
shown to be important for the same differentiation processes. This led us to 
hypothesize that transgenic miR-17~92 expression might also compensate for CD28 
signaling during early differentiation. We therefore performed differentiation assays 
with wt, CD28ko, rescue and miR1792tg cells and analyzed the development of TH1, 
TH17 and iTreg subsets during very early time points of differentiation.  
When we investigated TH1 differentiation (Figure 18), we found that already at 24h 
after plating in TH1 skewing conditions, Tbet upregulation was induced in wt, but 
almost absent in CD28ko cells. Transgenic expression of miR-17~92 over compensated 
for Tbet induction in rescue cells, and miR1792tg cells showed similar percentages (wt 
13.0±8.4%, CD28ko 3.3±3.1%, rescue 21.2±8.8%, miR1792tg 25.9±5.0% at 24h). At 
48h, however, also CD28ko cells induced Tbet, even though not as efficiently as wt, 
while rescue and miR1792tg were still higher in Tbet expression as compared to wt 
(wt 60.0±26.3%, CD28ko 48.8±13.6%, rescue 71.3±14.2%, miR1792tg 77.5±18.1% at 
48h). Until 72h post differentiation induction, all genotypes expressed similar 
percentages of Tbet (wt 80.5±7.8%, CD28ko 74.5±4.4%, rescue 74.9±6.2%, miR1792tg 
78.3±3.4% at 72h) which suggested that Tbet induction is delayed in CD28ko cells, and 
rescued by transgenic miR-17~92 expression. IFNγ production was very low at 24h in 
all genotypes, however already at 48h post induction IFNγ production was induced in 
wt cells. This was almost absent in CD28ko, and over compensated in rescue cells 
while miR1792tg cells expressed the most IFNγ (wt 5.1±5.7%, CD28ko 1.2±1.5%, 
rescue 23.4±10.9%, miR1792tg 35.5±12.9% at 48h). In contrast to Tbet induction, 
CD28ko cells were not able to reach wt IFNγ induction at 72h, while rescue and 
miR1792tg continued to express more IFNγ as compared to wt cells (wt 12.7±4.3%, 





concluded that miR-17~92 promotes different aspects of TH1 differentiation, which 
confirms published data [208]. Importantly, the same processes are regulated by CD28 
expression as well. Consequently, exogenous miR-17~92 expression rescued of 
delayed Tbet expression as well as IFNγ production in CD28ko cells. 
 
 
Figure 18. Transgenic miR-17~92 expression over compensates for CD28 signaling during in vitro TH1 
differentiation.  
Naïve CD4+ T cells were activated for 24h, 48h, and 72h with plate-bound antibodies (0.2µg/ml αCD28  
0.5µg/ml αCD3) in the presence of skewing conditions for the generation of TH1 (50U IL-2, 5ng/ml IL12 
and 10µg/ml αIL4 per ml T cell medium). wt (black, left), CD28ko (purple, second from left), rescue 
(dark blue, second from right) and miR1792tg (light blue, right). Data from two independent 
experiments are shown, with representative FACS plots of each timepoint and genotype. Error bars 
show mean ±SD, no statistical analysis was performed due to large variation. TH1 differentiation was 
stained with IFNγ and Tbet in viable CD4+ T cells, Tbet+ cells include both gates while Tbet+IFNγ+ are 
shown in the right gate only 
 
Next, we investigated TH17 differentiation (Figure 19). In contrast to TH1 
differentiation, induction of lineage-defining TF Rorγt induction was reduced in 
CD28ko but only partially rescued by exogenous miR-17~92 expression at 24h. 
Moreover, miR1792tg cells phenocopied CD28ko cells (wt 45.6±9.7%, CD28ko 
32.7±4.4%, rescue 38.9±6.6%, miR1792tg 31.9±8.1% at 24h). Interestingly, Rorγt 
induction of CD28ko cells was reduced also in following time points, and partially 
rescued at 48h. In addition, the miR1792tg cells resembled wt cells in their Rorγt 
induction (wt 80.7±7.8%, CD28ko 31.1±8.9%, rescue 51.8±10.0%, miR1792tg 





CD28ko cells in comparison to wt and miR1792tg, but fully rescued by transgenic miR-
17~92 expression (wt 69.3±14.0%, CD28ko 41.4±8.7%, rescue 67.8±14.6%, miR1792tg 
76.7±12.5% at 72h). Similar to TH1 differentiation, cytokine production only started at 
48h. Wt produced IL-17A, while CD28ko cells were deficient and only partially rescued 
by transgenic miR-17~92 expression while miR1792tg cells phenocopied rescue cells 
(wt 9.9±3.8%, CD28ko 2.0±0.6%, rescue 5.4±1.0%, miR1792tg 5.4±0.8% at 48h). All 
genotypes produced IL-17A at 72h, however CD28ko cells still produced less IL-17A in 
comparison to wt, which was only partially rescued by transgenic miR-17~92 
expression. Interestingly, miR1792tg cells resembled wt cells (wt 14.3±3.7%, CD28ko 
5.9±2.8%, rescue 8.7±2.3%, miR1792tg 12.9±1.0% at 72h). We therefore concluded 
that for in vitro TH17 differentiation, exogenous miR-17~92 expression can only 
partially compensate for CD28 signaling. Intriguingly, in this T cell subset the timing  
 
Figure 19. Transgenic miR-17~92 expression can partially compensate for CD28 signal during in vitro 
TH17 differentiation.  
Naïve CD4+ T cells were activated for 24h, 48h, and 72h with plate-bound antibodies (0.2µg/ml αCD28  
0.5µg/ml αCD3) in the presence of skewing conditions for the generation TH17 (50ng/ml IL6, 3ng/ml 
TGFβ, 5µg/ml αIFNγ and 10µg/ml αIL4 per ml T cell medium).  wt (black, left), CD28ko (purple, second 
from left), rescue (dark blue, second from right) and miR1792tg (light blue, right).  Data from two 
independent experiments are shown, with representative FACS plots of each timepoint and genotype. 
Error bars show mean ±SD, Tukey’s multiple comparison, p values: ns, not significant, *<0.005, 
**<0.002, ***<0.001, ****<0.0001. TH17 were stained for IL-17A and Rorγt in viable CD4+ T cells, 






seems to be very relevant for the role of the cluster. Our experiments confirm 
published data that miR-17~92 overexpression prevents TH17 differentiation [237] in  
early stage of in vitro differentiation, however in our setting at later time points the 
inhibitory effect is lost.  
Finally, we performed iTreg differentiation (Figure 20). At 24h post induction, the 
population of Foxp3+CD25+ cells was massively reduced in the CD28ko samples in 
comparison to wt, which was fully rescued by exogenous miR-17~92 expression. 
miR1792tg cells were similar to wt and rescue cells (wt 34.7±5.3%, CD28ko 16.2±3.2%, 
rescue 34.8±4.5%, miR1792tg 34.0±6.8% at 24h). Differentiation was increased in all 
genotypes at 48h, however CD28ko samples still showed reduced Foxp3+CD25+ 
populations in comparison to all other samples (wt 77.2±9.2%, CD28ko 42.4±11.0%, 
rescue 76.8±4.9%, miR1792tg 81.6±14.0% at 48h).  
 
While wt, rescue and miR1792tg stayed at high percentages at 72h post induction, 
CD28ko cells further increased their population (wt 73.8±21.7%, CD28ko 55.6±12.2%, 
 
Figure 20. Transgenic miR-17~92 expression can compensate for CD28 signal during in vitro iTreg 
differentiation.  
Naïve CD4+ T cells were activated for 24h, 48h, and 72h with plate-bound antibodies (0.2µg/ml αCD28  
0.5µg/ml αCD3) in the presence of skewing conditions for the generation of iTreg (250U IL-2, 0.75ng/ml 
TGFβ, 10µg/ml αIFNγ and 10µg/ml αIL4 plus 0.9mM retinoic acid).  wt (black, left), CD28ko (purple, 
second from left), rescue (dark blue, second from right) and miR1792tg (light blue, right).  Data from 
two independent experiments are shown, with representative FACS plots of each timepoint and 
genotype. Error bars show mean ±SD, Tukey’s multiple comparison, p values: ns, not significant, 






rescue 77.9±15.3%, miR1792tg 86.7±0.6% at 72h). We concluded that the induction 
of Foxp3+CD25+ differentiation is delayed in CD28ko cells, but can be fully rescued by 
transgenic miR-17~92 expression.  
For the analysis of differentiation of TH subsets and iTregs, we had pre-gated on viable 
CD4+ cells. Interestingly, when we investigated the viability of cells in all of these 
subsets, we additionally found time-, genotype- and subset specific differences: in TH1 
differentiation, viability was comparable among genotypes at each time point. In 
contrast, during TH17 differentiation at 72h CD28ko cells were markedly reduced in 
their viability as compared to wt cells. This was partially rescued by transgenic miR-
17~92 expression, and miR1792tg cells were similar to wt cells (viability in TH17 
differentiation wt 63.1±9.1%, CD28ko 29.4±6.2%, rescue 50.3±8.3%, miR1792tg 
62.8±17% at 72h) (Figure 21, middle). The same pattern could be observed in iTreg 
differentiation: CD28ko cells showed reduced viability in comparison to wt, while 
transgenic miR-17~92 partially rescued viability (though not significantly, which again 
might be due to sample size) and miR1792tg cells were comparable to wt cells 
(viability in iTreg differentiation wt 57.5±14.6%, CD28ko 21.9±8.1%, rescue 
 
Figure 21. CD4+ viability is decreased in CD28ko cells at 72h post differentiation induction in TH17 and 
iTreg differentiation  
Naïve CD4+ T cells were activated for 72h with plate-bound antibodies (0.2µg/ml αCD28  0.5µg/ml 
αCD3) in the presence of skewing conditions for the generation of TH1 (50U IL-2, 5ng/ml IL12 and 
10µg/ml αIL4 per ml T cell medium), TH17 (50ng/ml IL6, 3ng/ml TGFβ, 5µg/ml αIFNγ and 10µg/ml αIL4 
per ml T cell medium) and iTreg (250U IL-2, 0.75ng/ml TGFβ, 10µg/ml αIFNγ and 10µg/ml αIL4 plus 
0.9mM retinoic acid).  wt (black, left), CD28ko (purple, second from left), rescue (dark blue, second 
from right) and miR1792tg (light blue, right).  Data from two independent experiments are shown, 
with representative FACS plots of each timepoint and genotype. Error bars show mean ±SD, Tukey’s 






36.5±12.4%, miR1792tg 56.1±11.7% at 72h) (Figure 21, right). This data suggests that 
in addition to subset-specific induction of TFs and cytokines, miR-17~92 is important 
for survival at later time points as well as it was demonstrated before [261]. However, 
since at early time points no difference was seen among genotypes in any of the 
subsets, this also suggests that survival cannot account for differences in the outcome 
of early differentiation assays. 
Overall we found a defect for differentiation of CD28ko cells in all tested T cell subsets 
and could observe a partial or complete rescue effect by transgenic miR-17~92 
expression. However, timing and extent of rescue varied between subsets: while TH1 
was even promoted in comparison to wt in rescue cells, TH17 differentiation was only 
partially rescued and iTreg differentiation was fully rescued to wt percentage. We 
concluded from these experiments that exogenous miR-17~92 expression rescues 
TH1, TH17 and iTreg differentiation partially in the absence of CD28 stimulation, but the 
relative contribution is variable and context dependent. Moreover, since all of the 
tested subsets were affected, these results suggested that there might be targets of 
miR-17~92 that are common among different TH subsets.  
6.2.3. Transgenic miR-17~92 expression rescues CD28 deficiency in 
CD4+ T cells in vivo 
For an adaptive immune response, not only the secretion of cytokines by TH subsets is 
important, but also the specialized help of TFH to B cells, which is strongly dependent 
on CD28 co-stimulation [140] as well as miR-17~92 expression [134]. We therefore 
hypothesized that deficient TFH differentiation in CD28ko mice could be rescued by 
transgenic miR-17~92 expression. To investigate the generation of TFH and TH1 
responses in vivo we infected our mice with LCMV Armstrong. This virus strain is 
known to elicit an acute viral infection, causing TFH and TH1 differentiation, and is 
usually cleared by day eight post infection [262]. We infected wt, CD28ko and rescue 
mice and analyzed the spleens eight days post infection. In line with our in vitro data 
(Figure 17B), we observed a decreased CD44 expression in CD28ko CD4+ T cells in 
comparison to wt cells, which was rescued by transgenic miR-17~92 expression (wt 







Figure 22. CD44 upregulation in CD4+ T cells is rescued by transgenic miR-17~92 expression in vivo 
six to eight weeks old mice were infected with 2*105 PFU LCMV Armstrong i.p. and spleens were 
analyzed at day eight post infection. wt (black, left), CD28ko (purple, middle), CD28ko with transgenic 
miR-17~92 expression= rescue (dark blue, right).  left: representative histograms of CD44 expression 
gated on viable CD3+CD4+ cells, gate shows CD44hi population. right: data summary of %CD44hi 
population. Error bars represent mean ±SD, Dunn’s multiple comparison test, p values: ns=not 
significant, *<0.05, **<0.002, ***<0.0002, ****<0.0001. Data represent four independent 
experiments with four mice per group.  
 
To identify TFH we used key markers Bcl-6, ICOS, CXCR5 and PD-1 (Figure 23A). CD28ko 
mice showed a 5-fold reduced population in comparison to wt mice, which was 
rescued by transgenic miR-17~92 expression in Bcl-6/ICOS (wt 7.5±2.7%, CD28ko 
1.1±0.7%, rescue 5.7±5.1%) as well as CXCR5/PD1 expression (wt 6.2±3.8%, CD28ko 
1.3±0.8%, rescue 5.8±5.4%), independent from marker combination.  
TFH are essential for the formation of GC and the differentiation of GC B cells which 
are characterized by GL-7 and Fas expression. Consequently, also GC formation is 
strongly dependent on the CD28 co-stimulatory signal [140], therefore we 
investigated if GC B cells are rescued as a secondary effect of rescued TFH cells. We 
observed a significantly reduced population of GC B cells in CD28ko as compared to 
wt mice, which was rescued with transgenic miR-17~92 expression (Figure 23B) (wt 
8.0±2.3%, CD28ko 3.4±1.0%, rescue 6.9±3.7%). This was also visually apparent in 
histological staining (Figure 23C), where we stained cryo-sections of spleens for CD4 
and CD19 to distinguish B and T cell zones and then identified GC B cells as GL-7+. From 
this, we concluded that the TFH population is rescued in their function, i.e. GC B cell 
formation and structural organization of the GC. 
To test for TH1 differentiation we used GP-64, a peptide with the immunodominant 
epitope of LCMV-Armstrong [263, 264], for restimulation. Tbet expression was 2-fold 





cells (wt 23.2±14.4%, CD28ko 6.6±4.5%, rescue 17.8±14.3%) (Figure 24A, B). However, 
IFNγ production was 5-fold reduced in CD28ko in comparison to wt and fully restored 
by transgenic miR-17~92 expression (wt 9.4±4.2%, CD28ko 2.1±0.7%, rescue 
7.9±3.4%)(Figure 24A, C). The ratio of IFNγ producing cells to total Tbet expressing 
cells was similar among all genotypes (Figure 24D), suggesting that if a CD28ko cell 
expresses Tbet, it also produces IFNγ. This demonstrates that in CD28ko cells, 
differentiation is blocked at the TF, rather than at the cytokine production level. As a 
control, we also used non-specific restimulation with PMA and iono, which resulted in 
the same pattern (data not shown). 
 
 
Figure 23. TFH differentiation and function in CD28ko mice is rescued by transgenic expression of miR-
17~92 
six to eight weeks old mice were infected with 2*105 PFU LCMV Armstrong i.p. and spleens were 
analyzed at day eight post infection. wt (black, left), CD28ko (purple, middle), CD28ko with transgenic 
miR-17~92 expression= rescue (dark blue, right). Error bars represent mean ±SD, Dunn’s multiple 
comparison test, p values: ns=not significant, *<0.05, **<0.002, ***<0.0002, ****<0.0001. Data 
represent four independent experiments with four mice per group. A) TFH population was stained with 
Bcl-6, ICOS, CXCR5 and PD-1, pre-gating on viable CD4+CD3+ cells. top row:  representative contour 
plots of TFH markers Bcl-6 and ICOS, gate shows Bcl-6+ICOS+ population. Bottom row: representative 
contour plots of TFH markers CXCR5 and PD-1, gate shows CXCR5+PD-1+ population B) Germinal center 
B cells were stained with Fas and GL7, pre-gating on viable CD19+B220+ cells. Left: representative 
contour plots of Fas and GL7 expression, gate shows Fas+GL7+ population. C) Cryosections of spleens 






Figure 24. TH1 differentiation during acute LCMV infection is rescued by transgenic miR-17~92 
expression. 
six to eight weeks old mice were infected with 2*105 PFU LCMV Armstrong i.p. and spleens were 
analyzed at day eight post infection. wt (black, left), CD28ko (purple, middle), CD28ko with transgenic 
miR-17~92 expression= rescue (dark blue, right) TH1 response was addressed with restimulation of 
total splenocytes with GP-64 and BFA for 4h. Pre-gating on viable CD3+CD4+ cells. Top: representative 
contour plots of Tbet and IFNγ expression, bottom left: percentage of Tbet+ cells (top quadrants in the 
plots), bottom middle: percentage of Tbet+IFNγ+ (top right quadrants of the plots) bottom right: ratio 
of Tbet+IFNγ+ to total Tbet+ cells. Shown are three independent experiments with four samples per 
group. Error bars represent mean ±SD, Dunn’s multiple comparison test, p values: ns=not significant, 
*<0.05, **<0.002, ***<0.0002, ****<0.0001.  
 
Collectively, our data suggested dose-dependent effects for many of the examined 
parameters. Therefore, we additionally performed experiments to compare these 
genotypes to miR1792lox, miR1792tg and heterozygous rescue mice (Figure 25). 
Heterozygous rescue mice are full knockout for CD28, but only express one allele of 
the miR-17~92 transgene (hetrescue). In these experiments, we found that again 
miR1792lox phenocopied CD28ko mice, which was expected from the literature [134]. 
Furthermore, we confirmed published data that miR1792tg mice display increased TFH 
differentiation. In addition to increased TFH population in relative numbers, we noted 
a miR-17~92 and CD28 expression dependent increase in PD-1 and ICOS upregulation 
in the total CD4+CD3+ population. This is presumably an effect of increased T cell 
activation, leading to induction of ICOS [265] as well as PD-1 expression [266]. 
Interestingly, heterozygous expression of the miR-17~92 transgene was sufficient to 
rescue TFH and GC differentiation. As for TH1 differentiation, we noted a non-





Importantly, we addressed the viral clearance at day eight post infection in lung, liver, 
kidney and spleen [267]. Viral clearance was not affected by CD28 deficiency or miR-
17~92 transgenic expression and the virus was fully cleared in all organs of all 
genotypes. This is consistent with literature that showed that viral clearance at this 
time point is CD8 mediated and CD28 independent [268]. Thus, we excluded viral 
clearance as a possible confounding factor. 
Taken together, we concluded that also in vivo transgenic miR-17~92 expression 
rescues known defects of CD28ko cells, namely TFH and GC B cell differentiation. While 
homozygous expression of the transgene rescued TFH and GC as well as TH1 formation, 
heterozygous expression was also sufficient for the rescue of TFH and GC B cells but 








Figure 25. TFH and TH1 differentiation after LCMV Armstrong infection in wt, miR1792lox, CD28ko, 
hetrescue, rescue and miR1792tg mice 
six to eight weeks old mice were infected with 2*105 PFU LCMV Armstrong i.p. and spleens were analyzed 
at day eight post infection. wt (black, left), miR1792lox (grey, second from left), CD28ko (purple, third 
from left), CD28ko with only one allele transgenic miR-17~92 expression= hetrescue (dark blue empty 
circles, third from right), CD28ko with homozygous transgenic miR-17~92 expression= rescue (dark blue, 
second from right), miR1792tg (light blue, right). Error bars represent mean ±SD, Dunn’s multiple 
comparison test, p values: ns=not significant, *<0.05, **<0.002. Data represent four independent 
experiments (two for restimulation) with four mice per group. A) representative histograms of CD44 
expression gated on viable CD3+CD4+ cells, gate shows CD44hi population. right: data summary of 
%CD44hi population. TFH population was stained with Bcl-6, ICOS, CXCR5 and PD-1, pre-gating on viable 
CD4+CD3+ cells. B) representative contour plots of TFH markers Bcl-6 and ICOS, gate shows Bcl6+ICOS+ 





population. D) GC B cells were stained with Fas and GL7, pre-gating on viable CD19+B220+ cells. Left: 
representative contour plots of Fas and GL7 expression, gate shows Fas+GL7+ population. E) TH1 response 
was addressed with restimulation of total splenocytes with GP-64 and BFA for four hours. Pre-gating on 
viable CD3+CD4+ cells. Top: representative contour plots of Tbet and IFNγ expression, bottom left: 
percentage of Tbet+ cells (top quadrants in the plots), bottom middle: percentage of Tbet+IFNγ+ (top right 
quadrants of the plots) bottom right: ratio of Tbet+IFNγ+ to total Tbet+ cells.  
6.2.4. Transgenic miR-17~92 expression rescue effect is CD4+ T cell 
intrinsic 
Due to the nature of T cell development, also the CD8+ T cells in our rescue mice 
express the miR-17~92 transgene, which raised the question if our rescue effect was 
actually CD4+ T cell intrinsic. This was unlikely since CD28 signaling was shown to be 
dispensable for CD8+ T cells during LCMV infection [268], however, we performed 
adoptive cell transfer experiments to exclude any external influence. For this, we 
crossed the B6.CD4cre.Rosa26loxSTOPloxCAG-miR-17~92.CD28ko strain additionally to 
SMARTA TCR transgenic mice. This mouse line expresses an MHC class II restricted TCR 
with specificity for LCMV-GP, which consists of Vα2/Vβ8.3. We isolated naïve CD4+ T 
cells from SMARTA+wt, SMARTA+CD28ko, and SMARTA+rescue mice and adoptively 
transferred them into CD28ko host mice. Two days later the recipient mice were 
infected with LCMV Armstrong, and their mesenteric LN, peripheral LN and spleen 
were analyzed eight days post infection. Since our donor- and recipient strain express 
the same congenic markers, we decided to stain for Vα2+Vβ8.3+ CD4+ T cells to identify 
the donor cells. However, this has the caveat that also recipient cells will be contained 
in the gate that naturally express this combination of α- and β TCR chain and might 
expand upon LCMV infection. Therefore, we included a non-transferred mouse to 
display the intrinsic Vα2+Vβ8.3+ population, which is shown as dotted line in the plots. 
The cell-intrinsic Vα2+Vβ8.3+ population was negligibly small in comparison to mice 
receiving donor cells. In peripheral LN, we found less CD28ko Vα2+Vβ8.3+ CD4+ T cells 
as compared to wt (Figure 26A). This was rescued by transgenic miR-17~92 expression 
in percentage and also absolute numbers (%Vα2+Vβ8.3+ in wt 57.9±10.0%, CD28ko 
1.9±0.9%, rescue 26.4±12.9%, total number in wt 3.2*106±1.9*106, CD28ko 
9.3*104±3.1*104, rescue 8.4*105±5.0*105). We found a similar pattern in spleen 





in wt 1.3*107±6.34*106, CD28ko 9.9*104±4.8*104, rescue 2.7*106±1.2*106) and 
mesenteric LN (%Vα2+Vβ8.3+ in wt 29.7±2.5%, CD28ko 2.1±1.4%, rescue 12.7±4.9%, 
total number in wt 1.9*106±8.9*105, CD28ko 1.6*105±9.4*104, rescue 
6.8*105±1.7*105) (Figure 26B and C) as in the peripheral LN. The presence of less 
Vα2+Vβ8.3+ CD28ko cells suggested that CD28ko donor cells either had a proliferation- 
or a survival defect, which could be rescued by miR-17~92 expression. This goes in line 
with previously published literature showing the importance of miR-17~92 for survival 
and proliferation of T cells [134, 208]. 
 
 
Figure 26. Less CD28ko Vα2+Vβ8.3+ CD4+ T cells are found in recipient mice. 
Naïve SMARTA+ CD4+ T cells from six weeks old donor mice were transferred into CD28ko hosts i.v.. 
These were infected at day two post transfer with 2*105 PFU LCMV Armstrong i.p.. peripheral LN (A), 
spleen (B) and mesenteric LN (C) were analyzed at day eight post infection. Pre-gating on viability, CD3 
and CD4. Donor groups wt (black, left), CD28ko (purple, middle), CD28ko with transgenic miR-17~92 
expression= rescue (dark blue). Dotted line indicates non-transferred control. Error bars represent 
mean ±SD, Dunn’s multiple comparison test, p values: ns=not significant, *<0.05, **<0.002, 
***<0.0002. Data represent two independent experiments with four mice per group. 
 
Since our previous experiments had shown a defect in CD44 upregulation in CD28ko 
cells in vitro (see Figure 17B) as well as in vivo (see Figure 22), we hypothesized that 
proliferation might not be the only defect that CD28ko donor cells have in this system. 
We stained viable CD4+Vα2+Vβ8.3+ cells of peripheral LN for their CD44 expression 





compared to wt Vα2+Vβ8.3+ cells, which could be rescued by transgenic miR-17~92 
expression in percentage and also total numbers (%CD44hi in wt 98.7±0.2 %, CD28ko 
55.9±14.7%, rescue 96.15±2.2%, total number in wt 3.2*106±1.9*106, CD28ko 
5.4*104±2.8*104, rescue 8.1*105±5.0*105). Again, this pattern was found in peripheral 
LN, but also in spleen (%CD44hi in wt 97.6±0.5 %, CD28ko 59.9±22.0%, rescue 
94.8±1.8%, total number in wt 1.3*107±6.1*106, CD28ko 5.9*104±3.3*104, rescue 
2.6*106±1.2*106) (Figure 27B) and mesenteric LN (%CD44hi in wt 96.8±0.3 %, CD28ko 
52.2±20.0%, rescue 92.9±2.3%, total number in wt 1.8*106±8.6*105, CD28ko 
9.8*104±9.8*104, rescue 6.3*105±1.8*105) (Figure 27C). This suggested that there are 
not only fewer donor CD28ko cells present, they are also not as activated as their wt 
or rescue counterparts. Thus, these data unequivocally demonstrate that the rescue 
effect was cell intrinsic. 
 
 
Figure 27. CD28ko Vα2+Vβ8.3+ CD4+ T cells express less CD44 
Naïve SMARTA+ CD4+ T cells from six weeks old donor mice were transferred into CD28ko hosts i.v.. 
These were infected at day two post transfer with 2*105 PFU LCMV Armstrong i.p.. peripheral LN (A), 
spleen (B) and mesenteric LN (C). Pre-gating on viability, CD3 and CD4, Vα2+/Vβ8.3+ (Figure 26). Donor 
groups wt (black, left), CD28ko (purple, middle), CD28ko with transgenic miR-17~92 expression= 
rescue (dark blue). Dotted line indicates non-transferred control. Error bars represent mean ±SD, 
Dunn’s multiple comparison test, p values: ns=not significant, *<0.05, **<0.002, ***<0.0002. Data 





6.3. Molecular mechanism of the rescue effect 
6.3.1. miR-17~92 expression shapes the transcriptome during T cell 
activation 
We observed a strong effect of miR-17~92 expression on the T cell activation process. 
Therefore, we set out to determine the target genes of the miRNA cluster mediating 
this effect. Multiple targets for each member of the cluster were previously identified 
and validated (see section 3.2.3.3). Of note, limitation in expression of a target gene 
to one allele often led to a partial rescue of the corresponding miRNA knockout, e.g. 
Rorα limitation in miR1792lox cells during TFH differentiation [134]. However, each of 
these publications investigated a different time point, in different context and a 
different T cell subset, so that these targets might not necessarily be relevant for our 
setting. Moreover, there might be additional, so far unknown target genes that 
mediate the rescue effect. Importantly, this does not exclude that previously reported 
target genes are also repressed in our system, since miRNAs are known to act on 
multiple target genes simultaneously. We stimulated naïve CD4+ T cells from 
miR1792lox, wt and miR1792tg mice for 24h or 48h and isolated total RNA for 
sequencing. A PCA (Figure 28A) showed that the highest proportion of variance was 
caused by the process of activation itself (principal component 1 (PC1), explaining 
80.3% of the variance). The second PC separated the activation time points 24h and 
48h (PC2 9.5% of the variance), and the third PC separated the three genotypes (PC3, 
3.6% of the variance, Figure 28B). The transcriptome of naïve miR1792lox and wt cells 
was very similar (largely overlapping in the PCA plot, even on PC3), and only 40 genes 
were down- and 75 upregulated in the comparison between miR1792tg to wt (at 1% 
FDR, also see Figure 28C, top block). This was consistent with our in vitro experimental 
data, and suggests that the cluster is functionally less relevant for naïve cells. At 24h 
post activation, 216 genes were down- and 262 upregulated in the direct comparison 
of miR1792tg vs. miR1792lox cells (Figure 28C, middle block). At 48h, the total number 
of differentially expressed genes between miR1792tg and miR1792lox increased to 
625 down- and 459 upregulated, and the relative changes in expression of the genes 
(more intense red- or blue shading) that had already been differentially expressed at 





regulated in their expression upon miRNA targeting (negative correlation of miRNA 
expression and target). A positive correlation of miRNA with gene expression suggests 
that these genes are indirectly regulated, e.g. genes whose expression is regulated by 
an inhibitor which is targeted by miR-17~92. From this first analysis we concluded that 
differences in miR-17~92 expression during activation shape the transcriptome of 
CD4+ T cells. Our next aim was therefore to further characterize these differences in 
transcriptome and possibly define a mechanism which mediates these differences.  
 
 
Figure 28. Differences in the transcriptome between miR1792lox, wt and miR1792tg cells  
Naïve CD4+ T cells from miR1792lox (grey), miR1792tg (light blue) or cre negative littermates (wt, 
black) were activated for 0, 24h and 48h. Total RNA was extracted for bulk RNA-sequencing.  
A) and B) PCA analysis based on the top 25% most variable genes of the dataset. Dot size in the lower 
plot corresponds to time point. C) Heatmap of the gene set defined as abs(log2FC)>1 & FDR<0.01 in 
the miR1792tg vs. miR1792lox comparison at 24h. The heatmap displays the centered log of read 
counts per million read mapped (CPM), with blue indicating lower and red indicating higher expression. 
Top block: naïve samples, Middle: 24h activated cells, Bottom: 48h activated cells 
 
6.3.2. Cytokine and TF expression of different TH subsets are promoted 
by miR-17~92 expression 
We performed gene set enrichment analysis (GSEA) with our RNA-sequencing data in 
order to find pathways of genes that are regulated by miR-17~92 expression. We 
found an enrichment of gene sets that were associated with cytokine expression 





data (see also section 6.2.2), we then plotted known lineage-defining TF and cytokine 
genes of TH subsets that were rescued by transgenic miR-17~92 expression and found 
that TH1 as well as TH2 and TH17 cytokine expression was increased in miR1792tg cells 
(Figure 29). This argued that miR-17~92 controls a master regulatory pathway that is 
relevant for the differentiation of all of these TH subsets. One pathway that matches 
these criteria is the calcineurin-NFAT axis [128], and indeed, most of these genes had 
a binding site for NFAT in their promoter region. We therefore aimed for defining a 
list of bona fide target genes, and within this list finding candidate genes that might 
negatively regulate an inhibitor of the NFAT pathway. 
 
 
Figure 29. Expression of lineage defining TFs and cytokines in different TH subsets are promoted by 
increased miR-17~92 expression. 
miR1792lox (grey), wt (cre negative, black) and miR1792tg (blue) CD4+ T cells are compared at time 
points 0 (left), 24h (middle) and 48h (right) after activation in their expression of selected lineage 
defining cytokine and TF expression of TH1, TH2, TH17 and Treg lineages. + indicate which of these genes 






Table 2. Gene set enrichment analysis: Top 25 
The Top 25 most significant “curated gene sets” from KEGG/Biocarta/Reactome in the comparison 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.3.3. Identification of bona fide canonical miR-17~92 targets 
To identify the bona fide canonical target genes of the miR-17~92 cluster, we focused 
on the 24h time point because it was more likely to reflect primary effects of the 
miRNA cluster targeting. As opposed to this, changes in gene expression at 48h might 
also result from changes in the 24h time point as indirect effects. In the 24h data set, 
we wanted to specifically look at genes whose mRNA 3’UTR are bound by Ago2, i.e., 
genes that are targeted for degradation by the RISC complex after being bound by a 
microRNA (see section 3.2.2) at the moment of harvest. The High-throughput 
sequencing of RNA isolated by crosslinking immunoprecipitation (HITS CLIP) technique 
provides exactly this kind of biochemical evidence since a specific protein [269], in this 
case Ago2, is used for immunoprecipitation of the RNA of interest prior to sequencing. 
For our analysis, we took advantage of an Ago2-HITS CLIP (AHC) RNA sequencing data 
set from collaborators in Mark Ansel’s group at the University of California, San 
Francisco.  
We defined the following criteria for bona fide target genes: 
a) conserved seed match for at least one member of the miRNA cluster, 
according to the miRNA targets database TargetScan [270]. 
b) Coverage of more than 5 reads in the AHC data (AHC>5)  
The subsetting of genes with AHC and TargetScan reduced the list of in total 12’625 
genes that were detected in the sequencing to several hundred potential target genes 
per seed family, i.e. 532 for the miR-17 seed family, 98 for the miR-18 seed family, 488 
for the miR-19 seed family and 379 for the miR-92 seed family (Figure 30). Of note, 
with the above criteria we might miss some genuine target genes. For example, we 
exclude the non-canonical targets detected in the Ago2-HITS CLIP, namely those 
without seed match to one of the cluster members. These are also target genes, but 









Figure 30. Venn diagrams illustrating the criteria used to identify canonical target genes of each seed 
family of the miR-17~92 cluster. 
Number outside circles: genes that do not fulfill any of the criteria, white circle: genes with a seed 
match in their 3’ UTR, grey circle: genes with a conserved binding site according to TargetScan (TS), 
blue circle: genes that showed a coverage of more than 5 reads in the AHC. Of note, non-canonical 
targets are likely present among genes without seed match (darkest part of blue circle). 
 
We used cumulative distribution function (CDF) plots to verify whether we enrich for 
canonical target genes (Figure 31). For each seed family (see section 3.2.3.1), we 
visualize the distribution of logFC in comparisons across genotypes (miR1792lox vs. wt 
and miR1792tg vs. wt) for genes with a conserved seed sequence according to 
TargetScan (red curve) as well as the combination of the AHC and TargetScan criteria 
(blue curve), relative to genes without seed match and less than five AHC reads (black 
curve). We furthermore included miR-21 as a negative control, a miRNA which is 
induced upon T cell activation [271] independently from miR-17~92  and therefore its 
target genes should not display expression differences across genotypes (Figure 31A). 
If we enrich for real targets with these criteria, we expect the gene set to shift in the 
distribution of logFC towards higher FC in the miR1792lox vs. wt comparison and lower 
FC in the miR1792tg vs. wt comparison. We looked at all four seed families (see section 
3.2.3.1) separately: for the miR-17 seed family, there was no clear shift in the 
distribution of logFC from the comparison between naïve miR1792lox and wt cells for 
putative target gene sets (red and blue curves), relative to the control genes (black 
curve). However, we observed reduced log2FC in miR1792tg vs wt naïve and activated 
samples, and increased log2FC in activated miR1792lox and wt cells (Figure 31B). A 
similar, but weaker shifting was observed in the miR-19 (Figure 31D) and miR-92 
(Figure 31E) seed families. Of note, for the target genes of miR-18 (Figure 31C), the 
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with our selection criteria, this might indicate that miR-18 has no or only few target 
genes in this setting. Additionally, the processing of the different members of the 
miRNA might be time- and context dependent, which had also been reported before 
[237]. Importantly, for the target genes of miR-21a (Figure 31A), we did not observe 
any shift. From this analysis we concluded that our criteria did enrich for canonical 
target genes of different miRNAs of the miR-17~92 cluster, and that many of them are 
differentially expressed in this setting.   
Thus, to reduce the candidate list further for experimental validation, we included 
additional criteria like the exon-intron split analysis (EISA, [272]). This was especially 
important because of differences in transcriptional and post-transcriptional 
regulation: changes in transcriptional activity will be reflected by a change in intron as 
well as exon expression due to an increase in pre-mRNA, which is mostly nuclear RNA. 
In contrast to this, genes which are post-transcriptionally repressed by miRNAs should 
change their exon expression. Therefore, the log2FC in introns and exons is plotted 
(illustrated as an example for miR-17 seed family in Figure 32) to visualize which genes 
Genes of distinct seed families of miR-17~92 show similar behavior, except for the miR-18 seed family. 
miR-21a was used as a control miRNA. black curve: all genes of our data set that do not have a seed 
match and showed five or less AHC reads, red: subset of genes that has a seed sequence for the 
indicated seed family, blue: subset of genes that has a seed sequence for the indicated seed family plus 




Figure 32. Illustration of the intronic vs exonic expression fold change criteria 
Illustration shows the comparison of 24h activated miR1792tg vs wt cells, focused on miR-17 seed 
family. Bona fide target genes should only change at exonic level, indicating that the mature, spliced 
mRNA is changed in abundance (shift down in comparison to the red diagonal). A) 3’UTR seed match 
genes have a miR-17 seed family seed sequence (orange dots), B) TargetScan genes have a conserved 
miR-17 seed family seed sequence (red dots), C) AHC reads > 5 genes showed more than 5 reads in the 
AHC (purple dots), D) TargetScan + AHC reads > 5 match both of the latter two criteria (blue dots). 





change post-transcriptionally only [272] (shift down in this example, since we look at 
the comparison miR1792tg vs. wt in 24h activated cells).  
Additionally, we wanted to focus on genes which are significantly differentially 
expressed in the absence of miR-17~92 as well as in the overexpressing cells in 
comparison to wt. For direct targets, the expression should be increased in 
miR1792lox, but decreased in miR1792tg cells. This results in the following three 
additional criteria for bona fide canonical targets: 
c) differential expression (FDR < 0.01) in both lox vs. wt and tg vs. wt 
comparisons at 24h, 
d) log2FC > 0 in lox vs. wt and log2FC < 0 in tg vs. wt comparisons at 24h, 
e) no differential expression of introns (see Figure 32) (FDR >= 0.01) in both 
lox vs. wt and tg vs. wt comparisons at 24h. 
 With these criteria we result in the final canonical target candidate gene list of 125 
genes shown in Table 3. Of note, this list includes targets of all four seed families, and 
some candidates are targeted by multiple miRNAs of the cluster.  
 
Table 3. List of bona fide canonical target candidate genes 
ENTREZID SYMBOL GENENAME Seed family 
11308 Abi1 abl-interactor 1 miR-17 
11566 Adss adenylosuccinate synthetase, non muscle miR-19 
11798 Xiap X-linked inhibitor of apoptosis miR-17 
12380 Cast calpastatin miR-19 
12753 Clock circadian locomotor output cycles kaput miR-17, miR-19 
14007 Celf2 CUGBP, Elav-like family member 2 miR-17 
14055 Ezh1 
enhancer of zeste 1 polycomb repressive 
complex 2 subunit 
miR-17 
16451 Jak1 Janus kinase 1 miR-17 
17113 M6pr 








nuclear factor of activated T cells, cytoplasmic, 
calcineurin dependent 2 interacting protein 
miR-92 
19338 Rab33b RAB33B, member RAS oncogene family miR-19 
19344 Rab5b RAB5B, member RAS oncogene family miR-17, miR-19 
19357 Rad21 RAD21 cohesin complex component miR-17, miR-92 
20238 Atxn1 ataxin 1 
miR-17, miR-
19, miR-92 
20499 Slc12a7 solute carrier family 12, member 7 miR-17 
20544 Slc9a1 
solute carrier family 9 (sodium/hydrogen 
exchanger), member 1 
miR-19, miR-92 
21813 Tgfbr2 transforming growth factor, β receptor II miR-17, miR-19 
21815 Tgif1 TGFB-induced factor homeobox 1 miR-19, miR-92 





27999 Fam3c family with sequence similarity 3, member C miR-17 
29864 Rnf11 ring finger protein 11 miR-19 
30934 Tor1b torsin family 1, member B miR-17, miR-19 
50789 Fbxl3 F-box and leucine-rich repeat protein 3 miR-17 
52592 Brms1l breast cancer metastasis-suppressor 1-like miR-17 
52609 Cbx7 chromobox 7 miR-19 
52635 Esyt2 extended synaptotagmin-like protein 2 miR-92 
52864 Slx4 
SLX4 structure-specific endonuclease subunit 
homolog (S. cerevisiae) 
miR-17 
53902 RCAN3 regulator of calcineurin 3 miR-17 
54484 Mkrn1 makorin, ring finger protein, 1 miR-17 
54650 Sfmbt1 Scm-like with four mbt domains 1 miR-17 
56174 Nagk N-acetylglucosamine kinase miR-17, miR-92 
56613 Rps6ka4 ribosomal protein S6 kinase, polypeptide 4 miR-92 
57431 Dnajc4 
DnaJ heat shock protein family (Hsp40) member 
C4 
miR-17 
58205 Pdcd1lg2 programmed cell death 1 ligand 2 miR-17 
58244 Stx6 syntaxin 6 miR-19 
66505 Zmynd11 zinc finger, MYND domain containing 11 miR-17, miR-19 
67121 Mastl 
microtubule associated serine/threonine kinase-
like 
miR-19 
67229 Prpf18 pre-mRNA processing factor 18 miR-17, miR-18 
67276 Eri1 exoribonuclease 1 miR-17 
67894 Fam45a family with sequence similarity 45, member A miR-19 
68465 Adipor2 adiponectin receptor 2 miR-92 
68520 Zfyve21 zinc finger, FYVE domain containing 21 miR-19 
68801 Elovl5 
ELOVL family member 5, elongation of long 
chain fatty acids (yeast) 
miR-92 
69046 Isca1 iron-sulfur cluster assembly 1 miR-17 
69470 Tmem127 transmembrane protein 127 miR-17 
69721 Nkiras1 NFKB inhibitor interacting Ras-like protein 1 miR-19 
70186 Fam162a family with sequence similarity 162, member A miR-19 
70510 Rnf167 ring finger protein 167 miR-19 
70533 Btf3l4 basic transcription factor 3-like 4 
miR-17, miR-
19, miR-92 
70797 Ankib1 ankyrin repeat and IBR domain containing 1 miR-19, miR-92 
70827 Trak2 trafficking protein, kinesin binding 2 miR-17, miR-92 
71063 Zfp597 zinc finger protein 597 miR-17 
71704 Arhgef3 Rho guanine nucleotide exchange factor (GEF) 3 miR-17 
71819 Kif23 kinesin family member 23 miR-17 
71929 Tmem123 transmembrane protein 123 miR-17, miR-19 
73389 Hbp1 high mobility group box transcription factor 1 
miR-17, miR-
19, miR-92 
73469 Rnf38 ring finger protein 38 miR-17 
74114 Crot carnitine O-octanoyltransferase miR-19 
74256 Cyld CYLD lysine 63 deubiquitinase miR-17 
74360 Cep57 centrosomal protein 57 miR-19, miR-92 
74769 Pik3cb 
phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit β 
miR-19 
74868 Tmem65 transmembrane protein 65 miR-17 
75221 Dpp3 dipeptidylpeptidase 3 
miR-17, miR-
18, miR-19 
75580 Zbtb4 zinc finger and BTB domain containing 4 miR-92 
75627 Snapc1 







76089 Rapgef2 Rap guanine nucleotide exchange factor (GEF) 2 miR-92 
76740 Efr3a EFR3 homolog A miR-17 
76763 Mospd2 motile sperm domain containing 2 miR-17 
77644 C330007P06Rik RIKEN cDNA C330007P06 gene miR-17 
77975 Tmem50b transmembrane protein 50B miR-18, miR-19 
78334 Cdk19 cyclin-dependent kinase 19 miR-92 
80517 Herpud2 HERPUD family member 2 miR-17 
83924 Gpr137b G protein-coupled receptor 137B miR-17, miR-92 
98193 Dcaf8 DDB1 and CUL4 associated factor 8 miR-17 
98396 Slc41a1 solute carrier family 41, member 1 miR-17, miR-19 
100201 Tmem64 transmembrane protein 64 miR-92 
100383 Bsdc1 BSD domain containing 1 miR-17 
102595 Plekho2 
pleckstrin homology domain containing, family 
O member 2 
miR-19 
104625 Cnot6 CCR4-NOT transcription complex, subunit 6 miR-17 
108645 Mat2b methionine adenosyltransferase II, β miR-19 
108767 Pnrc1 proline-rich nuclear receptor coactivator 1 miR-17 
109161 Ube2q2 
ubiquitin-conjugating enzyme E2Q family 
member 2 
miR-17 
109168 Atl3 atlastin GTPase 3 miR-19 
170459 Stard4 
StAR-related lipid transfer (START) domain 
containing 4 
miR-17 
170719 Oxr1 oxidation resistance 1 miR-92 
170740 Zfp287 zinc finger protein 287 miR-17, miR-19 
192292 Nrbp1 nuclear receptor binding protein 1 miR-17, miR-92 
213056 Fam126b family with sequence similarity 126, member B miR-17, miR-19 
214897 Csnk1g1 casein kinase 1, γ 1 miR-17 
215751 Ginm1 glycoprotein integral membrane 1 miR-17 
216001 Micu1 mitochondrial calcium uptake 1 miR-19 
216527 Ccm2 cerebral cavernous malformation 2 miR-17, miR-92 
216558 Ugp2 UDP-glucose pyrophosphorylase 2 miR-92 
216742 Fnip1 folliculin interacting protein 1 miR-92 
217946 Cdca7l cell division cycle associated 7 like miR-17, miR-92 
218503 Fcho2 FCH domain only 2 miR-17 
218699 Pxk PX domain containing serine/threonine kinase miR-19 
223918 Spryd3 SPRY domain containing 3 miR-19 
224703 March2 membrane-associated ring finger (C3HC4) 2 miR-17 
225995 D030056L22Rik RIKEN cDNA D030056L22 gene miR-19 
226757 Wdr26 WD repeat domain 26 miR-17, miR-19 
228359 Arhgap1 Rho GTPase activating protein 1 miR-19 
229521 Syt11 synaptotagmin XI miR-92 
231070 Insig1 insulin induced gene 1 miR-17, miR-19 
231464 Cnot6l CCR4-NOT transcription complex, subunit 6-like miR-92 
231570 A830010M20Rik RIKEN cDNA A830010M20 gene miR-17, miR-19 
231986 Jazf1 JAZF zinc finger 1 miR-19 
232196 C87436 expressed sequence C87436 miR-18 
232430 Crebl2 cAMP responsive element binding protein-like 2 miR-17 
233765 Plekha7 




Rho guanine nucleotide exchange factor (GEF) 
10 
miR-17, miR-19 
236511 Ago1 argonaute RISC catalytic subunit 1 
miR-17, miR-
18, miR-19 
238673 Zfp367 zinc finger protein 367 miR-92 





242960 Fbxl5 F-box and leucine-rich repeat protein 5 miR-17, miR-92 
244650 Phlpp2 
PH domain and leucine rich repeat protein 
phosphatase 2 
miR-19 
266781 Snx17 sorting nexin 17 miR-92 
319263 Pcmtd1 
protein-L-isoaspartate (D-aspartate) O-
methyltransferase domain containing 1 
miR-19 
319701 Fbxo48 F-box protein 48 miR-17 
320191 Hook3 hook microtubule tethering protein 3 miR-17, miR-92 
330401 Tmcc1 transmembrane and coiled coil domains 1 miR-92 
338366 Mia3 melanoma inhibitory activity 3 miR-17, miR-92 
353047 Plekhm1 
pleckstrin homology domain containing, family 
M (with RUN domain) member 1 
miR-17 
433667 Ankrd13c ankyrin repeat domain 13c miR-19 
100504663 Atg14 autophagy related 14 miR-17 
 
 
Within this list, we find known target genes of miR-17~92 like Phlpp2, Tgfbr2 and 
Zbtb4F. These genes have been validated by others and serve as a positive control for 
our analysis. 
6.3.4. Exogenous miR-17~92 expression partially rescues the 
transcriptome of CD28ko cells  
Since we observed a rather strong rescue effect on different aspects of T cell activation 
and differentiation (see section 6.2), we wondered if this rescue was only phenotypical 
or if the transgenic miR-17~92 expression might also rescue the transcriptome of 
CD28ko cells. Following this hypothesis, we isolated RNA from naïve and 24h activated 
CD4+ T cells from CD28ko, wt, rescue, miR1792tg and miR1792lox mice to perform 
RNA sequencing again. In a PCA analysis, most of the variance was again explained by 
T cell activation (PC1 (90.7%)). PC2 (2.4%) separated the different genotypes, a pattern 
that was more apparent in activated samples, and while the miR1792lox, wt and 
miR1792tg genotypes did not separate clearly, the CD28ko samples were very 
different from the others. This was expected, since CD28 co-stimulation is known to 
have profound effects on the transcriptome during early T cell activation [273]. 
Strikingly, the overexpression of miR-17~92 in CD28ko cells partially rescued the 
transcriptome so that the rescue samples were more similar to 
miR1792lox/wt/miR1792tg (Figure 33). According to our hypothesis that miR-17~92 
promotes T cell activation, we expect “two extremes of activation”: the “super 
activated” miR1792tg cells and the “improperly activated” CD28ko cells. This was 








Figure 33. Exogenous miR-17~92 expression partially rescues CD28ko transcriptome during CD4+ T cell 
activation 
Naïve CD4+ T cells from miR1792lox (grey), miR1792tg (light blue), cre negative littermates (wt, black), 
CD28ko (purple), and rescue cells (dark blue) were activated for 24h, total RNA was extracted for bulk 
sequencing. PCA analysis was based on the 25% most variable genes of the dataset. 
 
The PCA analysis however suggested that the transcriptome differences between 
CD28ko and wt samples can only partially be rescued by forced miR-17~92 expression, 
at least until this time point in this context. We hypothesized that the rescued part of 
the transcriptome was including miR-17~92 targets and investigated our dataset like 
before (Figure 30 and Figure 31): We verified the log FC shifts in the comparisons 
across genotypes in activated cells for gene subsets with conserved binding sites 
according to TargetScan and with AHC data coverage. Additionally, we added in this 
analysis the list of bona fide canonical target genes that we had defined in the previous 
section as a new subset (green curve in Figure 34; these genes are by definition 
regulated by miR-17~92 expression). Similar to the shift towards increased FC in 
miR1792lox vs. wt (Figure 31), the FC of the same genes were also shifted to increased 
FC in CD28ko vs. wt (Figure 34, top row). This suggests that the genes that are 
repressed by miR-17~92 and therefore up-regulated upon miR-17~92 inactivation in 
activated cells were also up-regulated in CD28-deficient cells during activation. This 
shift mostly was reversed with transgenic expression of miR-17~92 in rescue cells 
(Figure 34, bottom row). Even more, the expression of the most relevant putative 
target genes (Table 3, green curve in Figure 34) was over compensated, so that the FC 
became even negative. From this analysis we concluded that a fraction of genes that 





Therefore, the exogenous expression of miR-17~92 led to a partial rescue of the 
CD28ko transcriptome in rescue cells. 
 
 
Figure 34. Bona fide canonical targets of miR-17~92 are also regulated by CD28 
Genome-wide transcriptome analysis, presented as the log2 value of the gene-expression ratio for each 
gene versus the cumulative fraction of all log2 ratios. Shown are the contrasts between activated 
samples separated by seed family, top row: CD28ko vs wt comparison, bottom row: rescue vs wt 
comparison. black curve: genes that do not have a seed match, five or less AHC reads, and no differential 
expression in the first RNA sequencing. red: genes with a conserved binding site for the indicated seed 
family, blue: genes with a conserved binding site for the indicated seed family and more than five reads 
in the AHC, green: genes with a conserved binding site for the indicated seed family, more than five 
reads in the AHC and differential expression in the first RNA sequencing data set 
 
 
6.3.5. Target gene RCAN3 expression is dependent on CD28 or miR-
17~92 expression 
Since cytokine expression was promoted by increased miR-17~92 expression (Figure 
29), and NFAT is a common regulator of most of these, we searched in our target gene 
list (Table 3) for candidates that might negatively regulate the calcineurin-NFAT 
pathway. One such candidate gene is Regulator of calcineurin 3 (RCAN3), which was 





We used published HITS-CLIP data [274] to investigate if the 3’UTR of our selected 
target candidate gene RCAN3 in this setting. The activation conditions of this 
published data set were not exactly the same as in our situation (longer activation), 
however they should still be within acceptable range of difference. The visualization 
showed that there are multiple binding sites for different miRNAs in the 3’UTR of 
RCAN3, though only the miR-17 binding site was occupied by Ago2 at the moment of 
sequencing (Figure 35), suggesting that this is a true target gene.  
 
 
Figure 35. Visualization of RCAN3 3’UTR: AHC track. 
Binding sites of Ago2 in 3’UTR of RCAN3 detected by HITS-CLIP (orange and red peaks), yellow flags and 
grey bars indicate potential binding sites for miRNA 
 
The second RNA sequencing dataset showed a ~0.5-fold in expression of RCAN3 RNA 
in CD28ko cells in comparison to wt. We then performed qPCR on RNA that we 
extracted from 24h activated miR1792lox, wt and miR1792tg cells to validate the 
sequencing results. RCAN3 mRNA expression was ~1.5-fold increased in miR1792lox 
as compared to wt cells, and ~0.6-fold reduced in miR1792tg as compared to wt 
(Figure 36A). 
The regulation of the mRNA is the first important aspect of target validation, but the 
translation into protein is of even greater importance. We therefore set out to test if 
RCAN3 protein abundance is also regulated. Since no antibody for FACS and no good 
antibody for WesternBlot was available for RCAN3, we performed targeted 
proteomics in order to address protein expression. RCAN3 protein expression was ~2-
fold increased in CD28ko and miR1792lox cells in comparison to wt, which was 
reduced by transgenic miR-17~92 expression in the rescue cells (Figure 36B). 





wt cells, protein was not significantly changed (normalized protein abundance in 
CD28ko 0.85±0.07, miR1792lox 1.03±0.09, rescue 0.60±0.13, wt 0.42±0.10 and 
miR1792tg 0.33±0.16). From this data, we concluded that RCAN3 RNA as well as 
protein expression is regulated by CD28 and miR-17~92.  
 
 
Figure 36. RCAN3 mRNA and protein is elevated in CD28ko, and reduced in rescue cells 
A) RCAN3 RNA expression detected with qPCR 24h after activation, shown is the fold change to wt from 
three independent experiments. miR1792lox (grey), wt (black), miR1792tg (light blue). mRNA 
expression was normalized to 18S ribosomal RNA. Error bars represent mean ±SD, Dunn’s multiple 
comparison test, p values: ns=not significant, *<0.05 ****<0.0001 B) RCAN3 protein abundance 
measured by targeted proteomics 24h after activation. CD28ko (purple), miR1792lox (grey), rescue 
(dark blue), and miR1792tg (light blue) are compared to wt (black). Numbers indicate p values from T-
test 
 
6.3.6. Sensitivity to Cyclosporin A is increased in CD28 deficient cells 
and rescued by transgenic miR-17~92 expression 
Our data on RCAN3 RNA and protein expression suggested the hypothesis that one so 
far unknown way of how miR-17~92 acts in T cell activation might be the regulation 
of calcineurin and NFAT via the inhibition of a cell-intrinsic calcineurin repressor, 
RCAN3. We hypothesized that increased RCAN3 expression in CD28ko cells might 
increase the sensitivity of the cells to the chemical calcineurin inhibitor CsA. To test 
this hypothesis, we activated wt, CD28ko and rescue CD4+ T cells in the presence of 
increasing concentrations of CsA for 48h. As already shown in Figure 17, all genotypes 
reached similar percentages of CD25+CD69+ expression. With increasing CsA 
concentrations, CD28ko cells showed reduced percentages of CD25+CD69+ expression 
in comparison to wt already at a concentration 6.25ng/ml (Figure 37A). Wt cells only 
reacted at a 4-fold higher concentration, while rescue cells were even more resistant 





differences in cell size: at 6.25ng/ml CsA, CD28ko cells were almost not blasting at all, 
wt cells were blasting, and rescue cells looked normal, which is shown as FSC-A in 
Figure 37B. This indicated a higher sensitivity to CsA for CD28ko cells, which could be 
rescued by transgenic miR-17~92 expression. 
 
 
Figure 37. CD28ko cells react more sensitively to CsA treatment, and rescue cells are more resistant 
wt (black), CD28ko (purple) and rescue (dark blue) cells were activated for 48h in the presence of 
increasing concentrations of Cyclosporin A (CsA) as indicated and stained for their expression of CD25 
and CD69. A) left: representative plots of CD25/CD69 expression in viable CD4+ T cells activated for 48h 
with no or 6.25ng/ml CsA. right: percentage of the CD25+CD69+ population as gated on the left. Shown 
are two independent experiments, error bars represent means ±SD. Tukey’s multiple comparison, p 
values: **<0.002, ****<0.0001 refer to the difference between CD28ko and wt. B) Representative 
example of the influence of 6.25ng/ml CsA on blasting (FSC-A of the lymphocyte gate) of viable CD4+ cells.  
 
The main mode of action of calcineurin inhibitors is to prevent nuclear localization of 
NFAT by inhibition of the phosphatase activity of calcineurin [275]. We therefore 
investigated nuclear localization of NFATc2 by ImageStream: again, CD4+ T cells were 
activated in the presence of 6.25ng/ml CsA. The acquisition showed small cells with 
most of the NFATc2 signal in the cytoplasm (Figure 38A, top row) and big cells in which 
the NFATc2 signal co-localized with the DAPI signal (Figure 38A, bottom row). The 
histogram of the similarity dilate, a value used to score co-localization of signals, 
indicates that at a concentration of 6.25ng/ml CsA in culture, CD28ko cells show less 







Figure 38. NFATc2 nuclear translocation is reduced in CD28ko cells and rescued by exogenous miR-17~92 
expression 
48h activated CD4+ T cells with 6.25ng/ml Cyclosporin A, stained for DAPI (blue) and NFATc2 (red).  
A) Examples of ImageStream acquisition images for not translocated (top) and translocated (bottom) 
NFAT in a CD28ko sample. B) ImageStream data: histogram of the similarity dilate for each sample, 
indicative of the co-localization of NFATc2 and DAPI signal, gates indicate the translocated population 
(high similarity dilate) and the non-translocated population (low similarity dilate) 
 
With this, we concluded that CD28ko cells are more sensitive to CsA as compared to 
wt cells, which is rescued by transgenic miR-17~92 expression in CD28ko cells. We 
suggest that this happens via a so far unknown mechanism, which is the promotion of 
calcineurin activity via regulation of the natural calcineurin inhibitor RCAN3. As this is 
an essential aspect of immune suppression, our work suggests new possibilities for 







The importance of miR-17~92 expression for the function of CD4+ T cells has been 
established by independent research groups for different TH subsets and models [134, 
208, 216, 234-237, 240].  Although some of these reports are in contrast to each other, 
a few key effects of miR-17~92 expression have been agreed on [227], which are 
mainly the amplification of cytokine expression as well as promotion of proliferation. 
Based on our own findings and published data [208] we hypothesized that 
overexpression of miR-17~92, which is normally induced with CD28 co-stimulation 
[215], might compensate for the co-stimulatory signal given by this receptor. Thus, we 
elucidated if transgenic miR-17~92 expression compensates for CD28 signaling in CD4+ 
T cell activation in vitro and in vivo. This concept was also suggested by Benhamou et 
al. [276] who could show that activation of B cells partially depends on PI3K activity, 
which is initiated by the co-stimulatory signal given by CD19 in this case. Similar to 
CD28ko T cells, CD19ko B cells are deficient in activation, proliferation and 
differentiation. Benhamou et al. showed that the artificial expression of miR-17~92 in 
B cells can partially compensate for CD19 deficiency [41]. Moreover, the authors 
investigated the role of a known miR-17~92 target, PTEN [277], which restricts the 
CD19-PI3K axis. They demonstrate an autostimulatory axis of c-Myc/miR-17~92/PTEN 
which regulates PI3K mediated positive and negative selection. However, other 
pathways than PI3K or other targets remain obscure in this publication. PTEN was also 
shown to be an important miR-17~92 target in T cells, though Baumjohann et al. 
showed that limitation of PTEN expression to one allele alone could not restore the 
phenotype of miR1792lox mice in TFH differentiation [134], which strongly suggests 
that other targets must be regulated in this setting as well. Many different targets for 
all members of the miR-17~92 cluster have been validated so far [227, 228]. We 
identify a new list of bona fide canonical target genes in our setting, which are not 
only regulated by miR-17~92 but also by CD28 expression. Importantly, by showing 
that the overexpression of miR-17~92 rescued the expression of these genes, we also 
provide evidence that the rescue is not only a phenotypic effect, but also manifested 





demonstrates that during activation of CD4+ T cells with CD28 co-stimulation, which is 
known to induce the expression of genes, also the repression of genes is essential.  
We searched for pathways other than PI3K that are regulated by miR-17~92 during 
CD4+ T cell activation, and found that also calcineurin-NFAT axis is promoted by miR-
17~92 expression. We suggest a new target for miR-17, which is the cell-intrinsic 
calcineurin inhibitor RCAN3 [112]. Repression of RCAN3 by miR-17 increases 
calcineurin activity, consequently leading to increased NFAT activity, with marked 
consequences for cell fate. 
 
7.1. miR-17~92 expression promotes CD4+ T cell activation 
Baumjohann et al. showed that reduced miR-17~92 expression decreases 
proliferation in vitro [134], while Xiao et al. showed increased proliferation due to miR-
17~92 overexpression [231]. Moreover, previous literature suggests that also cytokine 
expression is decreased in the absence of miR-17~92 expression, and increased in the 
case of miR-17~92 overexpression [231]. 
Here, we show that IL-2 production and secretion as well as proliferation are 
proportional to miR-17~92 expression. Of note, differences in miR1792lox vs wt as 
well as miR1792tg vs wt are relatively small, which reflects the general problem of 
subtle changes in miRNA studies. Usually, large number of samples are required to 
reach significant differences [278]. This is also partially caused by the paralogue 
clusters whose expression is unchanged in these mouse models, and their function 
which is partially redundant to miR-17~92 [192, 218]. From these experiments, we 
concluded that IL-2 production and proliferation is promoted by miR-17~92 
expression. These findings are in accordance with previously published literature.  
CD4+ T cell activation results in major changes in the CD4+ T cell’s metabolism 
regarding glucose uptake and glycolytic activity. MiR-17~92 is involved in the 
regulation of c-Myc, which is an important regulator of metabolism [279]. 
Interestingly, we found increased glucose uptake in naïve miR1792tg CD4+ T cells, but 
no difference in mitochondria stress tests. This suggests that glucose uptake is 
promoted by miR-17~92 expression, however it is not metabolized by glycolysis or 
oxidative phosphorylation. This shows that naïve miR1792tg CD4+ T cells metabolically 





transgenic miR-17~92 expression leads to some kind of metabolic checkpoint passage. 
We could probably argue that this is expected since miR-17~92 expression is usually 
only induced during CD4+ T cell activation [215] and target genes might not be 
expressed in the naïve setting. In activated CD4+ T cells, miR-17~92 expression 
correlates with metabolic activity. However, we suppose that this results from higher 
activation the more miRNA cluster is expressed as suggested already by our previous 
experiments.  
In order to get a deeper insight into the metabolic phenotype of activated CD4+ T cell 
cells of different miR-17~92 expression, we performed a metabolomics analysis on 
activated CD4+ T cell lysates. There we found only eight metabolites which were 
differentially abundant in the direct comparison of miR1792tg to miR1792lox cells. 
Moreover, these metabolites belonged to distinct pathways and FC were just above 
cut-off, which raised the question if the detected differences are biologically relevant. 
We investigated our RNA sequencing results for the same pathways, which did not 
reveal patterns of pathways being repressed or promoted by miR-17~92 expression. 
With these results we could not confirm, nor neglect, the hypothesis of metabolic 
checkpoint allowance by miR-17~92 expression during CD4+ T cell activation.  
 
From this first part of the thesis, we concluded that miR-17~92 expression directly 
correlates with CD4+ T cell activation, including IL-2 production as well as proliferation 
and metabolic activity. Notably, the differences relative to wt in these experiments 
were sometimes subtle, which provokes the question of biological significance. Blevins 
et al. suggested that the role of miRNAs is more the regulation of cell-to-cell variability 
than active meaningful changes in cell phenotype [186]. Thus, upregulation of miR-
17~92 expression regulates genes which are also upregulated during activation in 
feedback loops. However, the significance of the differences introduced by miRNAs 
have been extensively debated in the past (reviewed e.g. in [278]): with the regulation 
of genes close to specific threshold levels, miRNAs might, even if introducing only 
small changes in target gene expression, also mediate important on-off switches. 
Since CD4+ T cell activation is a very dynamic process of parallel changes in expression 
of surface molecules as well as intracellular proteins, we hypothesized that miR-17~92 





7.2. Exogenous miR-17~92 expression rescues CD28 
deficiency  
7.2.1. Exogenous miR-17~92 expression compensates for CD28 signal 
during in vitro activation 
Different key aspects of CD4+ T cell activation were shown to be regulated by CD28 as 
well as miR-17~92 expression. Xiao et al. showed that miR1792tg cells proliferate 
better than wt cells when stimulated with αCD3 alone [231]. Therefore, we expected 
from our B6.CD4cre.Rosa26loxSTOPloxCAG-miR-17~92.CD28ko (rescue) mouse model 
that proliferation and other aspects of CD4+ T cell activation are restored by 
exogenous miR-17~92 expression. We found that IL-2 production in rescue cells was 
not only rescued to the wt amount, but even higher as compared to wt cells. One 
explanation for this supraphysiologic rescue might be that with transgenic expression, 
more miR-17~92 expression is achieved than during activation of wt cells. Since miR-
17~92 was shown to promote PI3K dependent pathways, the PI3K dependent aspect 
of IL-2 production, which is IL-2 transcription [162], might be over-compensated. 
Moreover, this assay was performed with PMA/Iono stimulation. Iono initiates Ca2+ 
influx [280] while PMA acts on Ras [281], both resulting in increased IL-2 production.  
Thus, we might look at Ca2+ dependent pathways that could be promoted by 
transgenic miR-17~92 expression.  
As expected from the literature [231], proliferation and blasting was rescued by 
transgenic miR-17~92 expression. More surprising to us was that all genotypes 
induced CD25 and CD69 expression: CD25 was previously shown to be CD28 
dependent [282] while CD69 was not [117]. Investigation of the MFI revealed that 
CD69 is actually unchanged, while CD25 MFI depends on CD28 or miR-17~92 
expression. One explanation for this might be that exogenous IL-2 was present in the 
culture, which might lead to CD25 induction [283]. The differences that we observe in 
MFI might then originate from autocrine IL-2 stimulation. The differences in 
CD44hiCD62Llo populations were expected since we had shown in previous 
experiments that activation is rescued by exogenous miR-17~92 expression. However, 





These experiments demonstrated that exogenous miR-17~92 expression can indeed 
compensate for CD28 signaling during in vitro activation of CD4+ T cells in terms of IL-
2 production, proliferation and surface marker upregulation similar to what 
Benhamou et al. had reported for CD19 deficient B cells. 
 
7.2.2. Exogenous miR-17~92 expression compensates for CD28 
deficiency during in vitro differentiation 
After encountering an antigen in a specific context (e.g. cytokine milieu) during an 
infection, the CD4+ T cell fate changes according to extracellular signals. The networks 
of master regulators, STAT proteins and cytokines in TH differentiation are complex: 
Lineage fates influence each other by repression of TFs or interaction between master 
regulators. However, these networks are also partially redundant, with the 
consequence that differentiation is possible even if single players of the networks are 
absent [284]. For example, Usui et al. reported that Tbet is not absolutely essential for 
IFNγ production as long as IL-4 signals are blocked [285]. miRNAs were shown to 
influence differentiation of subsets e.g. by targeting TFs [134], therefore we expected 
an influence on differentiation of rescue cells as well.  
We observed that TH1 differentiation was delayed for Tbet production in CD28ko cells 
and rescued by exogenous miR-17~92 expression. IFNγ production was massively 
increased by exogenous miR-17~92 expression, which might be explained by the fact 
that STAT5, a signaling molecule downstream of IL-2R, regulates IFNγ locus availability 
[94, 286], and we showed that IL-2 production is increased with miR-17~92 
expression. In this case, on one hand cell-intrinsic IL-2 production might promote IFNγ 
production in rescue cells, but additionally reduced expression of CD25 in CD28ko cells 
as seen in previous experiments might reduce signaling from IL-2 contained in the 
culture. 
Rorγt expression was impaired in CD28ko cells as compared to wt during TH17 
differentiation, and exogenous miR-17~92 expression led to a rescue, even though 
with different kinetics in Rorγt induction as compared to wt. Moreover, miR1792tg 
cells even expressed less Rorγt than wt at 24h post induction, while later on 





cells, and only partially rescued by exogenous miR-17~92 expression. MiR1792tg cells 
also were delayed in their IL-17A production as compared to wt.  
The data for CD28ko cells looks like contrast to published literature which showed that 
CD28 co-stimulation actually inhibits in vitro generation of IL-17A producing cells 
[165]. Of note, Bouguermouh et al. stain their cells at day four or five (other than our 
experiments which end on day three) after six hours of PMA/Iono restimulation. 
Moreover, in their publication most of the experiments were conducted without the 
addition of neutralizing antibodies for IL-2 and IFNγ. However, the authors also include 
one experiment where they added these antibodies, with the result that IL-17A 
production was similar between CD28ko and wt cells. They therefore claim that CD28 
inhibits TH17 differentiation by promoting IL-2 and IFNγ. This means that this 
publication is actually not necessarily in contrast to our experiments, since we 
included neutralizing antibodies in our culture, and we observed a delay in IL-17A 
expression induction in CD28ko cells. The data on rescue and miR1792tg cells argues 
for a complex network of regulatory mechanisms which are partially influenced by 
miR-17~92 in a timing-dependent manner. One possible explanation for this 
phenotype might be that not all members of the miR-17~92 cluster promote the same 
differentiation processes: Montoya et al. showed that miR-18a has an inhibitory effect 
on TH17 development [237], while miR-17 family members promoted cytokine 
production. This indicates that different TH17 inhibitory- and promoting mechanisms 
are happening at the same time and sequentially after each other in this setting, 
resulting in a mixed, timing-dependent phenotype. Additionally, the Montoya et al. 
show that during TH17 differentiation, not all members of the cluster are regulated or 
processed to the same extent, resulting in differential expression of different cluster 
members. This suggests that during differentiation, timing of individual miRNA 
expression is very important, target mRNAs might be upregulated early and get 
repressed later, which would explain why miR1792tg cells are first delayed in Rorγt 
induction but later on produce more IL-17A than wt. Our observation at 24h suggests 
that excess miR-17~92 expression is inhibitory for TH17 differentiation in early stages 
(which is consistent with the findings from Montoya at al.). However, at a later time 
point, the miR-17~92 is needed to some extent since miR-17~92 expression does 





what Montoya et al. showed, since they investigated day 3.5 post differentiation, 
which might be regulated by a different interplay of miRNAs and targets again. 
Surprisingly, we observed reduced differentiation into iTreg cells in CD28ko cells and 
complete rescue by exogenous miR-17~92 expression. This was unexpected because 
so far, miR-17~92 was reported to inhibit iTreg differentiation [208]. Several 
differences in the experimental procedure might explain for this discrepancy: first of 
all, the time point of harvest by Jiang et al. was at day six (other than day one to three 
in our experiment). Second, they only used 50U/ml of IL-2 during their culture, which 
is 5-fold less than what we use for iTreg differentiation. Additionally, the amount of 
αCD28/αCD3, which is not indicated in their publication, might change the relevance 
of miR-17~92 cluster expression during the experiment [134]. Moreover, strong CD28 
signals were shown to inhibit Foxp3 induction [287]. Assuming that miR-17~92 
amplifies CD28 signaling, co-stimulation with higher concentrations than in our setting 
might therefore lead to different experimental outcomes. 
Of note, at 72h post induction also viability was impaired in CD28ko samples of TH17 
and iTreg differentiation, which was expected from the literature since CD28 was 
shown to induce pro-survival gene B-cell lymphoma-extra large (Bcl-XL)[288]. 
Interestingly, exogenous miR-17~92 partially rescued viability during in vitro 
differentiation. To look into this, we used our second RNA sequencing set, for which 
we had extracted RNA from 24h activated wt, CD28ko, rescue, miR1792tg and 
miR1792lox cells (see section 6.3.4). Of note, other than the in vitro differentiation, 
these cells are only activated but not skewed into a specific subset. We confirmed with 
RNA sequencing data that Bcl-XL expression is indeed reduced in CD28ko as compared 
to wt during CD4+ T cell activation, but partially rescued upon exogenous miR-17~92 
expression, which fits previous literature showing a beneficial effect of miR-17~92 
expression on survival [208]. However, miR1792tg cells showed similar viability as wt 
cells, and Bcl-XL expression is similar. This suggests that an expression threshold of Bcl-
XL might be achieved by natural miR-17~92 induction in activated wt cells, so that 
additional miR-17~92 from the transgene does not further increase Bcl-XL expression. 
 
Overall, these in vitro differentiation assays led to the conclusion that also for complex 





CD28 deficiency. Of note, the extent of rescue is time- and subset dependent, but in 
all subsets a rescue could be observed. This suggests that different targets are 
regulating processes of CD4+ T cell differentiation, and all of them have their individual 
contribution, which emphasizes the need for the identification of miR-17~92 targets. 
Moreover, since all subsets were affected, this also implied that there might be targets 
that are common among distinct TH subsets 
 
7.2.3.  Exogenous miR-17~92 expression rescues CD28 deficiency in 
CD4+ T cells in vivo 
The importance of CD28 as well as miR-17~92 expression for TFH and germinal center 
differentiation has been established [134, 140, 216]. Additionally, CD44 was shown to 
positively correlate with miR-17~92 expression during acute viral infection [134, 216]. 
Similar to our in vitro results and in accordance to this literature, CD44 is reduced in 
CD28ko cells as compared to wt, and rescued upon exogenous miR-17~92 expression. 
If CD44 is a “side-effect” or active contributor to the enhanced activation cannot be 
decided at this point: CD44 cannot induce proliferation of CD4+ T cells, but it was 
reported to promote Lck and Fyn, suggesting an influence on T cell activation [289, 
290].  
As expected from the literature, TFH (CD3+CD4+CXCR5+Bcl-6+ICOS+PD-1+) and GC B cells 
(CD19+B220+Fas+GL7+) are reduced in CD28ko as compared to wt mice [140] in our 
experiments. Exogenous miR-17~92 expression restored both TFH as well as GC 
populations. The development of GC B cells suggests for a functional TFH 
differentiation.  This raises the question whether miR-17~92 consequently also 
rescues the functionality of GC B cells. Additional experiments to test this would be to 
investigate the antibody repertoire for isotype switch and specificity, as well as 
cytokine secretion, e.g. IL-21. Especially, we report a strong effect of miR-17~92 
expression on ICOS as well as PD-1 induction. This could be interpreted as a direct 
consequence of CD28 signaling independent from TFH differentiation, since ICOS 
expression is induced on CD4+ T cells via CD28 dependent and independent pathways 
[149, 159]. DiToro et al. recently showed that those CD4+ T cells which produce IL-2 





are not able to differentiate to TFH [291]. Moreover, they reported that the most 
significantly enhanced gene sets in IL-2 producers were those of Myc and E2F family 
of TFs. This is especially interesting because these TFs are known to be involved in 
auto-regulatory loops with miR-17~92 [224, 225, 230], which might suggest that these 
cells express miR-17~92, promoting IL-2. This might represent another, so far 
unknown possibility of how miR-17~92 contributes to increased TFH differentiation. 
DiToro et al. further propose that their phenotype results from thresholds in T cell 
activation, with stronger activation leading to IL-2 production and TFH differentiation. 
Considering this literature, we suggest that (among other effects, like e.g. the 
targeting of Rorα [134]) miR-17~92 enhances T cell activation with cell-intrinsic IL-2 
production, which allows wt, miR1792tg and rescue cells to acquire TFH phenotype, 
and accordingly reduces TFH differentiation in CD28ko and miR1792lox.  
Other than in our in vitro experiments, IFNγ production was not overcompensated in 
the rescue cells as compared to CD28ko cells, which might be due to the more 
physiologic differentiation conditions in vivo, or the different time point that we 
investigate in this experiment. Similar to the in vitro data, also in vivo we can speculate 
that reduced IL-2 production in CD28ko mice leads to reduced IFNγ production. 
Moreover, for TH1 differentiation, we assume that CD44 upregulation in wt and rescue 
cells might enhance differentiation in this setting, since Baaten et al. reported that 
CD44 expression promoted TH1 effector cell survival [292].  
Overall, we concluded from our experiments that also in vivo, exogenous miR-17~92 
expression compensates for CD28 deficiency in terms of TFH and TH1 differentiation.  
 
7.2.4. Exogenous miR-17~92 expression rescue effect is CD4+ T cell 
intrinsic 
One caveat of our rescue mouse model is that CD4cre expression might lead to side 
effects in cell populations other than CD4+ T cells, raising the question if the rescue 
effect that we observed in our in vivo experiments was CD4+ T cell intrinsic. We found 
fewer Vα2+Vβ8.3+ CD28ko cells in all investigated organs after adoptive transfer of 
SMARTA+ cells with subsequent LCMV infection. Importantly, the population was 





proliferation defect which we showed in previous experiments, this effect might be 
mediated by IL-2: IL-2 production in recipient CD28ko mice is reduced [162], so that 
IL-2 produced by donor cells is needed for proper expansion. Since our in vitro 
experiments showed that IL-2 production is reduced in CD28ko but rescued by 
exogenous miR-17~92 expression, we propose that expansion might also be reduced 
due to low IL-2 abundance in CD28ko recipients. Moreover, Vα2+Vβ8.3+ CD28ko cells 
were reduced in their CD44 expression as compared to wt, which was fully rescued by 
exogenous miR-17~92 expression. This argues that not only expansion, but also 
activation is diminished in CD28ko cells. Again, further experiments will be interesting 
to elucidate if CD44 expression is actually a consequence or a precondition for T cell 
differentiation at this point, and also if this is a direct or an indirect effect of miR-17~92 
expression. Possible experiments to test this would be the use of CD44 blocking 
antibodies or, in a more laborious approach, CD44 gene targeting.  
So far, we concluded from these transfer experiments that the rescue effect of miR-
17~92 expression was CD4+ T cell intrinsic. Moreover, as mentioned in the previous 
section, effects on IL-2 production could explain for some, but not all of the results. 
We could test this by the addition of IL-2 blocking antibodies or IL-2 injections. 
However, we set priority on elucidating if the rescue was phenotypic or actually 
mediated in the transcriptome, which on one hand might show how IL-2 is regulated 







7.3. Molecular mechanism of the rescue effect 
Many targets for miR-17~92 have been described and validated so far, among them 
PTEN [218, 232], Klf2 [242], TGFβRII [208] and PHLPP2 [216]. Some of them might also 
contribute to our phenotype, explaining for the effect of miR-17~92 on T cell 
activation. Most likely, multiple targets cooperate in their function, resulting in a 
complex network of parallel processes to synergistically amplify activation. Clearly, 
PI3K is established as a pathway that is promoted by miR-17~92 e.g. through 
repression of PTEN. However, the possibility remained that there are still unknown 
targets that regulate other pathways, which were not detected in previous screenings 
e.g. due to different experimental setup.  
We show that miR-17~92 expression shapes the transcriptome during CD4+ T cell 
activation. Importantly, changes start at 24h post activation and possibly have 
secondary effects so that even more genes are differentially expressed at 48h. With 
GSEA we detected that cytokines are promoted by miR-17~92, which in principle was 
known before [208, 231, 234, 235]. However, what has not been addressed before is 
that different cytokines can be promoted by one common pathway, which is the 
calcineurin-NFAT axis [128]. Of note, differences in IL-2 mRNA expression at 24h or 
48h are not striking in this heatmap. This might be reasoned by different regulatory 
mechanisms of IL-2 production as previously mentioned, but also in different 
experimental conditions: ELISA at 48h was measured from culture supernatants 
without the addition of exogenous IL-2 at the beginning, so that intrinsic IL-2 
production by each cell type might result in auto-stimulatory loops, which then 
amplified the differences. 
 
7.3.1. Identification of miR-17~92 bona fide canonical target genes 
during activation 
We used stringent criteria to identify bona fide canonical target genes in our list of 
thousands of genes which were identified by RNA sequencing. This came at the cost 
of excluding target genes that might be relevant in some “unconventional” way. For 
example, with this analysis we excluded so-called non-canonical miRNA targets: the 





were shown to also bind to RNA with bulges and wobbles, thus non-perfect seed 
matches. Moreover, the targeting can happen also outside the 3’UTR and in a RISC-
independent manner [293]. Thus, our data set theoretically allows also for the 
identification of non-canonical targets, however we prioritized the canonical targets. 
With contrasts between activated miR1792lox and wt as well as miR1792tg and wt, 
we show that RISC-bound genes from each seed family are increased in their FC in the 
absence of miR-17~92, and also decreased in FC in miR-17~92 overexpression. 
Notably, distinct miRNA seed families show slightly different behavior: while miR-17 
seed family members shift very clearly, the shift is less pronounced in miR-18, miR-19 
and miR-92 seed families. Different explanations might account for this phenotype.  
First of all, the regulation of miRNA targets is context dependent so that one seed 
family or miRNA might be more important in a specific setting as compared to a 
different miRNA of the same cluster. Second, there might be less genes expressed that 
are targeted by a specific seed family in this setting. Third, the efficiency of targeting 
(i.e. resulting in a change in expression of the targeted gene) also depends on the 
target abundance: Mukherji et al. showed that low abundant targets can be 2-fold 
suppressed effectively with only one miRNA binding site, and seven binding sites 
reduce the target 10-fold. However, if the target is highly expressed, no matter if one 
or seven binding sites were present, only a 2-fold reduction was achieved [187]. With 
this, we can clearly say that miRNAs set thresholds in gene expression, which enables 
them on one hand to mediate on-off switch of genes at low target expression but also 
fine-tuning at high target expression. Additionally, the individual members of miR-
17~92 might be differentially regulated, resulting in different abundance and 
consequently differential regulation of the specific target genes [216, 237]. The 
contrasts of naïve cells were not shifted for the miR1792lox vs. wt. We might speculate 
from this data that miR-17~92 expression is not essential in naïve CD4+ T cells, which 
would also fit the fact that the cluster expression is only induced upon CD28 co-
stimulation [215]. Alternatively, since the literature suggests redundancy for some 
targets, paralogue clusters might compensate for miR-17~92 function in the naïve 
setting [24]. Other than suggested by PCA, the CDF plot for the contrast between naïve 
miR1792tg and wt cells shows a shift for miR-17, miR-19 and miR-92 family members, 





well. However, we focus on the analysis of genes that are differentially expressed 
during activation. The difference between CDF plot and PCA might originate from less 
restrictions in the PCA: the CDF plots focus on genes which are also detected in the 
AHC. 
Some more targets might be excluded with the EISA criterium: if a gene is regulated 
transcriptionally as well as post-transcriptionally, it is also excluded from our analysis. 
Moreover, genes that are targeted by miRNAs from paralogue clusters might not be 
contained in our list, since redundant function might prevent changes in the 
miR1792lox vs. wt situation, while there might be a significant change in the 
miR1792tg vs wt contrast. 
Any gene in the list of 125 canonical bona fide target genes might contribute to the 
rescue phenotype. However, this does not imply that the changes in expression of 
these genes introduced by miRNA in this setting are actually biologically relevant. As 
mentioned previously, small changes at threshold expression level might have a bigger 
impact as compared to larger changes at higher expression. Importantly, some of 
these genes also harbor multiple seed sequences for different family members, which 
also opens possibilities for multiple regulatory mechanisms that depending on the 
abundance of individual miRNAs. Another effect that we do not cover in this project 
is the possibility of selective avoidance, which is the shortening of the 3’UTR during 
activation and proliferation, leading to the loss of miRNA binding sites and therefore 
escape of repression in ongoing activation. In our bona fide canonical target gene list 
we find known and validated target genes like TGFβRII [208] and PHLPP2 [216], which 
serve as positive controls for our analysis. Of note, we do not expect all of the “typical” 
target genes in this list since timing and experimental conditions might be different 
from the settings in which they were published. However, the question remained if 
the transcriptome of CD28ko cells was rescued by exogenous miR-17~92 expression 
as well, and if the genes that we identified as bona fide canonical target genes might 






7.3.2. Exogenous miR-17~92 expression partially rescues the 
transcriptome of CD28ko cells  
CD28 was shown to be an essential contributor to shaping the transcriptome during 
CD4+ T cell activation [273]. We confirmed these data and additionally demonstrate 
that exogenous miR-17~92 expression partially rescues the transcriptome of CD28ko 
cells. Furthermore, even if miR1792lox cells phenocopied CD28ko cells in CD4+ T cell 
activation, their transcriptome was markedly different. Following our hypothesis that 
exogenous miR-17~92 expression amplifies CD28-dependent CD4+ T cell activation, 
we note that miR1792tg cells (most activated) showed the biggest difference to 
CD28ko (least activated) cells. Importantly, the bona fide canonical target genes that 
we identified with the previous RNA sequencing data set were also dysregulated in 
the CD28ko vs. wt contrast, which argues that these genes are regulated by CD28 as 
well as miR-17~92. The contrast of rescue vs. wt samples shows that the same genes 
are also rescued in their expression FC by exogenous miR-17~92 expression. This 
confirms that these target genes actually do mediate the rescue that we observe 
phenotypically also in the transcriptome. Of note, the miR-18 seed family again shows 
a milder phenotype, indicating that genes which are targeted by this family are not 
fully rescued by exogenous miR-17~92 expression. Like before, differential expression 
of individual miRNAs and timing might account for this difference. Moreover, miR-18 
has been reported to antagonize the function of other miR-17~92 family members 
[237], which might also be the case in this setting. Since also in our target gene list we 
only find five genes that are targeted by a miR-18 seed family member, most likely 
target genes of miR-18 are not as relevant in this setting as targets of other seed 
families.  
Most importantly, we conclude from this dataset that not only the CD28 signaling 
dependent induction of transcription contributes to CD4+ T cell activation, but also the 
repression of genes which is mediated by miR-17~92. This concept resembles of TH 






7.3.3. Target gene RCAN3 expression is dependent on CD28 or miR-
17~92 expression 
As mentioned previously, the NFAT pathway is an interesting candidate to investigate 
for target genes since it is one common factor promoting cytokines of different TH 
subsets [128]. Increased NFAT activity might also explain increased expression of ICOS: 
an elegant study performed by Tan et al. investigated different TCR and CD28 
dependent signaling molecules for their potential to induce ICOS expression. Using 
selective chemical inhibitors, the authors found that Fyn promotes ICOS expression 
via NFATc2, while MEK and Erk also induce ICOS in an independent pathway [149]. 
Within our list of 125 bona fide canonical target genes, we identified RCAN3, a 
regulator of calcineurin activity, as a target gene that might influence T cell activation 
by regulating NFAT. Among all different miRNA binding sites in the 3’UTR of RCAN3, 
only the miR-17-5p/20-5p/93-5p/106-5p site was bound to Ago2, indicating that this 
is the only active miRNA target site in this setting. qPCR confirms that RCAN3 mRNA is 
negatively correlated with miR-17~92 expression. Interestingly, RCAN3 protein 
abundance was increased in CD28ko and miR1792lox while wt, rescue and miR1792tg 
cells were comparable in their expression. This suggests that differences in mRNA 
abundance due to miRNA targeting translate into protein. However, it also indicates 
that a certain miR-17~92 expression threshold is sufficient to repress RCAN3. In 
αCD3/αCD28 activated wt cells, this is reached by natural miR-17~92 induction while 
exogenous miR-17~92 in rescue cells reduces RCAN3 expression. 
The gold standard for the ultimate validation of RCAN3 would be the interruption of 
the miR-17~92-RCAN3-calcineurin/NFAT pathway. Distinct approaches for this are 
possible, from the complete RCAN3ko to mutations in the calcineurin interaction 
motif or mutation of the miRNA target site. Canaider et al. successfully knocked out 
RCAN3 expression in HUVEC cells using small interfering RNA (siRNA) [294], which 
reduced proliferation. We attempted to do the same in primary CD4+ T cells, however 
in our setting we could not measure an impact of RCAN3 siRNA on any of our 
parameters. Nevertheless, it was unclear if the experimental set up was suitable for 
our case, since CD4+ T cells need to get activated before they can be electroporated. 





for resting the cells before analysis. Different targeting strategies are possible for the 
gene editing approach. Importantly, several publications [294, 295] have shown that 
Exon 1 of RCAN3 can be non-coding, making it unattractive for gene editing purposes. 
We rather suggest to target the region harboring the CIC motif within Exon 5, which 
was found to be the interacting domain for calcineurin [112]. Preliminary results 
suggest that editing efficiency of 50-60% can be achieved in this locus. Further 
experiments will show if these mutations have any biological effect, e.g. increase IL-2 
production.  
Another approach is the mutation of the miR-17 seed sequence of RCAN3 to 
investigate the functional importance of this miRNA:mRNA interaction [278, 296]. For 
this, we suggest to use rescue cells and target their miR-17 seed sequence in the 
RCAN3 3’UTR. This should reduce the RCAN3 targeting, and abolish the rescue affect. 
However, also this experiment will need careful optimization: with the use of classical 
Cas9 derived from S.pyogenes, we are dependent on the abundance of the 
protospacer adjacent motif (PAM) sequence NGG directly downstream of the target 
locus [297, 298], which will induce a double strand break in the DNA 4bp upstream of 
the PAM. The challenge at this point is that the seed sequence is only 8nt in length, 
and the PAMs around this seed allow only double strand breaks right after and before 
the seed. Since disruption of the seed or deletion is needed, this suggests the use of a 
multiplexing approach, introducing two double strand breaks at both sides of the 
seed, with the chance of recombination without the seed. However, this might result 
in a mild phenotype: due to redundancy of miRNA function, the phenotypic 
consequences of a single miRNA:target disruption can be very minor [299].  
Over all, these experiments to knock out RCAN3 are possible but will need careful 
optimization and control of the experimental setup. So far, we suggest that RCAN3 is 
most likely targeted by miR-17, leading to differences in mRNA and protein expression 






7.3.4. Exogenous miR-17~92 expression decreases sensitivity to 
Cyclosporin A 
The activity of calcineurin leads to NFAT de-phosphorylation, translocation to the 
nucleus [51] and initiation of transcriptional activation. Therefore, the consequences 
of increased (or decreased) RCAN3 expression are crucial for CD4+ T cell activation and 
differentiation. Current immunosuppressive drugs like CsA and FK506 target CD4+ T 
cell activation by inhibition of the enzymatic activity of calcineurin [300]. This leads to 
a very efficient inhibition of the NFAT pathway and T cell activation, however it comes 
at the cost of severe side effects [301].  We hypothesized that manipulation of a 
natural calcineurin inhibitor like RCAN3 with miR-17~92 modifies the sensitivity to 
CsA. Indeed, we demonstrate that CD28ko cells react more sensitively to CsA than wt 
and rescue cells, which was also manifested in decreased nuclear localization of NFAT. 
CD28 so far had only been shown to be essential for nuclear localization of NFκB [162], 
and it had been demonstrated before that NFAT dependent transcription of IL-2 was 
abolished by CsA [302, 303]. Surprisingly, nuclear localization of NFAT in CD28ko was 
only partially reduced in low concentrations of CsA. However, this seemed to be 
sufficient to reduce activation. 
Usually, cytokines bind to their corresponding receptors which signal via STAT proteins 
to initiate transcription of TFs and cytokines, which then act in a feedback loop [125, 
284, 285, 304]. We suggest that this loop is interrupted in CD28ko cells through 
increased RCAN3 expression, resulting in decreased NFAT nuclear localization and 
reduced cytokine production. With exogenous miR-17~92 expression, leading to 
targeting and repression of RCAN3, NFAT activity is increased, cytokine expression is 
promoted and the loop is at least partially restored. 
These experiments indicate that miR-17~92 and CD28 expression are contributing 
factors to CsA responsiveness. We propose that this effect is mediated by RCAN3 
repression, which consequently promotes calcineurin activity. This discovery bears 
great potential for development of new therapeutic approaches in 






7.4. Relevance and future perspective 
The relevance of CD28 for immune therapy is diverse. On one hand, it has been shown 
to be essential for the efficacy of PD-1 checkpoint blockade [147, 148] and immune 
suppression [305] but also lately in the development of chimeric antigen receptor 
(CAR) T cells, intracellular CD28 signaling domains have been shown to be crucial for 
function [306]. The role of miR-17~92 in the context of CD28 that we demonstrated in 
this thesis therefore bears great potential for the development of new therapies. 
However, the translation of our findings in mice to human is delicate and will need 
detailed investigation. The exact translation of miRNA findings from mouse to human 
is usually difficult. Expression of targets, miRNAs and conservation has to be verified 
[192, 307]. miR-17~92 is highly conserved between mice and humans, has been shown 
to be expressed in human CD4+ T cells, and it was demonstrated to be important for 
the human CD4+ T cell function (see section 3.2.3.4). For example, in Jurkat cells, an 
immortalized cell line of human T lymphocytes, transgenic expression of miR-17~92 
led to increased IL-2 production [308]. We therefore expect that the role for miR-
17~92 in CD28 dependent co-stimulation of human CD4+ T cells is similarly important 
as in murine CD4+ T cells, although this still has to be investigated. The expression of 
target gene RCAN3 is a separate question. Interestingly, more than 20 (theoretical) 
splice variants of this protein were reported so far, however some of them in tissue 
and context dependent manner [309]. It will therefore be crucial to determine which 
RCAN3 variant is present, if the variant is changed upon activation, and if miR-17 also 
suppresses RCAN3 in human CD4+ T cells. Moreover, assuming that this will be the 
case, the sensitivity to calcineurin inhibitors need to be investigated. 
The calcineurin inhibitors FK506 (Tacrolimus) and CsA have been used for treatment 
in the field of organ transplantation for more than 30 years [54]. Both of them share 
their pharmacodynamic property of inhibition of calcineurin [310]. However, even if 
great success in terms of prevention of organ rejection are reached with these 
calcineurin inhibitors, it comes at the cost of nephrotoxicity [311] as well as 
neurotoxicity [312]. The two inhibitors differ in their detailed toxicity profile, however 
both of them induce severe side effects. Even if many attempts for therapy 





inhibitors comes with significantly higher risk of rejection and/or graft loss [54]. With 
our results showing that miR-17~92 promoting calcineurin-NFAT, we identify a new 
potential target for calcineurin inhibition. The idea of promoting RCAN3 activity 
instead of inhibiting calcineurin was already proposed when the molecule was 
described to inhibit calcineurin activity [112]. We suggest to target the miRNA which 
targets RCAN3 for immune modulation: through interfering with miR-17 expression, 
the natural inhibition of calcineurin by RCAN3 might be enhanced. Several 
mechanisms of how targeting of miRNAs could be achieved in patients have been 
suggested [313, 314], e.g. miRNA sponges, antisense oligonucleotides and small 
molecule inhibitors. The first miRNA drug, which is miravirsen targeting miR-122 in 
Hepatitis C treatment, is currently in clinical trials [315, 316]. Thus, targeting of 
miRNAs in patients seems possible, though careful investigation and monitoring of 
potential new side effects will be crucial. 
Another possibility for application would be the exploitation of increased resistance 
to calcineurin inhibitors due to exogenous miR-17~92 expression. This is especially 
interesting in the case of transplantation of engineered cells, e.g. CAR T cells, to 
immunosuppressed patients. Transgenic expression of miR-17~92 in CAR T cells was 
already shown to augment proliferation, IFNγ and targeting efficacy [317]. In addition 
to the beneficial effect of miR-17~92 expression leading to “more activation”, we 
expect to achieve resistance to ongoing immunosuppressive medication, paving the 
way for CAR T cell therapy in organ transplant recipients. 
Next to the potential of RCAN3 and NFAT as new targets of miR-17~92, our data also 
provide the potential for further research. It will be interesting to look into our bona 
fide canonical target gene list and elucidate their role in T cell activation. For this, the 
use of focused candidate gene deletion with CRISPR/Cas9 is the most promising. 
Furthermore, as already mentioned, we restrict our analysis to canonical targets, 
while non-canonical targets might be important for CD4+ T cell activation as well.   
After all, we provide strong evidence that miR-17~92 not only promotes PI3K pathway 
via PTEN repression [218, 232] but also promotes NFAT pathway via RCAN3 targeting. 
It is important to keep in mind that rather the combination of pathways than a single 





investigate combinations of gene deletions to address their cooperative role and 
synergistic effects during CD4+ T cell activation in the future. 
  




8. Conclusion and model 
In the present thesis project, we showed that  
 
1. miR-17~92 is an important modulator of CD28 co-stimulation 
2. exogenous miR-17~92 expression can rescue CD28 deficiency in vitro and 
in vivo  
3. bona fide canonical target genes are regulated by miR-17~92 and CD28, 
and the rescue effect is mediated at transcriptome level 
4. not only induction of expression, but also repression of genes is important 
during CD28 co-stimulation 
5. miR-17~92 promotes calcineurin/NFAT most likely by repressing 
calcineurin inhibitor RCAN3, with modulates sensitivity to calcineurin 
inhibitors 
 
Our results are surprising regarding the fact that other than conventional TFs, miRNAs 
are often seen as fine tuners of expression rather than master regulators of gene 
expression [299]. Importantly, we show that miR-17~92 is an essential contributor to 
CD28 co-stimulation, which possibly results from the sum of different targets and 
pathways regulated by miR-17~92, of which so far only the PI3K pathway has been 
known. We show that also the NFAT pathway is regulated by miR-17~92, most likely 
by targeting RCAN3. This leads to increased expression of NFAT-induced genes, e.g. 








Figure 39. Suggested model for miR-17~92 influence on NFAT pathway  
CD4+ T cell activation with CD28 co-stimulation initiates many different processes, among which is the 
activation of PI3K, recruitment of PLCγ and cleavage of PIP2 to DAG and IP3. IP3 binds to Ca2+ channels 
in the ER membrane, releasing Ca2+ from the ER stores. This is sensed by STIM1/2, which therefore 
interact with ORAI1/2. These change their conformation, allowing Ca2+ influx and activation of 
calcineurin. Calcineurin de-phosphorylates NFAT, which translocates to the nucleus where it dimerizes 
with other factors to initiate transcription. Calcineurin is inhibited by immunosuppressive drugs like CsA 
and FK506. miR-17~92 is also induced with CD28 co-stimulation and regulates different targets, e.g. 
PTEN and PHLPP2 which in turn are inhibitors of the PI3K pathway. We newly suggest RCAN3 as a target 
for miR-17~92, which is a natural inhibitor of calcineurin. Thereby, miR-17~92 indirectly promotes NFAT 










1. Bretscher, P. and M. Cohn, A theory of self-nonself discrimination. Science, 1970. 169(3950): 
p. 1042-9. 
2. Lafferty, K.J. and A.J. Cunningham, A new analysis of allogeneic interactions. Aust J Exp Biol 
Med Sci, 1975. 53(1): p. 27-42. 
3. Schwartz, R.H., et al., T-cell clonal anergy. Cold Spring Harb Symp Quant Biol, 1989. 54 Pt 2: p. 
605-10. 
4. Jenkins, M.K., et al., Inhibition of antigen-specific proliferation of type 1 murine T cell clones 
after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol, 1990. 144(1): p. 
16-22. 
5. June, C.H., et al., The B7 and CD28 receptor families. Immunol Today, 1994. 15(7): p. 321-31. 
6. Truitt, K.E., C.M. Hicks, and J.B. Imboden, Stimulation of CD28 triggers an association between 
CD28 and phosphatidylinositol 3-kinase in Jurkat T cells. J Exp Med, 1994. 179(3): p. 1071-6. 
7. Prasad, K.V., et al., T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-
kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc Natl Acad Sci U S A, 1994. 91(7): p. 
2834-8. 
8. August, A. and B. Dupont, CD28 of T lymphocytes associates with phosphatidylinositol 3-kinase. 
Int Immunol, 1994. 6(5): p. 769-74. 
9. Kapeller, R. and L.C. Cantley, Phosphatidylinositol 3-kinase. Bioessays, 1994. 16(8): p. 565-76. 
10. Meuer, S.C., et al., Clonotypic structures involved in antigen-specific human T cell function. 
Relationship to the T3 molecular complex. J Exp Med, 1983. 157(2): p. 705-19. 
11. Reinherz, E.L., S.C. Meuer, and S.F. Schlossman, The Delineation of Antigen Receptors on 
Human Lymphocytes-T. Immunology Today, 1983. 4(1): p. 5-8. 
12. Reth, M., Antigen Receptor Tail Clue. Nature, 1989. 338(6214): p. 383-384. 
13. Baker, P.E., S. Gillis, and K.A. Smith, Monoclonal Cytolytic T-Cell Lines. Journal of Experimental 
Medicine, 1979. 149(1): p. 273-278. 
14. Chu, K. and D.R. Littman, Requirement for kinase activity of CD4-associated p56lck in antibody-
triggered T cell signal transduction. J Biol Chem, 1994. 269(39): p. 24095-101. 
15. D'Oro, U. and J.D. Ashwell, Cutting edge: The CD45 tyrosine phosphatase is an inhibitor of Lck 
activity in thymocytes. Journal of Immunology, 1999. 162(4): p. 1879-1883. 
16. Bergman, M., et al., The Human P50(Csk) Tyrosine Kinase Phosphorylates P56(Lck) at Tyr-505 
and down Regulates Its Catalytic Activity. Embo Journal, 1992. 11(8): p. 2919-2924. 
17. Pelosi, M., et al., Tyrosine 319 in the interdomain B of ZAP-70 is a binding site for the Src 
homology 2 domain of Lck. Journal of Biological Chemistry, 1999. 274(20): p. 14229-14237. 
18. Au-Yeung, B.B., et al., The structure, regulation, and function of ZAP-70. Immunol Rev, 2009. 
228(1): p. 41-57. 
19. Zhang, W., et al., LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular 
activation. Cell, 1998. 92(1): p. 83-92. 
20. Okkenhaug, K. and B. Vanhaesebroeck, PI3K in lymphocyte development, differentiation and 
activation. Nat Rev Immunol, 2003. 3(4): p. 317-30. 
21. Raab, M., et al., p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, 
growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: 
implications for T-cell costimulation. Proc Natl Acad Sci U S A, 1995. 92(19): p. 8891-5. 
22. Auger, K.R., et al., Phosphatidylinositol 3-Kinase and Its Novel Product, Phosphatidyl-Inositol 3-
Phosphate, Are Present in Saccharomyces-Cerevisiae. Journal of Biological Chemistry, 1989. 
264(34): p. 20181-20184. 
23. Thompson, C.B., et al., CD28 activation pathway regulates the production of multiple T-cell-
derived lymphokines/cytokines. Proc Natl Acad Sci U S A, 1989. 86(4): p. 1333-7. 
24. Acuto, O. and F. Michel, CD28-mediated co-stimulation: a quantitative support for TCR 
signalling. Nat Rev Immunol, 2003. 3(12): p. 939-51. 
25. Williamson, J.R., Inositol Trisphosphate and Diacylglycerol as Intracellular Second Messengers. 
Federation Proceedings, 1985. 44(3): p. R9-R9. 






27. Roskoski, R., Jr., ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res, 
2012. 66(2): p. 105-43. 
28. Jain, J., et al., Nuclear factor of activated T cells contains Fos and Jun. Nature, 1992. 356(6372): 
p. 801-4. 
29. Lin, X., et al., Protein kinase C-theta participates in NF-kappa B activation induced by CD3-CD28 
costimulation through selective activation of I kappa B kinase beta. Molecular and Cellular 
Biology, 2000. 20(8): p. 2933-2940. 
30. Mor, A., M.L. Dustin, and M.R. Philips, Small GTPases and LFA-1 reciprocally modulate 
adhesion and signaling. Immunol Rev, 2007. 218: p. 114-25. 
31. Menasche, G., et al., RIAM links the ADAP/SKAP-55 signaling module to Rap1, facilitating T-
cell-receptor-mediated integrin activation. Molecular and Cellular Biology, 2007. 27(11): p. 
4070-4081. 
32. Ma, Q., et al., Activation-induced conformational changes in the I domain region of lymphocyte 
function-associated antigen 1. J Biol Chem, 2002. 277(12): p. 10638-41. 
33. Burkhardt, J.K., E. Carrizosa, and M.H. Shaffer, The actin cytoskeleton in T cell activation. Annu 
Rev Immunol, 2008. 26: p. 233-59. 
34. Abe, K., et al., Vav2 is an activator of Cdc42, Rac1, and RhoA. Journal of Biological Chemistry, 
2000. 275(14): p. 10141-10149. 
35. Pearce, E.L., Metabolism in T cell activation and differentiation. Curr Opin Immunol, 2010. 
22(3): p. 314-20. 
36. Kane, L.P. and A. Weiss, The PI-3 kinase/Akt pathway and T cell activation: pleiotropic 
pathways downstream of PIP3. Immunol Rev, 2003. 192: p. 7-20. 
37. Frauwirth, K.A., et al., The CD28 signaling pathway regulates glucose metabolism. Immunity, 
2002. 16(6): p. 769-77. 
38. Gamper, C.J. and J.D. Powell, All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent 
and independent signaling pathways in T cells. Front Immunol, 2012. 3: p. 312. 
39. Imboden, J.B. and J.D. Stobo, Transmembrane signalling by the T cell antigen receptor. 
Perturbation of the T3-antigen receptor complex generates inositol phosphates and releases 
calcium ions from intracellular stores. J Exp Med, 1985. 161(3): p. 446-56. 
40. Feske, S., Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol, 2007. 
7(9): p. 690-702. 
41. Stathopulos, P.B., et al., Structural and mechanistic insights into STIM1-mediated initiation of 
store-operated calcium entry. Cell, 2008. 135(1): p. 110-22. 
42. Hogan, P.G., R.S. Lewis, and A. Rao, Molecular basis of calcium signaling in lymphocytes: STIM 
and ORAI. Annu Rev Immunol, 2010. 28: p. 491-533. 
43. Liou, J., et al., STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ influx. 
Curr Biol, 2005. 15(13): p. 1235-41. 
44. Muik, M., et al., Dynamic coupling of the putative coiled-coil domain of ORAI1 with STIM1 
mediates ORAI1 channel activation. J Biol Chem, 2008. 283(12): p. 8014-22. 
45. Li, Z., et al., Mapping the interacting domains of STIM1 and Orai1 in Ca2+ release-activated 
Ca2+ channel activation. J Biol Chem, 2007. 282(40): p. 29448-56. 
46. Feske, S., et al., A mutation in Orai1 causes immune deficiency by abrogating CRAC channel 
function. Nature, 2006. 441(7090): p. 179-85. 
47. Vaeth, M., et al., ORAI2 modulates store-operated calcium entry and T cell-mediated immunity. 
Nat Commun, 2017. 8: p. 14714. 
48. Prakriya, M., et al., Orai1 is an essential pore subunit of the CRAC channel. Nature, 2006. 
443(7108): p. 230-3. 
49. Putney, J.W., Jr., A model for receptor-regulated calcium entry. Cell Calcium, 1986. 7(1): p. 1-
12. 
50. Shaw, P.J. and S. Feske, Physiological and pathophysiological functions of SOCE in the immune 
system. Front Biosci (Elite Ed), 2012. 4: p. 2253-68. 
51. Jain, J., et al., The T-cell transcription factor NFATp is a substrate for calcineurin and interacts 
with Fos and Jun. Nature, 1993. 365(6444): p. 352-5. 
52. Liu, J., et al., Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 
complexes. Cell, 1991. 66(4): p. 807-15. 
53. Loh, C., et al., Calcineurin binds the transcription factor NFAT1 and reversibly regulates its 





54. Azzi, J.R., M.H. Sayegh, and S.G. Mallat, Calcineurin inhibitors: 40 years later, can't live without. 
J Immunol, 2013. 191(12): p. 5785-91. 
55. Desvignes, L., et al., STIM1 controls T cell-mediated immune regulation and inflammation in 
chronic infection. J Clin Invest, 2015. 125(6): p. 2347-62. 
56. Oh-Hora, M., et al., Dual functions for the endoplasmic reticulum calcium sensors STIM1 and 
STIM2 in T cell activation and tolerance. Nat Immunol, 2008. 9(4): p. 432-43. 
57. Shaw, J.P., et al., Identification of a putative regulator of early T cell activation genes. Science, 
1988. 241(4862): p. 202-5. 
58. Flanagan, W.M., et al., Nuclear association of a T-cell transcription factor blocked by FK-506 
and cyclosporin A. Nature, 1991. 352(6338): p. 803-7. 
59. Crist, S.A., D.L. Sprague, and T.L. Ratliff, Nuclear factor of activated T cells (NFAT) mediates 
CD154 expression in megakaryocytes. Blood, 2008. 111(7): p. 3553-61. 
60. Zanoni, I., et al., CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT 
activation. Nature, 2009. 460(7252): p. 264-8. 
61. Shukla, U., et al., Tyrosine phosphorylation of 3BP2 regulates B cell receptor-mediated 
activation of NFAT. J Biol Chem, 2009. 284(49): p. 33719-28. 
62. Muller, M.R., et al., Requirement for balanced Ca/NFAT signaling in hematopoietic and 
embryonic development. Proc Natl Acad Sci U S A, 2009. 106(17): p. 7034-9. 
63. Heit, J.J., et al., Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. 
Nature, 2006. 443(7109): p. 345-9. 
64. Negishi-Koga, T. and H. Takayanagi, Ca2+-NFATc1 signaling is an essential axis of osteoclast 
differentiation. Immunol Rev, 2009. 231(1): p. 241-56. 
65. Northrop, J.P., et al., NF-AT components define a family of transcription factors targeted in T-
cell activation. Nature, 1994. 369(6480): p. 497-502. 
66. Hoey, T., et al., Isolation of two new members of the NF-AT gene family and functional 
characterization of the NF-AT proteins. Immunity, 1995. 2(5): p. 461-72. 
67. Lopez-Rodriguez, C., et al., NFAT5, a constitutively nuclear NFAT protein that does not 
cooperate with Fos and Jun. Proc Natl Acad Sci U S A, 1999. 96(13): p. 7214-9. 
68. Macian, F., NFAT proteins: key regulators of T-cell development and function. Nat Rev 
Immunol, 2005. 5(6): p. 472-84. 
69. Klee, C.B., H. Ren, and X. Wang, Regulation of the calmodulin-stimulated protein phosphatase, 
calcineurin. J Biol Chem, 1998. 273(22): p. 13367-70. 
70. Muller, M.R. and A. Rao, NFAT, immunity and cancer: a transcription factor comes of age. Nat 
Rev Immunol, 2010. 10(9): p. 645-56. 
71. Luo, C., et al., Recombinant NFAT1 (NFATp) is regulated by calcineurin in T cells and mediates 
transcription of several cytokine genes. Mol Cell Biol, 1996. 16(7): p. 3955-66. 
72. Garcia-Cozar, F.J., et al., Two-site interaction of nuclear factor of activated T cells with 
activated calcineurin. J Biol Chem, 1998. 273(37): p. 23877-83. 
73. Shaw, K.T., et al., Immunosuppressive drugs prevent a rapid dephosphorylation of transcription 
factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci U S A, 1995. 92(24): p. 11205-9. 
74. Okamura, H., et al., Concerted dephosphorylation of the transcription factor NFAT1 induces a 
conformational switch that regulates transcriptional activity. Mol Cell, 2000. 6(3): p. 539-50. 
75. Chen, L., et al., Structure of the DNA-binding domains from NFAT, Fos and Jun bound 
specifically to DNA. Nature, 1998. 392(6671): p. 42-8. 
76. Graef, I.A., et al., Evolutionary relationships among Rel domains indicate functional 
diversification by recombination. Proc Natl Acad Sci U S A, 2001. 98(10): p. 5740-5. 
77. Macian, F., C. Lopez-Rodriguez, and A. Rao, Partners in transcription: NFAT and AP-1. 
Oncogene, 2001. 20(19): p. 2476-89. 
78. Mognol, G.P., et al., Cell cycle and apoptosis regulation by NFAT transcription factors: new roles 
for an old player. Cell Death Dis, 2016. 7: p. e2199. 
79. Kim, H.P. and W.J. Leonard, The basis for TCR-mediated regulation of the IL-2 receptor alpha 
chain gene: role of widely separated regulatory elements. EMBO J, 2002. 21(12): p. 3051-9. 
80. van Rietschoten, J.G., et al., Silencer activity of NFATc2 in the interleukin-12 receptor beta 2 
proximal promoter in human T helper cells. J Biol Chem, 2001. 276(37): p. 34509-16. 
81. Macian, F., C. Garcia-Rodriguez, and A. Rao, Gene expression elicited by NFAT in the presence 





82. Zhou, L. and D.R. Littman, Transcriptional regulatory networks in Th17 cell differentiation. Curr 
Opin Immunol, 2009. 21(2): p. 146-52. 
83. Tone, Y., et al., Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. 
Nat Immunol, 2008. 9(2): p. 194-202. 
84. Bronevetsky, Y., et al., T cell activation induces proteasomal degradation of Argonaute and 
rapid remodeling of the microRNA repertoire. J Exp Med, 2013. 210(2): p. 417-32. 
85. Torgerson, T.R., et al., FOXP3 inhibits activation-induced NFAT2 expression in T cells thereby 
limiting effector cytokine expression. J Immunol, 2009. 183(2): p. 907-15. 
86. Yang, T.T. and C.W. Chow, Transcription cooperation by NFAT.C/EBP composite enhancer 
complex. J Biol Chem, 2003. 278(18): p. 15874-85. 
87. Yang, X.Y., et al., Activation of human T lymphocytes is inhibited by peroxisome proliferator-
activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with 
transcription factor NFAT. J Biol Chem, 2000. 275(7): p. 4541-4. 
88. Ho, I.C., et al., The proto-oncogene c-maf is responsible for tissue-specific expression of 
interleukin-4. Cell, 1996. 85(7): p. 973-83. 
89. Avni, O., et al., T(H) cell differentiation is accompanied by dynamic changes in histone 
acetylation of cytokine genes. Nat Immunol, 2002. 3(7): p. 643-51. 
90. Rengarajan, J., et al., Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate 
interleukin 4 gene expression. J Exp Med, 2002. 195(8): p. 1003-12. 
91. Lee, D.U., et al., A distal enhancer in the interferon-gamma (IFN-gamma) locus revealed by 
genome sequence comparison. J Biol Chem, 2004. 279(6): p. 4802-10. 
92. Decker, E.L., et al., Early growth response proteins (EGR) and nuclear factors of activated T cells 
(NFAT) form heterodimers and regulate proinflammatory cytokine gene expression. Nucleic 
Acids Res, 2003. 31(3): p. 911-21. 
93. Youn, H.D., T.A. Chatila, and J.O. Liu, Integration of calcineurin and MEF2 signals by the 
coactivator p300 during T-cell apoptosis. EMBO J, 2000. 19(16): p. 4323-31. 
94. Ansel, K.M., et al., Deletion of a conserved Il4 silencer impairs T helper type 1-mediated 
immunity. Nat Immunol, 2004. 5(12): p. 1251-9. 
95. Vaeth, M., et al., Store-Operated Ca(2+) Entry Controls Clonal Expansion of T Cells through 
Metabolic Reprogramming. Immunity, 2017. 47(4): p. 664-679 e6. 
96. Feske, S., et al., Gene regulation mediated by calcium signals in T lymphocytes. Nat Immunol, 
2001. 2(4): p. 316-24. 
97. Macian, F., et al., Transcriptional mechanisms underlying lymphocyte tolerance. Cell, 2002. 
109(6): p. 719-31. 
98. Heissmeyer, V. and A. Rao, E3 ligases in T cell anergy--turning immune responses into 
tolerance. Sci STKE, 2004. 2004(241): p. pe29. 
99. Gauld, S.B., et al., Maintenance of B cell anergy requires constant antigen receptor occupancy 
and signaling. Nat Immunol, 2005. 6(11): p. 1160-7. 
100. Parry, R.V., et al., Ligation of the T cell co-stimulatory receptor CD28 activates the serine-
threonine protein kinase protein kinase B. Eur J Immunol, 1997. 27(10): p. 2495-501. 
101. Beals, C.R., et al., Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science, 
1997. 275(5308): p. 1930-4. 
102. Okamura, H., et al., A conserved docking motif for CK1 binding controls the nuclear localization 
of NFAT1. Mol Cell Biol, 2004. 24(10): p. 4184-95. 
103. Chow, C.W., et al., Nuclear accumulation of NFAT4 opposed by the JNK signal transduction 
pathway. Science, 1997. 278(5343): p. 1638-41. 
104. Chow, C.W., et al., c-Jun NH(2)-terminal kinase inhibits targeting of the protein phosphatase 
calcineurin to NFATc1. Mol Cell Biol, 2000. 20(14): p. 5227-34. 
105. Cross, D.A., et al., Inhibition of glycogen synthase kinase-3 by insulin mediated by protein 
kinase B. Nature, 1995. 378(6559): p. 785-9. 
106. Diehn, M., et al., Genomic expression programs and the integration of the CD28 costimulatory 
signal in T cell activation. Proc Natl Acad Sci U S A, 2002. 99(18): p. 11796-801. 
107. Hogan, P.G., et al., Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev, 
2003. 17(18): p. 2205-32. 
108. Sun, L., et al., Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. 





109. Klauck, T.M., et al., Coordination of three signaling enzymes by AKAP79, a mammalian scaffold 
protein. Science, 1996. 271(5255): p. 1589-92. 
110. Kashishian, A., et al., AKAP79 inhibits calcineurin through a site distinct from the immunophilin-
binding region. J Biol Chem, 1998. 273(42): p. 27412-9. 
111. Rothermel, B., et al., A protein encoded within the Down syndrome critical region is enriched 
in striated muscles and inhibits calcineurin signaling. J Biol Chem, 2000. 275(12): p. 8719-25. 
112. Mulero, M.C., et al., RCAN3, a novel calcineurin inhibitor that down-regulates NFAT-dependent 
cytokine gene expression. Biochim Biophys Acta, 2007. 1773(3): p. 330-41. 
113. Esau, C., et al., Deletion of calcineurin and myocyte enhancer factor 2 (MEF2) binding domain 
of Cabin1 results in enhanced cytokine gene expression in T cells. J Exp Med, 2001. 194(10): p. 
1449-59. 
114. Mulero, M.C., et al., Inhibiting the calcineurin-NFAT (nuclear factor of activated T cells) 
signaling pathway with a regulator of calcineurin-derived peptide without affecting general 
calcineurin phosphatase activity. J Biol Chem, 2009. 284(14): p. 9394-401. 
115. Strippoli, P., et al., A new gene family including DSCR1 (Down Syndrome Candidate Region 1) 
and ZAKI-4: characterization from yeast to human and identification of DSCR1-like 2, a novel 
human member (DSCR1L2). Genomics, 2000. 64(3): p. 252-63. 
116. Shay, T. and J. Kang, Immunological Genome Project and systems immunology. Trends 
Immunol, 2013. 34(12): p. 602-9. 
117. Testi, R., J.H. Phillips, and L.L. Lanier, Leu 23 induction as an early marker of functional CD3/T 
cell antigen receptor triggering. Requirement for receptor cross-linking, prolonged elevation of 
intracellular [Ca++] and stimulation of protein kinase C. J Immunol, 1989. 142(6): p. 1854-60. 
118. Pure, E. and C.A. Cuff, A crucial role for CD44 in inflammation. Trends Mol Med, 2001. 7(5): p. 
213-21. 
119. Ansel, K.M., D.U. Lee, and A. Rao, An epigenetic view of helper T cell differentiation. Nat 
Immunol, 2003. 4(7): p. 616-23. 
120. Ansel, K.M., et al., Regulation of Th2 differentiation and Il4 locus accessibility. Annu Rev 
Immunol, 2006. 24: p. 607-56. 
121. O'Shea, J.J. and W.E. Paul, Mechanisms underlying lineage commitment and plasticity of helper 
CD4+ T cells. Science, 2010. 327(5969): p. 1098-102. 
122. Monney, L., et al., Th1-specific cell surface protein Tim-3 regulates macrophage activation and 
severity of an autoimmune disease. Nature, 2002. 415(6871): p. 536-41. 
123. Szabo, S.J., et al., A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell, 
2000. 100(6): p. 655-69. 
124. Szabo, S.J., et al., Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma 
production in CD4 and CD8 T cells. Science, 2002. 295(5553): p. 338-42. 
125. Lighvani, A.A., et al., T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid 
cells. Proceedings of the National Academy of Sciences of the United States of America, 2001. 
98(26): p. 15137-15142. 
126. Afkarian, M., et al., T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T 
cells. Nat Immunol, 2002. 3(6): p. 549-57. 
127. Schulz, E.G., et al., Sequential polarization and imprinting of type 1 T helper lymphocytes by 
interferon-gamma and interleukin-12. Immunity, 2009. 30(5): p. 673-83. 
128. Hermann-Kleiter, N. and G. Baier, NFAT pulls the strings during CD4+ T helper cell effector 
functions. Blood, 2010. 115(15): p. 2989-97. 
129. Miller, J.F. and G.F. Mitchell, Cell to cell interaction in the immune response. Transplant Proc, 
1969. 1(1): p. 535-8. 
130. Nurieva, R.I., et al., Bcl6 mediates the development of T follicular helper cells. Science, 2009. 
325(5943): p. 1001-5. 
131. Crotty, S., Follicular helper CD4 T cells (TFH). Annu Rev Immunol, 2011. 29: p. 621-63. 
132. Johnston, R.J., et al., Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular 
helper cell differentiation. Science, 2009. 325(5943): p. 1006-10. 
133. Yu, D., et al., The transcriptional repressor Bcl-6 directs T follicular helper cell lineage 
commitment. Immunity, 2009. 31(3): p. 457-68. 
134. Baumjohann, D., et al., The microRNA cluster miR-17 approximately 92 promotes TFH cell 






135. von Herrath, M. and J.L. Whitton, Animal models using lymphocytic choriomeningitis virus. 
Curr Protoc Immunol, 2001. Chapter 19: p. Unit 19 10. 
136. Chen, L. and D.B. Flies, Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat 
Rev Immunol, 2013. 13(4): p. 227-42. 
137. Rudd, C.E. and H. Schneider, Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. 
Nat Rev Immunol, 2003. 3(7): p. 544-56. 
138. Waterhouse, P., et al., Lymphoproliferative disorders with early lethality in mice deficient in 
Ctla-4. Science, 1995. 270(5238): p. 985-8. 
139. Tivol, E.A., et al., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan 
tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 1995. 3(5): 
p. 541-7. 
140. Wang, C.J., et al., CTLA-4 controls follicular helper T-cell differentiation by regulating the 
strength of CD28 engagement. Proc Natl Acad Sci U S A, 2015. 112(2): p. 524-9. 
141. Walunas, T.L., et al., CTLA-4 can function as a negative regulator of T cell activation. Immunity, 
1994. 1(5): p. 405-13. 
142. Linsley, P.S., et al., Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation 
molecule. Science, 1992. 257(5071): p. 792-5. 
143. Freeman, G.J., et al., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family 
member leads to negative regulation of lymphocyte activation. J Exp Med, 2000. 192(7): p. 
1027-34. 
144. Riley, J.L., PD-1 signaling in primary T cells. Immunol Rev, 2009. 229(1): p. 114-25. 
145. Nishimura, H., et al., Immunological studies on PD-1 deficient mice: implication of PD-1 as a 
negative regulator for B cell responses. Int Immunol, 1998. 10(10): p. 1563-72. 
146. Iwai, Y., et al., Involvement of PD-L1 on tumor cells in the escape from host immune system and 
tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A, 2002. 99(19): p. 12293-7. 
147. Hui, E., et al., T cell costimulatory receptor CD28 is a primary target for PD-1-mediated 
inhibition. Science, 2017. 355(6332): p. 1428-1433. 
148. Kamphorst, A.O., et al., Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-
dependent. Science, 2017. 355(6332): p. 1423-1427. 
149. Tan, A.H., S.C. Wong, and K.P. Lam, Regulation of mouse inducible costimulator (ICOS) 
expression by Fyn-NFATc2 and ERK signaling in T cells. J Biol Chem, 2006. 281(39): p. 28666-
78. 
150. Weber, J.P., et al., ICOS maintains the T follicular helper cell phenotype by down-regulating 
Kruppel-like factor 2. J Exp Med, 2015. 212(2): p. 217-33. 
151. Bossaller, L., et al., ICOS deficiency is associated with a severe reduction of CXCR5+CD4 
germinal center Th cells. J Immunol, 2006. 177(7): p. 4927-32. 
152. Green, J.M., et al., Absence of B7-dependent responses in CD28-deficient mice. Immunity, 
1994. 1(6): p. 501-8. 
153. Rudd, C.E., A. Taylor, and H. Schneider, CD28 and CTLA-4 coreceptor expression and signal 
transduction. Immunol Rev, 2009. 229(1): p. 12-26. 
154. Dodson, L.F., et al., Targeted knock-in mice expressing mutations of CD28 reveal an essential 
pathway for costimulation. Mol Cell Biol, 2009. 29(13): p. 3710-21. 
155. Harada, Y., et al., Critical requirement for the membrane-proximal cytosolic tyrosine residue 
for CD28-mediated costimulation in vivo. J Immunol, 2001. 166(6): p. 3797-803. 
156. Rohr, J., et al., Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. 
Leukemia, 2016. 30(5): p. 1062-70. 
157. Shahinian, A., et al., Differential T cell costimulatory requirements in CD28-deficient mice. 
Science, 1993. 261(5121): p. 609-12. 
158. Ferguson, S.E., et al., CD28 is required for germinal center formation. J Immunol, 1996. 156(12): 
p. 4576-81. 
159. Linterman, M.A., et al., CD28 expression is required after T cell priming for helper T cell 
responses and protective immunity to infection. Elife, 2014. 3. 
160. King, C.L., et al., CD28-deficient mice generate an impaired Th2 response to Schistosoma 
mansoni infection. Eur J Immunol, 1996. 26(10): p. 2448-55. 
161. Guo, F., et al., CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J 





162. Sanchez-Lockhart, M., et al., Cutting edge: CD28-mediated transcriptional and 
posttranscriptional regulation of IL-2 expression are controlled through different signaling 
pathways. J Immunol, 2004. 173(12): p. 7120-4. 
163. Zhang, R., et al., An obligate cell-intrinsic function for CD28 in Tregs. J Clin Invest, 2013. 123(2): 
p. 580-93. 
164. Zhang, R., et al., Requirement for CD28 in Effector Regulatory T Cell Differentiation, CCR6 
Induction, and Skin Homing. J Immunol, 2015. 195(9): p. 4154-61. 
165. Bouguermouh, S., et al., CD28 co-stimulation down regulates Th17 development. PLoS One, 
2009. 4(3): p. e5087. 
166. Pearce, E.L. and E.J. Pearce, Metabolic pathways in immune cell activation and quiescence. 
Immunity, 2013. 38(4): p. 633-43. 
167. Hough, K.P., D.A. Chisolm, and A.S. Weinmann, Transcriptional regulation of T cell metabolism. 
Mol Immunol, 2015. 
168. Frauwirth, K.A. and C.B. Thompson, Regulation of T lymphocyte metabolism. J Immunol, 2004. 
172(8): p. 4661-5. 
169. Macintyre, A.N., et al., The glucose transporter Glut1 is selectively essential for CD4 T cell 
activation and effector function. Cell Metab, 2014. 20(1): p. 61-72. 
170. Jacobs, S.R., et al., Glucose uptake is limiting in T cell activation and requires CD28-mediated 
Akt-dependent and independent pathways. J Immunol, 2008. 180(7): p. 4476-86. 
171. Wang, R.N., et al., The Transcription Factor Myc Controls Metabolic Reprogramming upon T 
Lymphocyte Activation. Immunity, 2011. 35(6): p. 871-882. 
172. Fox, C.J., P.S. Hammerman, and C.B. Thompson, Fuel feeds function: energy metabolism and 
the T-cell response. Nat Rev Immunol, 2005. 5(11): p. 844-52. 
173. Geiger, R., et al., L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-
tumor Activity. Cell, 2016. 167(3): p. 829-842 e13. 
174. Carr, E.L., et al., Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK 
during T lymphocyte activation. J Immunol, 2010. 185(2): p. 1037-44. 
175. Powell, J.D., et al., Regulation of immune responses by mTOR. Annu Rev Immunol, 2012. 30: p. 
39-68. 
176. Slack, M., T. Wang, and R. Wang, T cell metabolic reprogramming and plasticity. Mol Immunol, 
2015. 
177. Dang, E.V., et al., Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell, 2011. 
146(5): p. 772-84. 
178. Phan, A.T. and A.W. Goldrath, Hypoxia-inducible factors regulate T cell metabolism and 
function. Mol Immunol, 2015. 
179. Doedens, A.L., et al., Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells 
to persistent antigen. Nat Immunol, 2013. 14(11): p. 1173-82. 
180. Nakamura, H., et al., TCR engagement increases hypoxia-inducible factor-1 alpha protein 
synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T 
cells. J Immunol, 2005. 174(12): p. 7592-9. 
181. Ambros, V., The functions of animal microRNAs. Nature, 2004. 431(7006): p. 350-5. 
182. Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004. 116(2): p. 
281-97. 
183. Rodriguez, A., et al., Identification of mammalian microRNA host genes and transcription units. 
Genome Res, 2004. 14(10A): p. 1902-10. 
184. Concepcion, C.P., C. Bonetti, and A. Ventura, The microRNA-17-92 family of microRNA clusters 
in development and disease. Cancer J, 2012. 18(3): p. 262-7. 
185. Song, G. and L. Wang, MiR-433 and miR-127 arise from independent overlapping primary 
transcripts encoded by the miR-433-127 locus. PLoS One, 2008. 3(10): p. e3574. 
186. Blevins, R., et al., microRNAs regulate cell-to-cell variability of endogenous target gene 
expression in developing mouse thymocytes. PLoS Genet, 2015. 11(2): p. e1005020. 
187. Mukherji, S., et al., MicroRNAs can generate thresholds in target gene expression. Nat Genet, 
2011. 43(9): p. 854-9. 
188. Lee, Y., et al., MicroRNA genes are transcribed by RNA polymerase II. EMBO J, 2004. 23(20): p. 
4051-60. 
189. Cai, X., C.H. Hagedorn, and B.R. Cullen, Human microRNAs are processed from capped, 





190. Gregory, R.I., et al., The Microprocessor complex mediates the genesis of microRNAs. Nature, 
2004. 432(7014): p. 235-40. 
191. Hutvagner, G., et al., A cellular function for the RNA-interference enzyme Dicer in the 
maturation of the let-7 small temporal RNA. Science, 2001. 293(5531): p. 834-8. 
192. Baumjohann, D. and K.M. Ansel, MicroRNA-mediated regulation of T helper cell differentiation 
and plasticity. Nat Rev Immunol, 2013. 13(9): p. 666-78. 
193. Kim, V.N., MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol, 2005. 
6(5): p. 376-85. 
194. Baek, D., et al., The impact of microRNAs on protein output. Nature, 2008. 455(7209): p. 64-
71. 
195. Selbach, M., et al., Widespread changes in protein synthesis induced by microRNAs. Nature, 
2008. 455(7209): p. 58-63. 
196. Su, H., et al., Mammalian hyperplastic discs homolog EDD regulates miRNA-mediated gene 
silencing. Mol Cell, 2011. 43(1): p. 97-109. 
197. Krek, A., et al., Combinatorial microRNA target predictions. Nat Genet, 2005. 37(5): p. 495-500. 
198. Friedman, R.C., et al., Most mammalian mRNAs are conserved targets of microRNAs. Genome 
Res, 2009. 19(1): p. 92-105. 
199. Kloosterman, W.P., et al., Substrate requirements for let-7 function in the developing zebrafish 
embryo. Nucleic Acids Res, 2004. 32(21): p. 6284-91. 
200. Xia, Z., et al., Molecular dynamics simulations of Ago silencing complexes reveal a large 
repertoire of admissible 'seed-less' targets. Sci Rep, 2012. 2: p. 569. 
201. Lal, A., et al., miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle 
genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell, 2009. 35(5): 
p. 610-25. 
202. Vella, L.A., R.S. Herati, and E.J. Wherry, CD4(+) T Cell Differentiation in Chronic Viral Infections: 
The Tfh Perspective. Trends Mol Med, 2017. 23(12): p. 1072-1087. 
203. Ha, M. and V.N. Kim, Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol, 2014. 15(8): p. 
509-24. 
204. Hu, H.Y., et al., Sequence features associated with microRNA strand selection in humans and 
flies. BMC Genomics, 2009. 10: p. 413. 
205. Chong, M.M., et al., Canonical and alternate functions of the microRNA biogenesis machinery. 
Genes Dev, 2010. 24(17): p. 1951-60. 
206. Babiarz, J.E., et al., Mouse ES cells express endogenous shRNAs, siRNAs, and other 
Microprocessor-independent, Dicer-dependent small RNAs. Genes Dev, 2008. 22(20): p. 2773-
85. 
207. Siomi, H. and M.C. Siomi, Posttranscriptional regulation of microRNA biogenesis in animals. 
Mol Cell, 2010. 38(3): p. 323-32. 
208. Jiang, S., et al., Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting 
Th1 responses and preventing inducible Treg differentiation. Blood, 2011. 118(20): p. 5487-97. 
209. Cobb, B.S., et al., A role for Dicer in immune regulation. J Exp Med, 2006. 203(11): p. 2519-27. 
210. Chong, M.M., et al., The RNAseIII enzyme Drosha is critical in T cells for preventing lethal 
inflammatory disease. J Exp Med, 2008. 205(9): p. 2005-17. 
211. Cobb, B.S., et al., T cell lineage choice and differentiation in the absence of the RNase III enzyme 
Dicer. J Exp Med, 2005. 201(9): p. 1367-73. 
212. Muljo, S.A., Aberrant T cell differentiation in the absence of Dicer. Journal of Experimental 
Medicine, 2005. 202(2): p. 261-269. 
213. Zhou, X., et al., Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J 
Exp Med, 2008. 205(9): p. 1983-91. 
214. Jeker, L.T., et al., DGCR8-mediated production of canonical microRNAs is critical for regulatory 
T cell function and stability. PLoS One, 2013. 8(5): p. e66282. 
215. de Kouchkovsky, D., et al., microRNA-17-92 regulates IL-10 production by regulatory T cells and 
control of experimental autoimmune encephalomyelitis. J Immunol, 2013. 191(4): p. 1594-605. 
216. Kang, S.G., et al., MicroRNAs of the miR-17 approximately 92 family are critical regulators of 
T(FH) differentiation. Nat Immunol, 2013. 14(8): p. 849-57. 
217. Ota, A., et al., Identification and characterization of a novel gene, C13orf25, as a target for 





218. Ventura, A., et al., Targeted deletion reveals essential and overlapping functions of the miR-17 
through 92 family of miRNA clusters. Cell, 2008. 132(5): p. 875-86. 
219. Houbaviy, H.B., M.F. Murray, and P.A. Sharp, Embryonic stem cell-specific MicroRNAs. Dev Cell, 
2003. 5(2): p. 351-8. 
220. Tanzer, A. and P.F. Stadler, Molecular evolution of a microRNA cluster. J Mol Biol, 2004. 339(2): 
p. 327-35. 
221. Xiao, C. and K. Rajewsky, MicroRNA control in the immune system: basic principles. Cell, 2009. 
136(1): p. 26-36. 
222. Han, Y.C., et al., An allelic series of miR-17 approximately 92-mutant mice uncovers functional 
specialization and cooperation among members of a microRNA polycistron. Nat Genet, 2015. 
223. He, L., et al., A microRNA polycistron as a potential human oncogene. Nature, 2005. 435(7043): 
p. 828-833. 
224. Mu, P., et al., Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell 
lymphomas. Genes Dev, 2009. 23(24): p. 2806-11. 
225. O'Donnell, K.A., et al., c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 2005. 
435(7043): p. 839-43. 
226. Izreig, S., et al., The miR-17 approximately 92 microRNA Cluster Is a Global Regulator of Tumor 
Metabolism. Cell Rep, 2016. 16(7): p. 1915-28. 
227. Mogilyansky, E. and I. Rigoutsos, The miR-17/92 cluster: a comprehensive update on its 
genomics, genetics, functions and increasingly important and numerous roles in health and 
disease. Cell Death Differ, 2013. 20(12): p. 1603-14. 
228. Baumjohann, D., Diverse functions of miR-17-92 cluster microRNAs in T helper cells. Cancer 
Lett, 2018. 423: p. 147-152. 
229. Gerstein, M.B., et al., Architecture of the human regulatory network derived from ENCODE 
data. Nature, 2012. 489(7414): p. 91-100. 
230. Woods, K., J.M. Thomson, and S.M. Hammond, Direct regulation of an oncogenic micro-RNA 
cluster by E2F transcription factors. J Biol Chem, 2007. 282(4): p. 2130-4. 
231. Xiao, C., et al., Lymphoproliferative disease and autoimmunity in mice with increased miR-17-
92 expression in lymphocytes. Nat Immunol, 2008. 9(4): p. 405-14. 
232. Buckler, J.L., et al., Cutting edge: T cell requirement for CD28 costimulation is due to negative 
regulation of TCR signals by PTEN. J Immunol, 2006. 177(7): p. 4262-6. 
233. Wu, T., et al., Cutting Edge: miR-17-92 Is Required for Both CD4 Th1 and T Follicular Helper Cell 
Responses during Viral Infection. J Immunol, 2015. 195(6): p. 2515-9. 
234. Simpson, L.J., et al., A microRNA upregulated in asthma airway T cells promotes TH2 cytokine 
production. Nat Immunol, 2014. 15(12): p. 1162-70. 
235. Liu, S.Q., et al., miR-17-92 cluster targets phosphatase and tensin homology and Ikaros Family 
Zinc Finger 4 to promote TH17-mediated inflammation. J Biol Chem, 2014. 289(18): p. 12446-
56. 
236. Zhu, E., et al., miR-20b suppresses Th17 differentiation and the pathogenesis of experimental 
autoimmune encephalomyelitis by targeting RORgammat and STAT3. J Immunol, 2014. 
192(12): p. 5599-609. 
237. Montoya, M.M., et al., A Distinct Inhibitory Function for miR-18a in Th17 Cell Differentiation. J 
Immunol, 2017. 199(2): p. 559-569. 
238. Yang, H.Y., et al., MicroRNA-17 Modulates Regulatory T Cell Function by Targeting Co-
regulators of the Foxp3 Transcription Factor. Immunity, 2016. 45(1): p. 83-93. 
239. Wu, Y., et al., MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-
versus-host disease in mice. Blood, 2018. 131(17): p. 1974-1986. 
240. Jeker, L.T. and J.A. Bluestone, MicroRNA regulation of T-cell differentiation and function. 
Immunol Rev, 2013. 253(1): p. 65-81. 
241. de Pontual, L., et al., Germline deletion of the miR-17 approximately 92 cluster causes skeletal 
and growth defects in humans. Nat Genet, 2011. 43(10): p. 1026-30. 
242. Serr, I., et al., miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human 
T follicular helper precursors in T1D islet autoimmunity. Proc Natl Acad Sci U S A, 2016. 113(43): 
p. E6659-E6668. 
243. Lee, P.P., et al., A critical role for Dnmt1 and DNA methylation in T cell development, function, 





244. Oxenius, A., et al., Virus-specific MHC class II-restricted TCR-transgenic mice: effects on 
humoral and cellular immune responses after viral infection. European Journal of Immunology, 
1998. 28(1): p. 390-400. 
245. Vigne, S., et al., IL-36R ligands are potent regulators of dendritic and T cells. Blood, 2011. 
118(22): p. 5813-23. 
246. Barrat, F.J., et al., In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is 
induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing 
cytokines. J Exp Med, 2002. 195(5): p. 603-16. 
247. Chen, W.J., et al., Conversion of peripheral CD4(+)CD25(-) naive T cells to CD4(+)CD25(+) 
regulatory T cells by TGF-beta induction of transcription factor Foxp3. Journal of Experimental 
Medicine, 2003. 198(12): p. 1875-1886. 
248. Gubser, P.M., et al., Rapid effector function of memory CD8+ T cells requires an immediate-
early glycolytic switch. Nat Immunol, 2013. 14(10): p. 1064-72. 
249. Dobin, A., et al., STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 2013. 29(1): p. 15-
21. 
250. Gaidatzis, D., et al., QuasR: quantification and annotation of short reads in R. Bioinformatics, 
2015. 31(7): p. 1130-1132. 
251. Robinson, M.D., D.J. McCarthy, and G.K. Smyth, edgeR: a Bioconductor package for differential 
expression analysis of digital gene expression data. Bioinformatics, 2010. 26(1): p. 139-140. 
252. Robinson, M.D. and A. Oshlack, A scaling normalization method for differential expression 
analysis of RNA-seq data. Genome Biol, 2010. 11(3): p. R25. 
253. Wu, D. and G.K. Smyth, Camera: a competitive gene set test accounting for inter-gene 
correlation. Nucleic Acids Res, 2012. 40(17): p. e133. 
254. Subramanian, A., et al., Gene set enrichment analysis: A knowledge-based approach for 
interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 2005. 102(43): p. 
15545-15550. 
255. Kanehisa, M., et al., KEGG: new perspectives on genomes, pathways, diseases and drugs. 
Nucleic Acids Res, 2017. 45(D1): p. D353-D361. 
256. Fabregat, A., et al., The Reactome Pathway Knowledgebase. Nucleic Acids Res, 2018. 46(D1): 
p. D649-D655. 
257. Ritchie, M.E., et al., limma powers differential expression analyses for RNA-sequencing and 
microarray studies. Nucleic Acids Res, 2015. 43(7): p. e47. 
258. Shi, L.Z., et al., HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint 
for the differentiation of TH17 and Treg cells. J Exp Med, 2011. 208(7): p. 1367-76. 
259. Levine, B.L., et al., Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in 
the absence of exogenous feeder cells. J Immunol, 1997. 159(12): p. 5921-30. 
260. Kim, H.P., J. Imbert, and W.J. Leonard, Both integrated and differential regulation of 
components of the IL-2/IL-2 receptor system. Cytokine & Growth Factor Reviews, 2006. 17(5): 
p. 349-366. 
261. Li, Y., et al., MYC through miR-17-92 suppresses specific target genes to maintain survival, 
autonomous proliferation, and a neoplastic state. Cancer Cell, 2014. 26(2): p. 262-72. 
262. Wherry, E.J., et al., Viral persistence alters CD8 T-cell immunodominance and tissue distribution 
and results in distinct stages of functional impairment. J Virol, 2003. 77(8): p. 4911-27. 
263. Oxenius, A., et al., Presentation of endogenous viral proteins in association with major 
histocompatibility complex class II: on the role of intracellular compartmentalization, invariant 
chain and the TAP transporter system. Eur J Immunol, 1995. 25(12): p. 3402-11. 
264. Wolint, P., et al., Immediate cytotoxicity but not degranulation distinguishes effector and 
memory subsets of CD8+ T cells. J Exp Med, 2004. 199(7): p. 925-36. 
265. Hutloff, A., et al., ICOS is an inducible T-cell co-stimulator structurally and functionally related 
to CD28. Nature, 1999. 397(6716): p. 263-6. 
266. Rekik, R., et al., PD-1 induction through TCR activation is partially regulated by endogenous 
TGF-beta. Cellular & Molecular Immunology, 2015. 12(5): p. 648-649. 
267. Kagi, D., et al., Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in 
perforin-deficient mice. Nature, 1994. 369(6475): p. 31-7. 
268. Christensen, J.E., et al., Role of CD28 co-stimulation in generation and maintenance of virus-





269. Licatalosi, D.D., et al., HITS-CLIP yields genome-wide insights into brain alternative RNA 
processing. Nature, 2008. 456(7221): p. 464-9. 
270. Agarwal, V., et al., Predicting effective microRNA target sites in mammalian mRNAs. Elife, 
2015. 4. 
271. Kim, C., et al., Activation of miR-21-Regulated Pathways in Immune Aging Selects against 
Signatures Characteristic of Memory T Cells. Cell Rep, 2018. 25(8): p. 2148-2162 e5. 
272. Gaidatzis, D., et al., Analysis of intronic and exonic reads in RNA-seq data characterizes 
transcriptional and post-transcriptional regulation. Nat Biotechnol, 2015. 33(7): p. 722-9. 
273. Martinez-Llordella, M., et al., CD28-inducible transcription factor DEC1 is required for efficient 
autoreactive CD4+ T cell response. J Exp Med, 2013. 210(8): p. 1603-19. 
274. Loeb, G.B., et al., Transcriptome-wide miR-155 binding map reveals widespread noncanonical 
microRNA targeting. Mol Cell, 2012. 48(5): p. 760-70. 
275. Kapturczak, M.H., H.U. Meier-Kriesche, and B. Kaplan, Pharmacology of calcineurin 
antagonists. Transplant Proc, 2004. 36(2 Suppl): p. 25S-32S. 
276. Benhamou, D., et al., A c-Myc/miR17-92/Pten Axis Controls PI3K-Mediated Positive and 
Negative Selection in B Cell Development and Reconstitutes CD19 Deficiency. Cell Rep, 2016. 
16(2): p. 419-31. 
277. Anzelon, A.N., H. Wu, and R.C. Rickert, Pten inactivation alters peripheral B lymphocyte fate 
and reconstitutes CD19 function. Nat Immunol, 2003. 4(3): p. 287-94. 
278. Bartel, D.P., MicroRNAs: target recognition and regulatory functions. Cell, 2009. 136(2): p. 215-
33. 
279. Morrish, F., et al., The oncogene c-Myc coordinates regulation of metabolic networks to enable 
rapid cell cycle entry. Cell Cycle, 2008. 7(8): p. 1054-1066. 
280. Roehrl, M.H.A., et al., Selective inhibition of calcineurin-NFAT signaling by blocking protein-
protein interaction with small organic molecules. Proceedings of the National Academy of 
Sciences of the United States of America, 2004. 101(20): p. 7554-7559. 
281. Li, Y.Q., et al., Regulation of lymphotoxin production by the p21(ras)-raf-MEK-ERK cascade in 
PHA/PMA-stimulated Jurkat cells. Journal of Immunology, 1999. 162(6): p. 3316-3320. 
282. Ledbetter, J.A., et al., Cd28 Ligation in T-Cell Activation - Evidence for 2 Signal Transduction 
Pathways. Blood, 1990. 75(7): p. 1531-1539. 
283. Sereti, I., et al., Interleukin 2 leads to dose-dependent expression of the alpha chain of the IL-2 
receptor on CD25-negative T lymphocytes in the absence of exogenous antigenic stimulation. 
Clin Immunol, 2000. 97(3): p. 266-76. 
284. Zhu, J., H. Yamane, and W.E. Paul, Differentiation of Effector CD4 T Cell Populations*. Annual 
Review of Immunology, 2010. 28(1): p. 445-489. 
285. Usui, T., et al., T-bet regulates Th1 responses through essential effects on GATA-3 function 
rather than on IFNG gene acetylation and transcription. Journal of Experimental Medicine, 
2006. 203(3): p. 755-766. 
286. Shi, M., et al., Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus 
during T helper 1 cell differentiation. Immunity, 2008. 28(6): p. 763-773. 
287. Semple, K., et al., Strong CD28 costimulation suppresses induction of regulatory T cells from 
naive precursors through Lck signaling. Blood, 2011. 117(11): p. 3096-103. 
288. Boise, L.H., et al., CD28 Costimulation Can Promote T Cell Survival by Enhancing the Expression 
of Bcl-x(L) (Reprinted from Immunity, vol 3, pg 87-98, 1995). Journal of Immunology, 2010. 
185(7): p. 3788-3799. 
289. Rozsnyay, Z., Signaling complex formation of CD44 with src-related kinases. Immunol Lett, 
1999. 68(1): p. 101-8. 
290. Foger, N., R. Marhaba, and M. Zoller, CD44 supports T cell proliferation and apoptosis by 
apposition of protein kinases. Eur J Immunol, 2000. 30(10): p. 2888-99. 
291. DiToro, D., et al., Differential IL-2 expression defines developmental fates of follicular versus 
nonfollicular helper T cells. Science, 2018. 361(6407). 
292. Baaten, B.J., et al., CD44 regulates survival and memory development in Th1 cells. Immunity, 
2010. 32(1): p. 104-15. 
293. Seok, H., et al., MicroRNA Target Recognition: Insights from Transcriptome-Wide Non-
Canonical Interactions. Mol Cells, 2016. 39(5): p. 375-81. 
294. Canaider, S., et al., Human RCAN3 gene expression and cell growth in endothelial cells. 





295. Strippoli, P., et al., The murine DSCR1-like (Down Syndrome Candidate Region 1) gene family: 
conserved synteny with the human orthologous genes. Gene, 2000. 257(2): p. 223-232. 
296. Dorsett, Y., et al., MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated 
Myc-Igh translocation. Immunity, 2008. 28(5): p. 630-8. 
297. Anders, C., et al., Structural basis of PAM-dependent target DNA recognition by the Cas9 
endonuclease. Nature, 2014. 513(7519): p. 569-+. 
298. Sternberg, S.H., et al., DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. 
Nature, 2014. 507(7490): p. 62-+. 
299. Vidigal, J.A. and A. Ventura, The biological functions of miRNAs: lessons from in vivo studies. 
Trends Cell Biol, 2015. 25(3): p. 137-147. 
300. Liu, J., et al., Calcineurin Is a Common Target of Cyclophilin-Cyclosporine-a and Fkbp-Fk506 
Complexes. Cell, 1991. 66(4): p. 807-815. 
301. Martinez-Martinez, S. and J.M. Redondo, Inhibitors of the calcineurin/NFAT pathway. Current 
Medicinal Chemistry, 2004. 11(8): p. 997-1007. 
302. Ragheb, J.A., M. Deen, and R.H. Schwartz, CD28-mediated regulation of mRNA stability 
requires sequences within the coding region of the IL-2 mRNA. Journal of Immunology, 1999. 
163(1): p. 120-129. 
303. Abraham, C. and J. Miller, Molecular mechanisms of IL-2 gene regulation following 
costimulation through LFA-1. Journal of Immunology, 2001. 167(9): p. 5193-5201. 
304. Afkarian, M., et al., T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4(+) T 
cells. Nature Immunology, 2002. 3(6): p. 549-557. 
305. Esensten, J.H., et al., CD28 Costimulation: From Mechanism to Therapy. Immunity, 2016. 44(5): 
p. 973-88. 
306. Maher, J., et al., Human T-lymphocyte cytotoxicity and proliferation directed by a single 
chimeric TCR zeta/CD28 receptor. Nature Biotechnology, 2002. 20(1): p. 70-75. 
307. Pagani, M., et al., Role of microRNAs and long-non-coding RNAs in CD4(+) T-cell differentiation. 
Immunol Rev, 2013. 253(1): p. 82-96. 
308. Sasaki, K., et al., miR-17-92 expression in differentiated T cells - implications for cancer 
immunotherapy. J Transl Med, 2010. 8: p. 17. 
309. Facchin, F., et al., Complexity of Bidirectional Transcription and Alternative Splicing at Human 
RCAN3 Locus. Plos One, 2011. 6(9). 
310. Fruman, D.A., et al., Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 
and cyclosporin A. Proc Natl Acad Sci U S A, 1992. 89(9): p. 3686-90. 
311. Calne, R.Y., et al., Cyclosporin A in patients receiving renal allografts from cadaver donors. 
Lancet, 1978. 2(8104-5): p. 1323-7. 
312. Ishikura, K., et al., Posterior reversible encephalopathy syndrome in children: its high 
prevalence and more extensive imaging findings. Am J Kidney Dis, 2006. 48(2): p. 231-8. 
313. Jeker, L.T. and R. Marone, Targeting microRNAs for immunomodulation. Current Opinion in 
Pharmacology, 2015. 23: p. 25-31. 
314. Simonson, B. and S. Das, MicroRNA Therapeutics: the Next Magic Bullet? Mini-Reviews in 
Medicinal Chemistry, 2015. 15(6): p. 467-474. 
315. Lindow, M. and S. Kauppinen, Discovering the first microRNA-targeted drug. Journal of Cell 
Biology, 2012. 199(3): p. 407-412. 
316. Chakraborty, C., et al., Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next 
Generation Medicine. Molecular Therapy-Nucleic Acids, 2017. 8: p. 132-143. 
317. Ohno, M., et al., Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced 
with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J 








11.1. Cell culture media, buffers, solutions 
item ingredients supplier Catalogue number 
CD4+ T cell medium 
 
RPMI-1640 Medium 
10% FCS,  
1% HEPES,  
1% Sodium pyruvate,  
1% non-essential amino acids,  
1% Glutamax,  


















FACS buffer PBS 
2% heat-inactivated FCS 









80g NaCl (1.369M) 
2g KCl (0.027M) 
14.4g Na2HPO4 * 2H2O (0.08M) 









ACK lysis buffer 8.29g NH4Cl (0.155M) 
200µl 0.5M EDTA pH=8.0 







NaHCO3 0.1M pH=8.0 SIGMA S5761-500G 
Tail lysis buffer 0.1M Tris pH 8.5 
5mM EDTA 
0.2% SDS 
0.1M NaCl  













Dissolve in 1L dH2O SIGMA R6504-10X1L 
TE buffer  Sigma 93283-100ML 
11.2. Kits, reagents and further material 
item supplier Catalogue number 
Fixation/Permeabilization Concentrate invitrogen 00-5123-43 
Fixation/Permeabilization Diluent invitrogen 00-5223-5 
Permeabilization Buffer 10X eBioscience 00-8333-56 
Heparin-Na Braun 46613 
OneComp eBeads invitrogen 01-111-42 
Ethanol Sigma-Aldrich 51976-500ML-F 
Isopropanol Sigma-Aldrich I9516-500ML 
TRI Reagent Sigma-Aldrich T9424-200ML 
1-Bromo-3-chloropropane Sigma-Aldrich B9673-200ML 
M-MLV Reverse Transcriptase Sigma-Aldrich M1302-40KU 
TaqMan™ Fast Universal PCR Master Mix (2X), no AmpErase™ 
UNG 
ThermoFisher 4364103 
TaqMan Gene Expression Assays RCAN3  ThermoFisher 4351372 
TaqMan Gene Expression Assays 18S  ThermoFisher 4331182 
MicroAmp™ Fast Optical 96-Well Reaction Plate, 0.1 mL ThermoFisher 4346907 
EasySep naïve CD4+ T cell Isolation Kit STEMCELL 19765A 
CellTAK adhesive Corning 354241 





Oligomycin SIGMA 495445 
FCCP SIGMA C2920 
Rotenone SIGMA R8875 
D-(+)-Glucose Sigma-Aldrich G7021 
GoTaq G2 Green Master Mix Promega M782B 
ProLong Glass Antifade Mountant ThermoFisher P36982 
0.4µm filters Sefar  
Syringe for i.p. BD Micro-Fine (30G, 8mm) BD 324826 
Syringe for i.v. BD Micro-Fine (29G, 12.7mm) BD 324824 
ELISA MAX mouse IL-2 set BioLegend 431002 
Nunc-Immuno™ MicroWell™ 96 well solid plates SIGMA M9410-1CS 
Cryo embedding medium Medite 41-3011-00 
Acetone SIGMA 534064-500ML 
ELITE PAP pen Diagnostic Biosystems K039 
Universal Agarose Bio&Sell BS20.46.5000 
Zymol Directzol kit ZymoResearch R2060 
96 well cell culture cluster (96 well plate) Corning 3596 
24 well cell culture cluster (24 well plate) Corning 3526 
11.3. Antibodies, dyes, cytokines, stimulants 
reactive to clone fluorochrome supplier Catalogue number 
Fixable Viability Dye eF780 - eFluor 780 eBioscience 65-0865-14 
2-NBDG - - ThermoFisher N13195 
Cell Trace Violet (CTV) - - ThermoFisher C34557 
aCD4 RM4-5 or GK1.5 various Biolegend various 
aCD44 IM7 PerCP-Cy5.5, PE Biolegend 103032, 103008 
aCD62L MEL-14 APC Biolegend 104412 
aCD69 H1.2F3 BV711 Biolegend 104537 
aCD25 PC61 PeCy7 Biolegend 102016 
aTbet 4B10 PE Biolegend 644810 
aIFNg XMG1.2 Alexa 488 Biolegend 505813 
aIL-17a TC11-18H10.1 PE Biolegend 506904 
aRorgt Q31-378 PE-CF594 BD BioScience 562684 
aFoxp3 FJK-16s APC eBioscience 17-5773-82 
aFas (CD95) Jo2 Alexa488 BD BioScience 554257 
aGL-7 GL7 Alexa 488/PerCPCy5.5 Biolegend 144612, 144610 
aBcl-6 K112-91 PE BD BioScience 561522 
aICOS (CD278) C398.4A BV510 Biolegend 313525 
aCXCR5 (CD185) SPRCL5 PE-Texas eBioscience 145513 
aPD-1 (CD279) 29F.1A12 PeCy7 Biolegend 135216 
aB220 RA3-6B2 Alexa647, APC Biolegend, Tonbo 103229, 20-0452-
U100 
aCD19 1D3 BV711, Alexa647 Biolegend 115555, 115522 
aCD3e 145-2C11 various Biolegend various 
αIL-2 JES6-5H4 PE Biolegend 503808 
aVa2 B20.1 APC, PacBlue Biolegend,  127816,  
aVβ8.3 1B3.3 PE BD BioScience 553664 
aCD3 2C11 Unlabeled (coating) BioXcell BP0001-1 
aCD28 PV-1 Unlabeled (coating) BioXcell BE0015-5 
aCD16/32 2.4G2 Unlabeled (Fc block) BioXcell BE0307 
Phorbol 12-Myristate 13-
Acetate (PMA) 
- - Sigma P1585 
Ionomycin - - Sigma 10634-1MG 
Brefeldin A (BFA) - - Sigma B7651-5MG 
GP-64 - - Neosystem SP991567B 





aIL4 11B11 Unlabeled (blocking) UCSF AM039-PURE-B25 
aIFNg XMG1.2 Unlabeled (blocking) UCSF AM034-PURE-B25 
aIL12/23 C17.8 Unlabeled (blocking) UCSF AM037-PURE-B25 
Retinoic acid - For differentiation Sigma R2625 
rhTGFβ - For differentiation R&D P01137 
IL-6  For differentiation R&D 406ML 
Cyclosporin A - - Sigma 30024 
Goat anti-mouse IgG1 Alexa Fluor 647  ThermoFisher A21240 
DAPI   Sigma 10236276001 
IL-12   For differentiation R&D 419ML 
aNFATC2  25A10.D6.D2 biotinylated ThermoFisher MA1-025 
TMB  Substrate for HRP BD 555214 
 
11.4. Primers, oligomers and plasmids 
All primers were ordered from Microsynth, resuspend at a concentration of 100µM in 
TE buffer and stored at -80°C. 
Primer name purpose Sequence 5’ => 3’ 
112_LJ_CD4-cre_for  Genotyping CD4cre fwd ACG ACC AAG TGA CAG CAA TG 
113_LJ_CD4-cre_rev Genotyping CD4cre rev CTC GAC CAG TTT AGT TAC CC 
174_CD4-cre_for  Genotyping CD4cre fwd TTT CAC TGA AGG CGA GAG GG 
175_CD4-cre_rev Genotyping CD4cre rev TGG CTT AAT TAG CCC CAT CCT 
688_CD28ko_wtfwd Genotyping CD28ko wt fwd CTT TGA TTT CAG GGC AAT GG 
689_CD28ko_common Genotyping CD28ko common TTG ACG TGC AGA TTC CAG AG 
690_CD28ko_mutfwd Genotyping CD28ko mut fwd CCA GTC ATA GCC GAA TAG CC 
106 LJ_oIMR8916_miR17-92Tg  Genotyping miR-17~92 transgene CCA GAT GAC TAC CTA TCC TC 
107 LJ_oIMR8917_miR-17-92Tg  Genotyping miR-17~92 transgene GAG CTG CAG TGG AGT AGG CG 
108 LJ_oIMR8918_miR-17-92Tg  Genotyping miR-17~92 transgene ACC TCC CCC TGA ACC TGA AAC A 
109 LJ_oIMR8919_miR-17-92Tg Genotyping miR-17~92 transgene CAG TTT TAC AAG GTG ATG TTC TCT 
G 
110 LJ_oIMR8528_miR-17-92_lox  Genotyping miR-17~92 knockout TCG AGT ATC TGA CAA TGT GG 
111 LJ_oIMR8529_miR-17-92_lox Genotyping miR-17~92 knockout TAG CCA GAA GTT CCA AAT TGG 
207 Vα2 up primer Genotyping SMARTA by PCR ATA AAA AGG AAG ATG GAC GAT T 







11.5. PCR protocols 
11.5.1. miR-17~92 knockout genotyping 
Reagent V/rxn  Temp (°C) Time (min:sec) 
H2O 9.5  94 03:00  
Primer 106 (10 µM) 1  94 00:30  
Primer 107 (10 µM) 1  53 01:00   
Primer 108 (10 µM) 1  72 01:00 35x 
Primer 109 (10 µM) 1  72 03:00   
Go green Taq 12.5  10 hold  
DNA 1     
Total 25     
11.5.2. miR-17~92 transgene genotyping 
Reagent V/rxn  Temp (°C) Time (min:sec) 
H2O 9.5  94 03:00  
Primer 110 (10 µM) 1  94 00:30  
Primer 111 (10 µM) 1  53 01:00   
Go green Taq 12.5  72 01:00 35x 
DNA 1  72 03:00   
Total 25  10 hold  
11.5.3. SMARTA genotyping 
Reagent V/rxn  Temp (°C) Time (min:sec)  
H2O 9.5  94 02:00  
Primer 207 (10 µM) 1  94 00:20  
Primer  208 (10 µM) 1  52 00:15  
Go Green Taq 12.5  72 00:10 35x 
DNA 1  72 02:00   
Total 25  10 hold  
11.5.4. CD4cre genotyping 
Reagent V/rxn  Temp (°C) Time (min:sec) 
H2O 9.5  94 03:00  
Primer 112 (10 µM) 1  94 00:30  
Primer 113 (10 µM) 1  58 01:00   
Primer 174 (10 µM) 1  72 01:00 35x 
Primer 175 (10 µM) 1  72 03:00   
Go green Taq 12.5  10 hold  
DNA 1     
Total 25     
11.5.5. CD28 knockout genotyping 
wt   mut   Temp (°C) Time (min:sec)   
Reagent V/rxn  Reagent V/rxn  94 02:00   
H2O 8.5  H2O 7.5  94 00:20   -1.5°C per 
Primer 688 (10 µM) 1  Primer 689 (10 µM) 1  65 00:15 10x cycle 
Primer 689 (10 µM) 1  Primer 690 (10 µM) 2  68 00:10    
Go green Taq 12.5  Go green Taq 12.5  94 00:15     
DNA 2  DNA 2  50 00:15   32x 
Total 25  Total 25  72 00:10     
      72 02:00   







°C degree Celsius 
2-NBDG 2-deoxy-2-((7-nitro-2,1,3-benzoxadiazol-4-yl)amino)-D Glucose 
80k 80'000 
abs(log2FC) absolute log2 fold change 
ACK Ammonium-Chloride-Potassium 
Ago2 argonaute 2 
AHC Ago2 HITS CLIP 
Akt Protein Kinase B 
AP-1 activator protein 1 
APC antigen presenting cell 
ATP adenosine tri phosphate 
B6 Black 6 (mouse) 
Bcl-XL  B cell lymphoma-extra large  
BFA Brefeldin A 
bp base pairs 
C13ORF25 chromosome 13 open reading frame 25 
Ca2+ Calcium 
CAR chimeric antigen receptor 
CD cluster of differentiation/ designation or classification determinant 
CDF cumulative distribution function  
CPM counts per million reads mapped 
CRAC calcium release activated calcium channels 
CREB1 cAMP response element binding 
CRISPR clustered regularly interspaced short palindromic repeats 
CsA Cyclosporin A 
Csk C-terminal Src kinase 
CTLA-4 cytotoxic T lymphocyte antigen 4 
CTV cell trace violet 
d day 
DAG diacylglycerol 
DNA Deoxyribonucleic acid 
DAPI 4ʹ,6-diamidino-2-phenylindole 
DE differential expression 
dH2O distilled water 
DMSO Dimethyl sulfoxide 
e.g. exempli gratia 
EAE experimental autoimmune encephalitis 
ECAR extracellular acidification rate 
EISA exon intron split analysis 
ELISA enzyme-linked immunosorbent assay 
ENCODE encyclopedia of DNA elements 
ER endoplasmic reticulum 





FCCP Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
FDR false discovery rate 
FoxP3 forkhead box p3 
FSC-A forward scatter-area 
G Gauge 
GC germinal center 
GC-MS Gas chromatography- mass spectrometry 
GLUT1 glucose transporter 1 
GMPR guanosine monophosphate reductase 
GP glycoprotein 
GSEA gene set enrichment analysis 
h hours 
HITS CLIP High-throughput sequencing of RNA isolated by crosslinking immunoprecipitation 
i.e. id est 
i.p. intra peritoneal 
i.v. intra veneous 




IP3 inositol 1,4,5-triphosphate  
ITAM immunoreceptor tyrosine-based activation motifs 
iTreg induced T regulatory cell 
JNK jun kinase 
LAT linker of activated T cells 
LCMV Lymphocytic choriomeningitis virus  
LN lymph node 
logFC log fold change 
lox, miR1792lox B6.CD4cre.miR-17~92lox 
MFI median fluorescence intensity 
MHC major histocompatibility complex 
min minutes 
miR, miRNA microRNA 
MIR17HG miR-17~92 host gene 
ml milliliter 
mm millimeters 
mRNA messenger RNA 
ms millisecond 
mTORc mammalian target of rapamycin complex 
n.s. not significant 
NFAT nuclear factor of activated T cells 
NFκB nuclear factor kappa-light-chain-enhancer of activated B cells 
ng nanogram 







OCR oxygen consumption rate 
p value probability value 
PAM protospacer adjacent motif 
PBMC peripheral blood mononuclear cells 
PBS phosphate buffered saline 
PC principal component 
PCA principal component analysis 
PCR polymerase chain reaction 
PD-1 Programmed death 1  
PFU plaque forming units 
PHLPP2 PH domain and Leucine Rich Repeat Protein Phosphatase 2 
PI3K phosphatidyl inositol 3 kinase 
PIP2 phosphatidyl inositol 4,5-bisphosphate 
PIP3 phosphatidyl inositol 3,4,5-trisphosphate 
PLC-γ phospholipase C-γ  
PMA phorbol 12-myristate 13-acetate  
PTEN phosphatase and tensin homolog  
qPCR quantitative PCR 
RCAN Regulator of calcineurin, also known as members of Down’s syndrome critical region 
RISC RNA induced silencing complex 
RNA Ribonucleic acid 
Rorγt RAR related orphan receptor gamma 
rpm rounds per minute 
RT room temperature or reverse transcription 
SD standard deviation 
SH2 Src Homology 2 
siRNA small interfering RNA 
SOCE store operated calcium entry 
STAT Signal transducer and activator of transcription  
STIM 1/2 stromal interaction molecules 
Tbet T-box expressed in T cells 
TCR T cell receptor 
TF Transcription factor 
TFH T follicular Helper cell 
tg, miR1792tg B6.CD4cre.miR-17~92tg 
TGFβRII transforming growth factor beta receptor II 
TH T Helper 
TMB 3,3’,5,5’-Tetramethylbenzidine 
TNF tumor necrosis factor 
TS TargetScan 
U Units 







wt wild type 
αCD3 anti CD3 
µl micro liter 








13.1. Gating strategy LCMV experiments 
 
 
Figure 40. Gating strategy for LCMV infection experiments 
Cell suspensions were pre-gated for singlets, lymphocytes and viability. CD4+ T cells were gated with 
CD3/CD4 (including the cells down-regulating CD3 as a consequence of antigen encountering, “smear”). 
CD4+ T cells were further displayed with CXCR57PD-1, ICOS/Bcl6 and CD44. B cells were gated from the 






Figure 41. Gating strategy for adoptive transfer experiments 
Cell suspensions were pre-gated for singlets, lymphocytes and viability. CD4+ T cells were gated with 
CD3/CD4 (including the cells down-regulating CD3 as a consequence of antigen encountering, “smear”). 










13.2. GC-MS experimental procedure 
The following protocol was obtained from the NIH West coast Metabolomics Center. 
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